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Abstract 
Objectives: To evaluate the accuracy of the four main Intensive Care severity 
of illness scoring models using a large Scottish database, and to investigate 
different strategies for improving their accuracy in a Scottish setting. 
Method: Twenty two out of 25 general adult Intensive Care Units in Scotland 
collected data for two and half years to allow calculation of Acute Physiology 
and Chronic Health Evaluation (APACHE) version II and III, Simplified 
Acute Physiology Score (SAPS) version II, Mortality Probability Model 
(MPM) version II (calculated on admission and at 24 hours). The models' 
Goodness of Fit (discrimination and calibration) and performances in 
subgroups (Uniformity of Fit) was evaluated using Receiver Operating 
Characteristic Curves, Hosmer-Lemeshow Goodness of Fit test, Chi Squared 
test and Confidence Intervals. Three of the Models (APACHE II, SAPS II, 
and MPM II) were customised with Scottish data using logistic regression 
techniques. Data quality was monitored by rescoring 10% of records over the 
first nine months of the project, with only the MPMO model showing any bias 
in the probabilities because of data collection. errors. 
Results: All models had good discrimination but poor calibration. However, 
the SAPS II and APACHE II models appeared to have better calibration than 
other models. After excluding patients who where discharged before the first 
24 hours there was a deteriotion in both calibration and discrimination in all 
but the MPM24 model. APACHE III, SAPS II and MPM24 had superior 
discrimination to other models in this cohort. Analysis of the Uniformity of 
Fit showed significant differences between observed mortality and that 
estimated by the model in important subgroups of patients. 
Substituting a pre-sedated Glasgow Coma Score, when patients were sedated 
over the first 24 hours, improved the discrimination and calibration in 
patients with altered scores in both the APACHE II and APACHE III models. 
The performance of the APACHE III model improved, but despite improved 
discrimination the calibration of the APACHE II model deteriorated. 
After customisation all new models showed significant improvements in 
accuracy. However, only the new SAPS II models had no significant 
differences between the observed mortality and the estimated mortality using 
N 
the Hosmer-Lemeshow Goodness of Fit test. All models, except the new 
APACHE II model, showed significant differences in important subgroups. 
Conclusions: Questions remain about the accuracy of these models even after 
customisation. Further research is needed to investigate variations in 
Intensive Care Units and the relationship to clinical effectiveness. However, 
where case mix adjustment is needed the new customised models remain the 
most accurate means of doing this in Scottish data. 
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1.1 Introduction 
As the proportion of health care resources spent on Intensive Care increases, so too does 
the demand for accurate measures of quality of care. Also, with the emergence of the 
purchaser and provider split in the 1990s, there has been a focus on clinical effectiveness. 
More recently the White paper "Designed to Care" published in 1998 has highlighted the 
importance of clinical audit and the principles of clinical governance (1). 
A report into Intensive Care by the Kings Fund in 1989 tried to answer five questions 
(2): 
1. Is there scientific evidence that Intensive Care Units (lCU) cause a decrease in 
mortality and morbidity? 
2. What criteria should be set for admission and discharge to ICUs? 
3. Which classes of patients are likely to benefit most from which procedures that are 
carried out in ICU? 
4. For what extra cost is therapeutic benefit gained by using Intensive Care? 
5. What scale of provision is needed in the NHS? 
They concluded that: 
and 
" ....... the lack of data in the United Kingdom would make it impossible to answer the 
questions posed." 
" ..... the absence of data on workload, outcome and costs and the heterogeneity of 
ICUs, make it evident that any recommendation about future provision must be 
highly speculative." 
They also concluded that: 
"Each unit should collect and evaluate data on clinical outcome and costs, both in 
general and for the care of individual patients." 
It was against this background that the Scottish Intensive Care Society (SICS) applied to, 
and received money from, the Clinical Resource and Audit Group (CRAG) of the 
Scottish Office for a three year national audit of Intensive Care. The funding also 
included the monies for this research into the accuracy of existing severity of illness 
models. 
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The Objectives of this PhD were: 
• To test and assess the accuracy" in a Scottish setting, of the five severity of illness 
models most commonly in use. These being the Simplified Acute Physiology Score 
(SAPS) version II, Mortality Probability Model (MPM) version II, Acute Physiology 
and Chronic Health Evaluation (APACHE) version IT and lIT (3-6). 
• To assess the applicability of severity models in a Scottish setting and therefore 
assess the portability of these systems out of their original development setting. 
• To assess, where applicable, different strategies for improving the accuracy of these 
models within the Scottish Intensive Care population. 
• To improve, where possible, the accuracy of these models within the Scottish 
Intensive Care population. 
1.2 Layout of this thesis 
The thesis contains 9 chapters. All figures and tables appear as close to the text as 
possible and are numbered sequentially according to the chapter in which they appear, for 
example, Chapter 6 has figures 6.1- 6.9. Each chapter has a coloured first page with 
contents. References and appendices appear at the end of the thesis with appendices 
running from Appendix 1 to Appendix 3. 
1.3 The Chapters 
Chapter 2 reviews the literature and history of Intensive Care scoring models. The 
chapter also discusses the appropriate statistics by which the performance of scoring 
models are measured. It outlines the reasons the study was undertaken. 
Chapter 3 describes the units and patients used in this study. It also describes the methods 
used to collect data and the statistics and analysis used on the data. 
Chapter 4 describes the methods used to ensure data were consistent and accurate. It 
highlights areas of uncertainty where it was not possible to guarantee data quality. It 
describes the methods and presents analysis of the re-scoring of 10% of records over a 
nine month period. It discusses the analysis of this data making conclusions on the 
useability of the data. 
Chapter 5 describes the ICUs and patients in the study. It also presents the results from 
the analysis of the overall performance of each of the models. It discusses the 
implications of the results of this overall analysis. 
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Chapter 6 presents analysis of data assessing the uniformity of fit of the models. The 
results are discussed and conclusions made on the analysis 
Chapter 7 presents methods and results of analysis of the performance of the APACHE 
models when a pre-sedated Glasgow Coma Score (GCS) is used if patients are sedated 
for the first twenty four hours. The chapter discusses the results and the implications for 
the models. 
Chapter 8 describes the methods and analysis of results from a process of customisation. 
Implications from the results are discussed and conclusions on their accuracy are made. 
<?hapter 9 describes the methods and analysis of results~ from a process of customisation 
based on a temporal split in the data. Implications from the results are discussed. 
Chapter 10 discusses the results from this study and the implication for the future of these 
models. It discusses possible reasons for inaccuracies in the models and possible future 
uses for Intensive Care scoring models. 
1.4 Acknowledgements 
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thesis. 
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2.1 Intensive Care development and definition 
The development of Intensive Care can be traced to the emergence of endotracheal 
intubation with positive pressure ventilation. In 1952 a Danish epidemiologist reported 
reduced mortality rate in patients with respiratory failure as a result of endotracheal 
intubation and ventilation (7). Since then Intensive Care has developed into an important 
element of medicine. It consumes considerable resources, i.e. an estimated 1-2% of the 
hospital budget in the UK. and a considerably larger 22% in the United States of America 
(US)(8,9). Many countries now treat Intensive Care as a separate specialty. However, in 
the UK it still remains a subspecialty of either Anaesthesia or Surgery. 
Some have pointed to post-operative recovery rooms as being the earliest origins of 
Intensive Care with Florence Nightingale saying as early as 1852: 
"It is valuable to have one place in the hospital where post-operative and other· 
patients needing close attention can be watched. " 
As well as recovery units, there have been a number of areas where specialist units have 
developed, i.e. trauma, burns, cardiac and neurosurgical ICUs. Intensive Care is now an 
integral part of hospital medicine. 
There are a number of definitions of Intensive Care, a report from the King's Fund panel 
defined it as (2): 
"a service for patients with potentially recoverable diseases who can benefit from 
more detailed observation and treatment than is generally available in the 
standard wards and departments". 
This has been criticised as being too broad for clinical practice (10). The Intensive Care 
Society (lCS) in a report from the Standards Subcommittee (11) defined Intensive Care 
as: 
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" ...... the highest level of continuing patient care and treatment... It has as its 
primary objective the recovery of the patient at least to the stage of return to an 
intermediate care ward" 
and 
" .. .involves continuing supervision, care and treatment by doctors, nurses, 
physiotherapists, technicians, dieticians and others." 
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In 1990 the ICS (12) further defined it by saying it: 
" .. .is usually reserved for patients with potential or established organ failure ... " 
and 
" ... requires a multi-disciplinary team approach and the highest possible standards 
of nursing and medical care. A nurse/patient ratio of 1: 1 should be the minimum 
and the services of a full-time medical resident are essential." 
The ICS defined an ICU as: 
"a specially designed ward where facilities for the critically ill are concentrated 
and where the level of care and supervision is appreciably greater than on an 
ordinary ward. "(11) 
Rowan K. (13) argues that most definitions highlight two distinct tasks firstly: 
" ... the prevention of, or early detection of and rapid response to, life-threatening 
complications in patients who are judged to be at risk of becoming critically ill." 
and the second is: 
"the substitution, temporarily, for the physiological function of one or more organ 
systems that have failed, until the crisis is past." 
Although there is a general consensus as to what Intensive Care is, there is less certainty 
and a lack of evidence that it provides significant improvements in the outcome of those 
patients receiving it. There is general agreement that the development of Intensive Care 
was not accompanied by adequate evaluation. The Kings Fund panel in 1989 asked: 
"Is there scientific evidence that ICUs cause a decrease in mortality and 
morbidity?" 
They concluded that there was not enough data to answer this question (2). 
Some studies have questioned the effectiveness of Intensive Care. Hook et al have 
reported similar mortality in patients with pneumococcal bacteremia receiving Intensive 
Care and those receiving alternative treatment (14). However, this research is 
contradicted by Rogers et al (15) who showed a reduction in mortality in patients with 
acute respiratory failure following the introduction of an ICU. A study of provision of 
Intensive Care in England and Wales reported similar mortality rates in those receiving 
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Intensive Care and those patients who were refused admission (16). This study did not 
analyse the nature of those patients who were refused admission to the ICUs. 
In the early years of Intensive Care it would have been possible to have conducted 
randomised controlled trials to evaluate the effectiveness of Intensive Care and the 
treatments being administered. However, given the widespread use and acceptability of 
Intensive Care and ICUs it would now be unethical to evaluate treatment by refusing 
entry to ICUs to some people. This has lead to increasing pressure for clinicians to 
demonstrate the effectiveness of the treatment that they are giving. 
2.2 Audit in Intensive Care 
Clinical Audit has been described as: 
"systematic, critical analysis of the quality of medical care, including the 
procedures used for diagnosis and treatment, and the resulting outcome for the 
patient." (17) 
The process of Audit is often thought of in terms of a cycle (Fig 2.1) 
There are three things that can be measured i.e. structure, process and outcome. It is 
generally accepted that structure and process (the way care is provided) both affect 
outcome. Bion has suggested a more complex structure for Audit in Intensive Care (Fig 
2.2) (18). This is based on the review of standards in structure, process and outcome. The 
Department of Health has published guidelines that have recommended numbers of ICU 
beds as between 1-2% of the acute beds (18). Guidelines published by the ICS have 
recommended that an ICU should have a maximum occupancy of 70% to allow for 
periods of peak demand (11). There are also recommendations around nursing staff 
numbers. The ICS recommends that there should be a minimum of one nurse per patient 
(12) with most ICUs implementing this as practice. How this translates into actual 
numbers depends on the occupancy of each ICU. However, the ICS has given methods 
for calculating the numbers of nurses required (11). ICUs are also expected to provide 24 
hour consultant cover (18). Levels and experience of medical staff could be expected to 
have an effect on patient outcomes. 
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However, Audit in Intensive Care has tended to focus on outcome. The majority of this 
focus has been on mortality. Intensive care is unusual because by its very nature it is 
concerned with the care of the most sick patients, making death a fairly common event. If 
process affects outcome then it should be possible to relate it to mortality. However, this 
has been avoided in the past as it is difficult to disentangle all the factors that might be 
involved. Although it is clear that process is an important aspect of medical care it has 
been argued by Bion that: 
" .... given a choice between a high quality process of care with a poor 
outcome, or poor process with a good outcome, most people would choose 
the latter." (18) 
However, the use of mortality as an outcome measure is not as straightforward as it 
would seem. There is not necessarily a direct relationship between the effectiveness of 
care and mortality. A number of studies have shown a wide distribution of mortality in 
ICUs (19,20). The ICUs in the UK APACHE II study had a hospital mortality that 
ranged from 21% - 45%. The mortality rate in the ICUs in this study ranged from 23%-
42% (Table 5.1). It is not appropriate to compare mortality rates in ICU as a measure of 
quality of care. The mortality rate in an ICU will be related to the type of patient that is 
admitted. The reason for admission to an ICU is usually to support one or more organ 
. system. The causes of organ failure can be due to a number of underlying disease 
processes. The expected survival from individual diseases is very different, for example 
an acute but severe asthma attack may lead a patient to be admitted to an ICU for 
respiratory support. Similarly someone could be admitted with respiratory failure due to 
chronic emphysema, but the expected outcome from both these cases will be 
considerably different. Bion points to various determinants of outcome from critical 
illness (18). 
1. Severity of illness 
2. The type of disease process (diagnosis) 
3. Physiological reserve (previous health and age) 
4. Specificity and timing of treatment. 
Rowan pointed out that there will always be unquantifiable factors like "will to live" that 
will have an affect on outcome (13). 
The success of Audit depends on the ability to set measurable standards. As mortality is 
affected by a number of factors it is clear that some sort of case mix adjustment is needed 
before legitimately using it as an outcome measure. Increasingly, Intensive Care severity 
of illness models are being used to adjust for case mix and to allow the setting of 
standards. 
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2.3 Statistical issues in severity of illness modelling. 
There are a number of statistical issues to be considered when assessing the performance 
of Intensive Care scoring models. The problems are largely because the scoring models 
generate probabilities that are on a continuous scale, however the outcome measure 
(hospital mortality) that is used to assess the accuracy of these models, is dichotomous. 
The two areas of a model's accuracy that can be measured are discrimination and 
calibration. Discrimination is the ability of the model to separate survivors and non-
survivors. Calibration is the evaluation of the degree of correspondence between 
estimated mortalities and observed mortalities. Descriptions of discrimination and 
calibration and how they are measured are described in Chapter 3. 
2.3.1 Calibration verses discrimination 
The importance of discrimination and calibration will depend on the intended use of a 
model. Discrimination becomes more important if you are interested in individual 
mortality probabilities and their use to aid treatment decisions. However, as this study is 
interested in these models usage in measuring performance of different ICUs, calibration 
becomes more important. There is perhaps, some argument as to how much emphasis 
should be placed on the calibration of the models. Some have argued that discrimination 
should not be considered until a model can show acceptable calibration (21). Wagner, on . 
the other hand, while acknowledging a model must have adequate calibration argues that 
it must also have good discrimination (personal communication). While accepting that a 
model is unlikely to be used appropriately without good calibration, for a model to 
identify those who are likely to live and die it must have good discrimination. If these 
models are to be used to assess performance in different ICUs they must clearly be able 
to identify those at high and low risk. It would be possible for a model with virtually no 
ability to discriminate, to calibrate well, . especially if the probabilities were focused 
around the mortality level of the ICU population (although this is unlikely). 
2.3.2 Changing measures of accuracy 
The accepted tests for accuracy have changed as these models have been developed and a 
discussion of these developments takes place later in the chapter. When the first 
generation of the models examined in this thesis appeared, they reported only 
discrimination using crude classification tables. As the development of models continued 
the use of ROC curves became a standard measure of discrimination. Calibration curves 
were used initially as an indication of calibration. However, the development of the 
Hosmer-Lemeshow GOF test enabled this more robust measurement of calibration to be 
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adopted for most studies. A consensus conference into mortality probability models 
concluded that the performance of models should be determined by both ROC curves and 
the Hosmer-Lemeshow GOF tests (22). More recently, since the start of this study, some 
analysis of subgroups has been used to assess the accuracy of mortality probability 
models. When discussing the development of Intensive Care severity models, research 
reported in the literature will be described by the statistics originally used in the research. 
2.4 The development and history of Intensive Care severity of illness modelling. 
2.4.1 Critical Care Scoring Models 
There are a large number of ~coring models in medicine today, all desig'ned to help 
decision making in s'ome way. These vary from simple subjective models to more 
objective complex models based on statistical methods. The relatively low cost of 
computing has been partly responsible for the increase in the number of models. The use 
of computers to aid clinical decision making was demonstrated as early as the 1950s (23). 
Speglhalter and Knill-Jones have reviewed the different approaches to modelling in 
clinical decision making (23). 
A major factor in America contributing to the large rise in use of models is the way 
health care is funded. Hospitals in the US have increasingly been encouraged to 
demonstrate both their clinical and cost effectiveness. Diagnostic Related Groups 
(DRGs) were an early attempt to adjust for case mix, with patients being allocated into 
related groups more appropriate for payment (24). However, DRGs take no account of 
severity of illness. A number of models have been designed to address this problem and 
have been designed to adjust for hospital case mix (25-29). 
As there are such a large number of models designed to adjust for case mix, this review 
is based largelyqn those associated with critical illness. 
2.4.1.1 Trauma and associated models 
There have been a variety of models developed for trauma patients from the 1970s. These 
have tended to be either anatomical or physiological (13). The first of the anatomical 
models, the Abbreviated Injury Scale (AIS), was developed by the Committee on 
Medical Aspects of Automotive Safety (CMAAS) (30). There have been a series of 
anatomical models since then (31-34). 
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The first physiological trauma model to be developed was the Trauma Index in 1971 
(35). There have been a series of new models since then (36-39) with the most recent 
being the ASCOT model (40) 
2.4.1.2 Other models 
There have been a number of other models in other areas. In 1982 Durocher et al devised 
a pneumonia scoring index which used 12 physiological variables to generate a score to 
indicate severity of illness (41). In 1983 a sepsis score was proposed by Elebute and 
Stoner using 25 physiological variables (42). A model for indicating severity in patients 
with cirrhosis, the Child-Turcotte criteria in medically treated cirrhosis, used 
physiological variables to indicate the severity of the condition (43). There have also 
been a series of models developed for use on Coronary Care Patients (44) 
2.4.1.3 Glasgow Coma Score 
One of the most successful and most widely used scoring systems in critically ill patients 
is the Glasgow Coma Score (GCS). The Score proposed by Teasdale and Jennett in 1974, 
uses three variables to assess the level of neurological impairment (45). These three 
variables i.e. eye opening, motor and verbal responses, are scored as follows: 
Eye opening Motor Verbal 
4. Spontaneously 6. Obeys commands 5. Oriented 
3. To command 5. Localises pain 4. Confused 
2. To Pain 4. Flexion to pain 3. Words only 
1. None 3. Abnormal flexion 2. Sounds only 
2. Extension l. None 
1. None 
Lower scores are an indication of the severity on the coma scale. It is widely accepted 
that the GCS is a good measure of neurological impairment. It has been demonstrated 
that increased levels of severity, as measured by the GCS, can be related to increasing 
mortality (13,46). A study in Scotland, the Netherlands and the US used the GCS to 
adjust for the severity of head injury to allow comparisons of the treatment they were 
receiving (47). Despite a wide difference in severity of injury no difference was found in 
the outcome of the patients. While generally accepted as the best measure of the 
neurological impairment, there are still questions about its use in Intensive Care 
(46,48,49). These tend to focus on the fact that patients are often heavily sedated in 
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Intensive Care, which could give them a much lower GCS than they would have had 
otherwise. 
The models described above have had varying rates of success. It is clear that some fulfil 
the function of adjusting for severity in specific illness. However, they are all specific to 
certain types of disease or injury and do not adjust for case mix in the heterogeneous 
populations of ICUs. 
2.4.2 The development of scoring models in Intensive Care 
2.4.2.1 Therapeutic Intervention Scoring System 
One of the earliest models to attempt to adjust for case mix was the Therapeutic 
Intervention Scoring System (TISS) (50). The basis for the model was the idea that the 
level of intervention would act as a proxy for severity of illn~~s. The model had a list of 
57 variables, each with a weighting somewhere between 1 and 4, depending on the 
indication of severity. The types of variables included in the model ranged from the type 
of monitoring that the patient was receiving, to more invasive procedures like dialysis, or 
insertion and use of a pulmonary artery catheter. The premise was the greater the level of 
intervention the greater the level of severity of illness. 
However, the problem with this model is that intervention is not always associated with 
severity of illness, as the amount of intervention is dependant on the presenting disease. 
Clinicians may also vary in their practice, with some favouring more aggressive 
techniques, which would lead to higher scores than a clinician who favours a less 
interventionist approach. 
TISS has become widely used in ICUs but as a surrogate for workload and as a tool for 
assessing cost (51-54). The model has since been updated by Keene and Cullen in 1983 
(51). There are also many other ammended versions in use by other groups. As there are 
now a number of different versions of TISS, all with slightly different variable lists, there 
is a problem with comparing TISS scores on different units. As many units collect data 
for different versions of the model it makes it difficult to compare TISS scores. There 
has been considerable advances in the treatment and technology used in Intensive Care 
since the last update of the model, however, an ICS working group is presently updating 
and standardising the model. TISS has been used for a number of purposes: 
• Comparing patients (55,56) 
• Quantifying low and high risk patients (56,57) 
• Monitoring low and high risk patients (56-58) 
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• Monitoring Nursing Workload (51,52) 
• Current utilisation of beds and calculating future bed provision. (51,59,60) 
• Resource allocation (53,54) 
• Outcome comparisons in same unit over time and between different ICUs (59,61) 
There are a number of weaknesses in the TISS model, as it is limited in the interventions 
and care it measures. For example patients will often need considerable care even when 
they are less sick, recovering patients may be confused and require a lot of nursing 
attention but this will not be reflected in the TISS score. Dying patients may have 
reduced interventions but increased workload for the staff. 
2.4.2.2 Acute Physiology and Chronic Health Evaluation 
The development of the first Acute Physiology and Chronic Health Evaluation 
, .' 
(APACHE) model in 1981 (62) saw the beginning of the present generation of severity of 
illness models'. These ,were generic models that attempted to measure severity of illness 
directly, on all patients entering ICU. 
Variables for the model were selected, by a panel of seven "experts" representing three 
specialities (Anaesthesiology, Medicine, Surgery), tw'o of whom were the authors. The 
panel chose 34 variables that were considered to be helpful in estimating severity of 
illness, based on evidence found in the literature and on the opinions of the seven experts. 
Continuous variables were grouped into categories, with one category representing 
normal and subsequent categories representing more abnormal values, with the weights 
for most variables from 0-4 (some variables could only get 1 or 2 points). The 
combination of points for each variable then produced the Acute Physiology Score 
(APS), which represented a measurement of severity of illness. The model also included 
a chronic health evaluation, ranging from A to D, with Arepresenting prior good health, 
and D representing severe chronic illness prior to admission to the ICU. 
The first 32 hours after admission to the ICU was used as the time period for data 
collection. Variables not measured or unavailable from within the first 32 hours were 
presumed to be normal. Patients admitted with myocardial infarction, bums patients and 
patients who were in the unit for less than 16 hours were excluded 
Data were collected on 582 ICU admissions over an 8 month period. The authors then 
used multiple logistic regression and probit regression to examine the relationship 
between the APS and survival. The authors added other variables to the logistic 
Page 17 Chapter 2 Literature Review 
regression, age, sex, diagnostic system, chronic health and the patient's surgical status 
(operative or non operative). The authors reported a significant relationship between the 
APS and mortality. They also reported that the chronic health evaluation was only 
significant when it was at its most severe. The authors concluded that although the model 
was not significantly accurate for individual prediction it was an: 
." .... objective means for describing patient characteristics and estimating severity 
of illness over a broad range oflCU patients". 
They also concluded that the model would be able to assess the similarity of severity of 
illness in non-randomised studies. 
Application of the APACHE model: The APACHE model has been tested in a number 
of studies. A study of 700 consecutive admissions from five US surgical and medical 
ICU s that were not in the original study, demonstrated similar accuracy to that found in 
the original study (63). All five ICUs showed an average predicted mortality that was 
close to the observed mortality, The study was carried out by the original developers of 
the APACHE model and only included information from the first 24 hours rather than 
the first 32 hours. The model has also been applied to data from a number of European 
countries (France, Spain and Ireland) (64,65). These studies reported a significant 
relationship between the APS and hospital mortality. Data from a further 833 admissions 
were also analysed (66). Wagner et al reported that the APS from the APACHE model 
was 
" strongly and significantly associated with outcome within a number of 
specific cardiovascular, neurologic, respiratory and gastrointestinal diagnosis." 
The authors argued that after validation the model could be used in other institutions. 
The APACHE model has now been used to adjust for case-mix in a number of studies 
(54,59,67). 
The APACHE model however never gained widespread usage, partly because of the 
large number of variables and considerable effort required to collect the data. There have 
also been a number of criticisms of the APACHE model (68): 
• The variables were chosen and weighted by subjective methods. 
• The developers recognised that, depending on which measurements are made, it is 
possible for the severity to be underestimated. 
• Transfer from another hospital might lead to an underestimation of the model. 
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• As measures were done over the first 24-32 hours, it is not possible to rule out the 
effect of treatment causing an underestimation of severity of illness. 
• The model was large and required substantial effort to collect data on a routine basis. 
2.4.2.3 APACHE II model 
Knaus et al updated the model in 1985 (5). The new APACHE IT model had a reduced 
number of variables, with a shorter data collection period reduced from 32 hours to 24 
hours. The number of physiological variables in the model was reduced, using clinical 
judgement, from 34 to 12. The variable weights were changed on the GCS, creatinine and 
blood gas variables, with the remaining variables maintaining their original weightings. 
The APS in the new model also included variables for age and a new chronic health 
evaluation. The model also included an admitting diagnosis, with 34 separately weighted 
Table 2.1 Variables in the APACHE II model 
Temperature 
Mean arterial pressure 
Heart rate 
Respiratory rate 
Oxygenation 
Arterial pH 
Serum sodium 
Serum potassium 
Serum creatinine 
Heamatocrit 
White blood count 
GCS 
Age 
Chronic health 
Admitting diagnosis 
Score 
GCS, Glasgow Coma Score; APACHE, Acute Physiology and Chronic Health Evaluation. 
diagnoses and a variable for indicating whether the patient was an emergency surgical 
patient. The APS, diagnostic category and emergency operative status were entered into a 
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logistic regression model with the APS, emergency surgery variable, and the diagnosis. 
With the coefficients produced from the logistic regression it was possible to calculate 
probabilities of hospital mortality. There was considerable variation in the crude 
mortality rates in different diagnostic catogories. The authors used the equal performance 
of these groups once the model was applied as an argument for the inclusion of the 
diagnostic category in the model. The authors reported an ROC curve value of 0.86 and 
good association between rising APACHE IT scores and rising hospital mortality. 
Application of APACHE II: The APACHE II model has been tested in a number of 
studies both in the US and internationally. The performance has been variable with 
studies reporting very different results. A number of researchers have reported adequate 
performance claiming that the model is applicable within the pop\jlation tested (69-73) . 
. However, the overall picture varies with some studies reporting poor performance and 
many reporting, negative results in different types of .I?atients. There have been poor 
performances reported on patients with acute myocardial infarction, pulmonary oedema, 
trauma patients, post operative patients and patients receiving total parenteral nutrition 
(74-78). This picture is confusing and inconsistent as some studies report good 
performance in the same patients (79,80). 
One study in the UK is the most comprehensive analysis of the model in the UK (UK 
APACHE II Study) (13,20,73) . The study involved 26 general ICUs from Great Britain 
and Ireland, with 8796 admissions to the ICUs. The study, by the ICS, reported an overall 
GOF and predictive abiljty that was good while Rowan et al reported that they had only a 
slightly inferior performance to that in the original model. They reported an area under 
the ROC curve of 0.83, compared with 0.86 in the original study. They reported a Chi 
Squared value of 79.81 (8 degrees of freedom). However, although the study reported 
that this was a reasonable GOF ,they did not report that the Chi Squared value quoted 
demonstrates a significant difference (p<O.001) between observed mortality and 
predicted mortality. This result may be partly due to the large numbers in the study. 
Rowan et al did report significant differences between observed mortality and that 
predicted by the model in operative patients with cardiovascular, neurological and 
respiratory diagnoses. They also reported significant differences in non operative patients 
with neurological diagnoses. 
There are a number of smaller UK studies of APACHE II (81,82) also showing variable 
performance. Beck et al in 1997 reported poor performance of the APACHE II model in 
a small number of patients from one English ICU, with an overestimation of mortality 
and significant goodness of fit test (P<0.001) (83). A large study (12,762) involving 24 
ICUs in the South West Thames region, though not specifically reporting the 
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performance of the model, showed poor goodness of fit of the model with a Chi Squared 
value of 180.9 (P<0.001) (84). The overall picture remains varied and inconsistent 
The APACHE II model, despite this inconsistent picture, has become the model most 
widely used in both the US and the UK. The model has been applied to adjust for case 
mix for a number of purposes, using the model to: 
• demonstrate the level of severity of illness in research studies. (85) 
• compare units. (20,86) 
• evaluate the efficacy of new treatments (85,87) 
• evaluate cost effectiveness (88) 
• evaluate the outcome of patients (72,86) 
• predict individual mortality (89-91) 
There are a number of criticisms of the APACHE iI model. The model was developed 
and validated on the same patients. As the same patients have been used to develop the 
logistic regression coefficients as have been used to test the model, it would be expected 
that the model would appear to perform well in that data set. It is now widely accepted 
that models must be validated outside the data set in which they have been developed 
(22). The weights for the. variables that make up the APS are derived subjectivdy and 
may not represent the actual relationship the variable has to mortality. The model again 
treated missing results as normal and like the original APACHE model could be affected 
by the differences in data collection. The effect of treatment over the first 24 hours could 
not be ruled out. The start of data collection and where treatment begins could lead to 
possible underestimation of mortality (lead time bias). 
2.4.2.4 Development of APACHE III 
In 1991 Knaus et al proposed a new APACHE model (6). The new model was developed 
using data collected from 41 ICUs from across the US. They collected data on 17,440 
patients from both medical and surgical ICUs. The new model involved some 
fundamental changes from the APACHE II model. The authors compiled a Ii st of 212 
disease categories allowing the choice of a diagnosis to indicate the primary reason for 
admission. These diagnoses were classified into medical and surgical groups and by 
which major organ system was involved. The model also included variables indicating 
the patient's source of admission and length of time at this source. The authors used 20 
physiological variables based on past experience and evidence in the literature. 
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Table 2.2 Variables in the APACHE III Acute Physiology Score 
Pulse 
Mean blood pressure 
Temperature 
Respiratory rate 
Oxygenation 
Heamatocri t 
White blood count 
Creatinine 
Urine output 
Urea 
Sodium 
Albumin 
Bilirubin 
Glucose 
Acid base 
GCS 
GCS, Glasgow Coma Score. 
The data from all 40 ICUs were combined and patients were then randomly split into a 
development and validation set. Weights for physiological variables were derived using 
multiple logistic regression using a mixture of categorical and continuous variables. The 
authors investigated and found significant interactions between some variables. Where 
such interactions were present, combined variables were created and weighted 
accordingly. Weights for the physiological variables were derived from a development 
set and then tested on the validation set. 
Weights were derived for chronic health variables and five year age categories from the 
overall database. Weights for all variables were then converted to integer points to form 
the new APS. Weights for the diagnostic categories were generated from the overall 
sample. However, unlike previous models, the multiple logistic regression equation, and 
the coefficients generated were not published and are now proprietorial, with the rights to 
use the APACHE III model being held by a commercial company (APACHE Medical 
Systems Inc.). The authors also investigated the possibility of using the model as a basis 
for predictions over time. 
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The authors reported improved performance from that demonstrated by the APACHE II 
model. The APACHE III model had an improved discrimination with a reported area 
under the ROC curve of 0.90 compared with 0.85 in the APACHE II model. The overall 
correct classification at 0.50 predicted risk in the APACHE III model is 88.2% compared 
with 85.5% in the APACHE II model. However, as calibration curves were the only tool 
used for measuring the calibration, it is not possible to fully assess this aspect of the 
model. The authors reported that the model reduces the amount of unexplained variation 
in hospital mortality due to previously unmeasured patient characteristics. The authors 
imply that the addition of new variables and their change in approach to the weighting of 
physical variables has improved the model's ability to adjust for case mix. The authors 
claim that the model can be used to ensure that there is equal severity of illness in 
different groups in research trials: They also report that the new model accounts for a 
conside~able proportion of the difference in hospital mortality in different'ICUs 
(R2=O.90). They argue that the majority of the difference between ICUs can therefore b~ 
attributed to patient characteristics rather than treatment. They also go on to claim, that 
the difference between observed mortality is one measure of quality of care, but bed 
availability and screening for admission can vary in different hospitals which effects the 
legitimacy of this analysis. 
The authors, in 1994, continued to further extend the model to provide daily estimates of 
mortality (92). The authors reported good discrimination over the first 7 days of Intensive 
Care, with areas under the ROC curves ranging from 0.90 on the first day to 0.84 for 
patients still in the ICU on the seventh day. They concluded that daily estimates might 
help improve outcome from clinical decision making in Intensive Care. 
Application of APACHE III: The APACHE III model has been used in a number of 
studies (57,93-99). However, the model has not enjoyed such wide spread usage as the 
AP ACHE II model. This is almost certainly because in order to use the model, studies 
would have to pay a licence fee for both the usage of the software and the APACHE III 
equations, although the equations are available free on request to researchers. The 
reported studies investigating the performance of the APACHE III model have recorded 
differing performance. Other studies have reported similar results to the original model 
(100,101). However, a Brazilian study showed a considerable underestimation of 
mortality in 1,734 patients despite reasonable discrimination (area under the ROC curve 
0.82) (102). The study further reported that this discrepancy was, in part, associated with 
the level of technology available to the different units (103). 
A small study in a UK ICU reported that the APACHE III model had reasonable 
discrimination (area under the ROC curve 0.847) (83). However, the model showed poor 
calibration with a consistent underestimation of mortality, reflected in both the 
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calibration curve and the Hosmer-Lemeshow GOF test. The study also reported poor 
calibration in different diagnostic categories, but the results from the analysis were not 
consistent as some diagnostic groups showed poorer fit than others. The numbers in this 
study were relatively small (n=1,144) and it is therefore hard to draw any firm 
conclusions. There has been a large UK study of the APACHE III model in 17 ICUs in 
the South West Thames area. The study reported results on 12,793 patients (84,104, lOS). 
The results reported better discrimination than that reported in the original paper. But the 
study showed poor calibration and reported a significant difference between observed 
mortality and that predicted by the model, with a significant Hosmer-Lemeshow test 
(~=S43.12~ P<O.OOl). 
The APACHE III model has been used in a number of studies to: 
• assess the cost and outcome in different ICUs (96,97). 
• make comparisons of outcomejn d,ifferent ICUs (98) 
• predict the likelihood of life support in the following 24 hours (9S) 
• examine process in ICUs and compare with case mix adjusted mortality (94). 
• adjust for case mix in a study assessing the effectiveness of right heart catheterisation 
.(93). 
The new model was developed with less subjectivity, with weights being generated using 
statistical methods. Although the developers from the original studies have demonstrated 
improved performance in the APACHE III model there have been a number of criticisms 
of the model. Some of the weights in the new model were based on data from a 
development cohort and then tested on an independent cohort. However, the results from 
the overall model were from analysis of the total data set. There is general consensus that 
models must be validated and tested on independent cohorts (22). To use the model, 
ICU s must pay for both software and for the use of the equation, thus making access to 
validate the model difficult The authors of the original study have reported calibration 
curves but have not reported Hosmer-Lemeshow GOF. tests which is the standard 
measure of GOF (22) as indicated by a con~ensus conference on mortality prediction. 
2.4.2.S Development and Application of Simplified Acute Physiology Score 
The Simplified Acute Physiology Score (SAPS) model was proposed in an effort to 
produce a simpler severity of illness model than the APACHE model (106). Le Gall et al 
used statistical techniques to determine which of the 34 APS variables was significantly 
associated with mortality. The SAPS model reduced the number of variables to 13 
mandatory variables in an effort to reduce the bias produced by missing values. The 
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authors proposed the model as a means of classifying patients into groups that composed 
of comparable probabilities of death. 
As with the APACHE model, the authors showed good correlation with mortality when 
tested on 126 patients. The model has been applied in a number of studies with different 
groups of patients. (74,107-109) 
Development of SAPS II: The model was updated in 1993 by Le Gall et al (3). The new 
model (SAPS II) was based on a large cohort of patients (14,745) taken from 137 ICUs 
from 12 different countries. The authors split the database into a development set (8,369) 
to construct the model and a validation set to test the model (4,628). The study collected 
data on 37 v~ables ,and tested each to determine an independent association on hospital 
mortality: Of the 37 variables 17 were included in the final model. The LOWESS 
smoothing function was used to determine the categorisation of variables before using 
multiple logistic regression to determine the weightings for each of the variables and 
their categories. The development cohort was then used to develop a multiple logistic 
regression equation that would allow the calculation of a probability of mortality for each 
patient. The equation included the score but also a log transformation of the score to 
compensate for the skewed distribution of the score. Results reported for the new model 
suggested that the performance was good, with an area under the curve of 0.86 and a non 
significant Hosmer-Lemeshow test. Probabilities of mortality were calculated for the old 
SAPS model to allow comparisons with the older model. The new model would appear to 
be a significant improvement, with the area under the ROC curve for the old model of 
0.80 compared to 0.86 in the new model. 
The authors concluded that the model is 
" .... an extremely effective system for estimating the probability of mortality for 
ICU patients." 
However, they also concluded that any future research should concentrate on testing the 
model in common cohorts, using all available systems. The authors suggest that the 
system should be used for analysis of aggregated data rather than for individual patients 
and any result treated with considerable care. 
Page 25 Chapter 2 Literature Review 
Table 2.3 Variables in SAPS II model 
Heart rate 
Systolic pressure 
Temperature 
Pulmonary artery pressure (if ventilated) 
Urinary output 
Serum urea level 
White blood count 
Serum potassium 
Serum sodium 
Serum bicarbonate 
Bilirubin 
GCS 
Chronic health 
Type of admission 
GCS, Glasgow Coma Score 
Application of SAPS II: The new SAPS II model has been more widely used than the 
original model. There have been a number of studies looking at the performance of the 
SAPS II model with a variety of results (110-113). Castella et al published results based 
on the data from the European and American multi-centre study, from which the SAPS II 
model was developed and initially validated (21). These results showed that the SAPS II 
model had a better performance than the original model. However, by far the largest and 
most important evaluation of the SAPS II model has been as part of the EURICUS-l 
study (114,115). The model was tested on a database of 16,060 patients admitted 
consecutively to 89 ICUs. The model had good discrimination with an area under the 
ROC curve of 0.82. However, the model exhibited poor calibration with a significant 
Hosmer-Lemeshow test and large variations in the performance of different subgroups of 
patients. 
The Model has been used in a number of studies (41,116,117). 
The SAPS models have been criticised for not including a diagnostic element. The 
argument is that the probability of a patient surviving ICU treatment will be profoundly 
affected by the underlying diagnosis. Le Gall et al discuss this in the paper and conclude 
that it is not possible to accurately include a diagnostic weighting in the model (3). They 
point to the difficulty in choosing one diagnosis in ICU patients who often have very 
complex underlying disease processes. 
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2.4.2.6 Development of the Mortality Probability Model 
There have been two distinct phases in the development of the Mortality Probability 
Models (MPM). The first was the development of the original MPM model and the 
second the development of the MPM II model, which will be described later in this 
chapter. The development of the original MPM model occurred over a number of years 
and involved the production of a number of different models. 
In 1985 Lemeshow et al proposed two models which were both developed from an 
original data set of755 admissions to a single US ICU(118). They collected data on 137 
variables at admission and 75 variables at both 24_. and 48 hours. Using a stepwise linear 
discriminant function they determined which variables were significantly associated with 
mortality at admission and for patients who remained in the ICU after 24 hours. The 
developers produced two models, one including variables collected before or on 
admission (MPMo-of) and one using variables from both before and since admission up 
to an initial 24 hour period (MPM24). Each of the models contained 7 variables. The 
MPM models required only a yes/no answer to questions. This makes data collection 
much ea.sier with less likelihood of missing data. 
In 1987 a second admission model was proposed containing 3 more variables related to 
cardio-pulmonary resuscitation (MPM O-cpr) (119). In 1988 Lemeshow et al introduced 
three new models based on an increased data set of 1,997 patients (120): a new 24 hour 
model, a model calculated for patients remaining in ICU at 48 hours (MPM48) and a 
model predicted over time (MPMov. Underpinning the MPM models was the principle 
that the probability of mortality would change over time, and that the importance of 
different variables may change as well. The same principles of univariate testing of the 
variables for association with mortality, before entering into a multiple logistic regression 
model; were applied. ' 
Little is published on the performance of these early models. They report discrimination 
in the form of classification tables for a cut off point of typically 50%. The first 
admission model MPMO-ofm had a correct classification of 87% with the original 
MPM24 reporting 85% (118). Teres et al reported a correct classification for the original 
MPMO model of 86% with the new admission model MPMO-cpr having a classification 
of 85% (119). These are crude measures of discrimination and give us little picture of the 
overall performance of these models. Schaefer et al in 1990 validated the MPMo-cpr 
model on an independent database, describing a significantly higher mean probability of 
death for those that died than those that survived (121). 
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The numbers involved in constructing these models are small, with the revised models 
based on data sets of no more than 1,997 patients. It is also hard to get a picture of how 
these models correlated with severity. However, there were certain advantages in these 
new models when compared to their contemporary APACHE model. The models have 
small numbers of variables and data are therefore easy to collect, with data less likely to 
be missing. Also, as the data required could be collected in a boolean form (011), data 
collection was made easier. It can be argued that the avoidance of choosing a diagnosis or 
treatment variable can make the system much easier to use as it avoids the difficulty of 
having to choose a single precipitating factor for ICU admission. The MPMO model, 
calculated on admission, is unaffected by the treatment received on the ICU. 
i 
Although collection of data is easier, one criticism of the model is that to answer some of 
the qllestions requir:es a certain amount of interpretation which may introduce bias into 
the measurement. Another is that the model has not been adequately tested outside the 
institution within which it has been developed. Therefore it is impossible to make 
judgements about its applicability in other settings. 
2.4.2.7 Development ofMPM II 
In 1993 the authors published an updated version of the MPM model (MPM II) (4). The 
model used data gathered on 6 US adult general ICUs as well as data from the European 
and North American Study of Severity Systems used in the development of the SAPS II 
model. Data were collected from 137 ICUs from 12 different countries as well as the 6 
US ICUs. The data from the 6 US units were divided by time, 65% were taken from the 
earlier part of the study to form a development set. The remaining time period making up 
a validation set. The patients from the joint study were randomly divided in a 65/35 split 
with 65% forming the development set and the remaining patients going to the validation 
set. The two development sets and the two validation sets were combined to form one 
development set and one validation set. Data were collected on 19,124 patients who met 
the study inclusion categories, with 12,610 patients in the development set and 6,514 
patients in the validation set. 
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Table 2.4 Variables in MPMo model 
Coma or deep stupor 
Heart rate 2: 150 beats/min 
Systolic blood pressure::: 90 mm Hg 
Chronic renal insufficiency 
Cirrhosis 
Metastatic neoplasm 
Acute renal failure 
Cardiac dysrhythmia 
Cerebrovascular incident 
Gastrointestinal bleeding 
Intracranial mass effect 
Age 
Cardiopulmonary resuscitation prior to admission 
Mechanical ventilation 
Non elective surgery 
Table 2.5 Variables in MPM24 model 
Age 
Cirrhosis 
Intracranial mass effect 
Metastatic neoplasm 
Medical or unscheduled "" .. ·n",·., 
Coma or deep stupor at 24 hour 
Creatinine> 176.8 ~mollL (2.0 mg/dl) 
Confirmed infection 
Mechanical ventilation 
Partial pressure of oxygen (Pa02)< 7.98 kPa (60 mm Hg) 
Prothrombin time >3 sec above standard 
Urine output < 150 ml in 8 hour 
Vasoactive 
Two models were developed, one for patients on admission (MPMO) and one for patients 
who remained in ICU at 24 hours (MPM24). The MPMO model contained 15 variables 
(Table 2.4) all requiring yes/no answers. The MPM24 model was developed using 5 of 
the variables from the MPMO model which were significantly associated with mortality 
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for patients who remained in the ICU after 24 hours and 8 new variables significant over 
the 24 hour period. The authors used univariate analysis to select variables that were 
significantly associated with mortality before entering all significant variables into a 
multivariate logistic regression. 
The authors reported good discrimination and calibration, with an area under the ROC 
curve of 0.824 and a P-value for the Hosmer-Lemeshow GOF statistic of 0.327 in the 
validation set for the MPMO model. The MPM24 model was reported to have an area 
under the ROC curve of 0.836 and a P-value for the Hosmer-Lemeshow GOF statistic of 
0.231. The original MPM models were also applied to the data showing poor calibration 
with significant Hosmer-Lemeshow statistic (P<O.OOI) for both the MPMO and the 
MPM24 model. The authors argued that this demonstrated the need for regular updating 
of severity 'of illness models. The authors also demonstrated significant differences 
between patients t:emainingin the leu at 24 hours and those patients discharged alive· 
over the 24: hour period. This confirmed the argument for constructing two models for 
different time periods. 
Lemeshow et al developed models for 48 and 72 hours from the same database (122). 
Using the same variables from the 24 hour model, the authors re-weighted the variables 
to reflect changing probabilities over time. Both models showed better performance over 
time for the patients remaining in at 48 and 72 hours, than that demonstrated by the 
MPM24 model on the same cohorts. 
Application of MPM II: Like the APACHE II, APACHE III, and SAPS II models, the 
MPM II model has been used and evaluated in a number of studies (123-128). Results 
from analysis of the European and American multi-centre study showed that the older 
MPM models had poorer performance than the newer MPM II models (21). However, 
this is not surprising as these represented a large proportion of the patients from which 
the MPM II models were developed. Data from the EURICUS-l study showed that the 
MPMo model had poorer performance than that described in the original study, with the 
MPMO model significantly overestimating mortality (114,129). Although the model had 
reasonable discrimination, with an area under the curve of 0.785, the calibration was 
poor, with a significant Hosmer-Lemeshow test (P<0.001). The model also showed poor 
performance when analysed in important subgroups, with significant differences in the 
mortality observed and that estimated by the model. (115). 
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2.5 Developments since the beginning of study 
Funding for this study began in June 1994 with data collection beginning in January 
1995. At the beginning of the study little had been done to consider the performance of 
these models outside the populations in which they had been developed. Since the study 
began there has been a considerable amount of work carried out and published in this 
field some of which has already been described in this chapter. This literature has not 
only concentrated on looking at the performance of models in different populations, but 
has also included customisation of the models described earlier, where performance has 
been shown to be poor. There has also been considerable debate as to whether these 
models can be used for detecting differences in the quality of care in different units. The 
following sections will attempt to describe the developments in the area of severity of 
illness scoring models since the beginning of this study. 
2.5.1 Comparisons between models 
. There have been a considerable number of studies which have looked at the performance 
of the most up to date models we have described (APACHE II, APACHE III, SAPS II 
and MPM IT) (68,83,100,101,111-113,130-136). Most of these have been small, or have 
described the performance in certain types of patients. There have been two large 
international studies that have compared the performance of these models. The first of 
these used the data collected as part of the European and American multi-centre study 
(21). The development of both the SAPS II model and the MPM II model were based on 
data from this study. The study used all the data available when comparing the 
performance of the older systems (SAPS, MPMQ, MPM24 and APACHE IT) allowing the 
comparison on 12,802 patients. The newer models (APACHE ITI, MPM IT, and SAPS IT) 
were compared on the validation sample from both the MPM II and SAPS II studies, 
allowing the inclusion of 4,101 patients in the analysis. By using only the validation 
sample the authors were attempting to avoid the bias of using the development set, 
although the study only included the APACHE III score as the rest of the equation was 
not available. The study reported that the newer models had better performance then the 
older models. It concluded that 
" ..... the new systems represent real improvement in severity model performance. II 
The authors go on to say that no one model is superior to another and that all the models 
in the study can be used with reliability. However, they stress the importance for testing 
models to check for adequate fit before being applied in different countries. However, the 
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MPM II and SAPS II models were developed on data taken from the same ICUs. As the 
development set was a randomly selected group it would be expected that the profile of 
the validation cohort would be very similar to that of the development cohort. It would be 
expected that the MPM II and SAPS II models would have good performance, especially 
in calibration. The other "new" model, the APACHE III, could not be tested for 
calibration as the score was the only part of the model available. As none of the older 
models were developed on this population it is not surprising that these models showed 
poorer calibration. A critical appraisal and systematic review of these models published 
in the same year (68) concluded 
"Direct comparisons of existing severity indices with respect to their calibration, 
discrimination, and reliability in different population sets are necessary in order 
for consumers to make informed choices between available models." 
Teres and Lemeshow (137) in an editorial in Critical Care Medicine argue that there are 
only five studies (83,102,110,114,138) that have published enough detailed information 
on calibration and discrimination to allow any assessment on the performance of models 
in alternative settings to those in which they were originally developed. These, they, 
argue, are consistent in showing that the new generation of models have good 
discrimination but poor calibration. One of these studies is the only other large study to 
have compared the performance of models in a large data set (114). This study is part of 
the large EVRICUS-l study collecting information from 89 ICUs within 12 European 
Countries. The data on this study have been published in a number of papers 
(114,129,139,140). Reporting results on data collected from 16,060 patients, they include 
comparisons of performance between the SAPS II and MPM II (MPMO) models., The 
study shows better discrimination in the SAPS II model, which has an area under the 
ROC curve of 0.822 compared with the area under the ROC curve of 0.785 in the MPMO 
model. The calibration in both models has been poor with SAPS II having a Chi Squared 
value of 208.4 and the MPMO model having a Chi Squared value of 368.2. Both these 
values show significant differences between the observed mortality and the mortality 
predicted by the models (P<0.0001). The authors have also introduced the idea of 
uniformity of fit (115), where they argue that models must also have good performance 
in important subgroups. If models are to reliably identify quality of care issues then the 
adjustment for case mix must be adequate. This cannot be the case if certain subgroups 
with certain characteristics are poorly estimated. Other authors have pointed to this issue 
(73,86,110). The study showed in large important subgroups that there were significant 
differences between actual mortality and the mortality estimated by the models. 
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Data for the EURICUS-l study were collected on ICUs from 12 different European 
Countries. The ICUs are not necessarily representative of the ICU culture in their 
countries. There is a wide range of severity of illness in the different ICUs used in the 
study and this is reflected in the range of estimated mortality from the different ICUs 
(SAPS II, 2.9%-34.8%~ MPMO 3.9%-39.3%). This study has reported an average , 
hospital mortality rate of 20.0% which is considerably lower than the 27.7% and 26.3% 
reported in other studies from the UK (20,83). There are two elements of these models 
that still remain unanswered: 
• the performance of all the models (APACHE III, APACHE II, SAPS II, and MPM II) 
in the same independent large database. 
• the performance of all the models in a large database. in the same ICU culture or 
country. 
So, although there has been considerable work in this area, these two areas of model 
performance still remain to be evaluated. 
2.5.2 Customisation of models 
A possible solution to the apparent lack of fit of these models when applied to different 
settings, may be to use a process of customising the existing models so that they better 
reflect the mortality experience in different countries. Lemeshow et al introduced the idea 
of customising models to adjust for groups of patients who show poor fit (4). Le Gall et 
al reported analysis from a study customising the MPM II and SAPS II models to 
provide better fit with sepsis patients (141). The authors reported improved calibration 
with an improved Hosmer-Lemeshow test for the new models. 
Using data from six North American ICUs on 4,224 patients, Zhu et al investigated two 
strategies for customising the MPM II model (142). One strategy was to use the logit in a 
, regression model to produce a re-weighted model, the other strategy involved re-
weighting all the variables 'in the MPM II model. The study looked at the effect of 
customisation on changing accuracy of mortality of the MPM II model. This was done by 
simulating changes in mortality and analysing the effect this had on both the area under 
the ROC curve and the Hosmer-Lemeshow statistic. The authors then looked at the effect 
of the different customisation strategies and the effects these had on improving the 
accuracy of the mortality. The study concluded that both strategies could bring improved 
calibration to the model. However, the re-weighting of all the variables rather than just 
the logit was a better approach with a larger sample size. 
There have been two large studies looking at the effect of customisation on the accuracy 
of different severity models. The first used data from the EVRICUS-l study (n=16,060) 
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and looked at the effect of the two strategies outlined previously on changing the 
accuracy of the MPMO model (129,139). The authors reported little change in 
discrimination in the validation set for either types of customisation. There was 
considerable improvement in the calibration using both strategies illustrated by improved 
Chi Squared values. Results from comparisons in the validation sample showed an 
improved Chi Squared value in the customisation of the logit only model of 133.76 to 
2l.68. In the variable model, the improvement in the Chi Squared value was from 133.76 
to 20.94, with the lower Chi Squared value representing a better calibration. Both 
strategies resulted in models that had no significant differences between the observed 
mortality and the estimated mortality. However, despite the improvement in the model's 
calibration after customisation, the authors found insufficient improvement in the 
. . 
analysis of the uniformity of fit to overcome all the problems of applying the MPMO 
model to their data. Some subgroups of patients still had significant .differences between 
the observed mortality and the mortality estimated by the MPMo model. 
The other large study to have assessed the effect of customisation on the performance of 
a severity of illness model was the customisation of the APACHE III model in 10,929 
patients from 86 Spanish ICUs (143). The authors reported good performance in the new' 
model with an. area under the ROC curve of 0.82 and non significant Hosmer-Lemeshow 
test (.fl=12.27). No results of the model before calibration were reported, except to say 
that the original American model had a slight underestimation of hospital mortality. No 
analysis of the effect on uniformity of fit was reported either. It is hard to assess the 
effect of customisation in this study as results for the model before customisation were 
not published. 
2.5.3 To score or not to score? 
There has been a debate as to whether it is possible to use severity of illness models or 
not. Although, this study is not designed to answer this question, there are some relevant 
aspects of the debate. The debate is often dichotomised, and there is a presumption that 
there isa yes or no answer. However, the issues are more complex than this and many 
authors express caution rather than a belief that severity models cannot be used. 
It has been suggested that the severity models described above can be used to predict 
individual mortality. The reported accuracy of all these models would suggest that, as 
yet, this is not the case. Lemeshow et al (144) have said 
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" .. model s for estimating severity of illness in intensive care unit (ICU) patients, 
while demonstrating good agreement for describing patients in the aggregate, are 
shown to differ considerably for individual patients." 
They go on to conclude 
"This suggests that identifying patients unlikely to benefit from lCU care by using 
models must be approached with considerable caution." 
Kollef et al claimed that most physicians did not rely on scoring models to make 
decisions about individual predictions (145). However, the models could be used to add 
evidence to the decision making process. This point was made by Knaus et al (6) who 
said that scoring models 
" ...... canensu,re that the experiences·of the past are taken into consideration in an 
unbiased manner." 
However, there would appear to be a general consensus that these models are not 
accurate enough to predict individual mortality (146) 
In an editorial in the Lancet, Boyd and Grounds were among the first to question the use 
of scoring models for comparing ICU performance(147). With reference to APACHE II, 
the editorial highlights the effect treatment may have on the apparent performance of an 
lCU. The authors point to the fact that patients receiving poorer treatment but surviving 
will have a worse score than the equivalent patient who has received good treatment. The 
first patient's severity score will be higher because of poorer treatment. The authors 
conclude: 
"The very accuracy of these scoring systems for assessing the severity of illness 
. precludes their use for comparison and Audit" 
On the other hand, a small study in Canada used APACHE II to flag patients with a low 
severity of illness who subsequently died (148). They compared this method against a 
10% random sample in an effort to identify potential quality problems. Using a 
physician's evaluation as a gold standard, the study concluded that the performance of the 
AP ACHE II model in identifying problems of quality was much better than using a 10% 
random sample. Other studies have used severity models to highlight issues of quality. 
Wagner reported a New England study (149) that used a severity index to highlight 
problems of quality in cardiac surgery, allowing for a change in practice which 
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subsequently led to an apparent improvement in quality. A study by Zimmerman et al 
looked at data from nine units using the APACHE III model (94). The performance of the 
units was ranked using mortality ratios. Units were visited by a team of clinicians and 
organisational researchers who assessed the units on a number of aspects of the ward's 
performance. Areas thought to have a possible influence on outcome, like management 
structure, were assessed by the research team and then the ICUs were ranked according to 
how well the research team felt they had performed. The authors found that there was no 
correlation between the ranks produced by the team and those produced by the APACHE 
III model. The authors concluded that this showed clinicians were unable to assess 
quality of care. However, they could equally have concluded the same about the 
AP ACHE III model. The study's results were inconclusive and may have merely 
highlighted that there was little difference between the units. 
Teres et al argped in 1993 that Intensive Care severity models should be used with 
caution (150). The authors suggested that, despite being based on larger databases and 
despite increasing accuracy, these models may not adequately describe important 
conditions (acute respiratory distress syndrome and multi-organ dysfunction). 
Becker and Zimmerman (151) argued that 
"Any prognostic model that established a predicted hospital mortality rate for 
each ICU based on a representative data base and a patient-by-patient 
measurement of risk allows ICUs to compare their observed versus predicted 
outcomes". 
They also argued that the mortality ratio (observed/estimated) provides an outcome based 
measure of the effectiveness of care. Concerns over the influence of prior therapy and 
treatment on the accuracy of probabilities, they argued, have not been supported by data 
or comparative studies. They also said, in the same paper, that increasing evidence would 
suggest that the mortality ratio is little influenced by prior therapy but. gave no references 
to support this claim. They went on to state that too much time and effort is spent trying 
to "pass final judgement" on whether systems are "good" or "bad". The authors said that 
there is substantial evidence from existing studies that demonstrate the usefulness of 
these models. 
Sherck and Shatney in the same journal argued that it was not possible to measure ICU 
performance or quality of care using these models (146). The authors pointed to four 
reasons why the reliability of these models in comparing ICUs should be questioned. 
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I. The methodological problems of earlier systems have not been corrected entirely by 
the new systems. Missing variables are treated as normal, which remains questionable 
especially in the case of the GCS. Choosing a single diagnosis can be difficult especially 
in more complex Intensive Care patients. 
2. Some subgroups are poorly predicted. 
3. Potential variations in patient mix precludes accurate comparison. Models have been 
shown that they do not transport easily to other cultures. 
4. The models only evaluate mortality which is not in itself an accurate measure of 
quality. Other measures like quality of life may be more valid in ICU performance. 
They concluded that researchers have been driven by pressures from regulators and the 
desire to predict mortality objectively and reliably. They also concluded that despite the· 
advances in this area there is still no system that provides useful prognostic data. 
Fidler, using data from the EURICUS-I study, looked at the performance of 79. different 
ICUs(140). Using two differe~t types of regression (multiple regression and fixed effects 
logistic regression) they looked at a number of factors and their effect on the 
standardised mortality rate. The author found five factors that affected ICU performance. 
These were: 
I. Number of beds (optimal number is 9) 
2. Organisational commitment 
3. Results oriented culture 
4. Elementary organisational framework 
5. Country 
They also concluded that units who performed well on high risk patients did not 
necessarily perform well on low risk patients and vice versa. 
Those expressing caution in using these models for measuring ICU performance and 
more generally for case mix adjustment, have pointed to a number of weaknesses in the 
methodology of the models. Rowan argues that the reliability of case mix adjustment is 
determined by a number of factors (152). 
• Input variability 
- Location of the study 
- Ascertainment bias 
• Procedure variability 
- Exclusion criteria 
- Rules and definitions governing data collection 
- Time frame for data collection 
- Handling of data prior to analysis 
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• User variability 
The author went on to say that before adjustment for ICU performance takes place these 
factors must be taken into account. 
2.5.4 League tables 
Work in other areas of medicine has looked at the validity of ranking hospitals or units 
into "League tables". It is not the purpose of this thesis to examine the validity of League 
tables but there is some relevance in the debate to measuring ICU performance. The 
Clinical Resource and Audit Group (CRAG) in conjunction with the Information and 
Statistics Division (ISO) of the NHS' Common Services Agency have, since 1993, 
produced four reports into clinical outcomes (153-156). These are based on data collected 
on individual patients for every hospital admission in Scotland. These include· 3'0 
indicators from different areas of practice. There has been fierce debate as to the 
usefulness of these 30 indicators with their publication resulting ina number of studies 
into the legitimacy of League tables (157,158). However, in a recent paper Kendrick et al 
argued that despite the issues surrounding the validity of these indicators they are the best 
knowledge we have on outcome (159). If their use is collaborative and comparative then 
clinicians are more likely to use the best evidence around to judge best practice. 
Goldstein and Spiegel halter, while acknowledging the need for establishing appropriate 
measures of institutional outcomes, emphasise the need to understand the limitations of 
the statistical methods used in comparing performance of institutions (160). They say that 
" ... the continuing official publication and ranking of unadjusted scores lends any 
comparisons based on them an authority that they do not have. " 
However, they also say that 
" .... comparative information about institutions can be useful if handled sensitively 
with due regard for all their problems, and that this must inform public 
dissemination. " 
Leyland et al developed measures of performance of maternal and neonatal care by 
controlling for case mix (161), concluding that these measures were valid and allowed 
comparison between hospitals or comparison with the data for all Scottish maternity 
hospitals. Marshall and Spiegelhalter using data from 52 in vitro fertilisation clinics 
assessed the extent to which clinics could be "reasonably ranked" by live births rates 
(158). They concluded that the ranks were an extremely unreliable statistic in indicating 
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performance or change in performance. Parry et al also tried to assess the reliability of 
crude mortality as a measure of performance in neonatal ICUs and concluded that, as an 
indicator, it was not very reliable as a measure of performance or best practice (157). 
They also stated that any use of annual league tables based on crude mortality could be, 
at worst, detrimental or at best just irrelevant. 
Although this thesis is not about assessing the value of "League tables" it is possible that 
scoring systems analysed in this study may be used in this way. Also, the effect of 
inaccuracies in the models and their possible impact on ranking will be discussed in this 
thesis. 
It is clear that before using these models to assess ICU performance, they, need to be fully 
tested in the population in which it is intended to use them. Before applying these models 
to any Audit of Scottish ICUs, it is important to understand their possible weaknesses. 
Also, given the most recent studies in this subject, if the performance is poor then it is 
possible this may be improved by some sort of adjustment for the Scottish population. 
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3.1 Participating units 
In 1994 , 24 Scottish general ICU s were identified and were invited to take part in the 
study. Eighteen general ICU s of whom 8 were in teaching hospitals and 10 were from 
non teaching hospitals collected data for the study. Four units characterised as High 
Dependency Units (HOU) / ICUs also took part and were within non teaching hospitals. 
These units are in small district general hospitals and admit predominantly patients who 
do not require organ support. However, they do have the capacity to admit limited 
numbers of patients who require organ support. Consultants in these units were asked to 
identify from the outset when a patient was being admitted for a purpose other than 
recovery monitoring. Ideally, all admissions would have been admitted to the study, 
however, it would not.have been possible for such units to undertake the work involved 
in the scoring of all admissions. Thus, 22 ICUs in 22 hospitals collected data for a two 
year period from the 1st January 1995 to 31st December 1997. This represented all but 
three general adult ICUs known at that time. Two of these units agreed to take part in the 
study but wanted to maintain their own software. However, due to the difficulty in 
changing their exist~ng software these units were unable to provide the study with any 
data. A further unit was identified and has since been invited to join the Audit, but was 
not recruited in time for this study. All patients were followed up to hospital discharge to 
ensure that those HDU/ICU patients not entering the study had a mortality consistent 
with that expected for an HDU population. 
3.2 Audit personnel 
The Audit was co-ordinated from an office in the Victoria Infirmary anaesthetic 
department and had two full time staff (Table 3.1). The day to day running of and 
management of the Audit was undertaken by the author. A Research Nurse was 
employed to undertake a validation of the quality of the data collected for the study. The 
rest of the Audit's work was undertaken by volunteering medical and nursing staff. A 
consultant anaesthetist based in the Victoria Infirmary was responsible for the overall 
management of the project. Each unit designated a consultant with local responsibility for 
management of the Audit. A list of these can be seen in Appendix 1. The right to use the 
AP ACHE III model and software was purchased from APACHE Medical Systems Inc 
(AMS). 
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Table 3.1 Audit Personnel 
The Author 
(PhD studentshi p) 
Consultant 
Local Consultant 
Day to day management of 
Audit 
Overseeing of Study 
Local 
3.3 Installation of computers and software 
A computer, printer, modem, and software were installed on 21 of the participating ICUs. 
. ' 
The remaininglCU chose to update their existing PC-based software to collect the 
dataset required for the study. 'A training package for the installation of the computers, 
use of the software, and implemen~ation of the rules for data collection was developed. 
This training package was then piloted, changed and re-piloted before a final package 
was decided. This process and the issues around training have been reported elsewhere 
(162). In the pilot study training had taken place over a three day period. This was 
considered impractical as the time it would have taken to install all the computers would 
have seriously curtailed the data collection period. It was therefore decided to install 
computers and train staff in one day. 
3.4 Computer training. 
The training protocol was as follows: 
Preliminary visit to unit: All units were given a preliminary visit, to arrange a date for the 
installation and training in the use of the computers and software, and to allow the 
discussion of a number of issues regarding the study, i.e. wp.o would collect which data, 
who would be responsible for the management of the Audit, the need for a separate 
modem line and where the computer was situated (preferably on the unit). Although the 
study was being administered by the Scottish Intensive Care Society, a predominantly 
medical organisation, a member of both medical and nursing teams was requested to be 
present at this meeting. 
Computer set up: Computers and software were set up for each ICU before being 
delivered to the ward. This meant customising software for each unit to include a bed 
plan of their unit, lists of admitting consultants and wards, and the setting up of password 
protecti on. 
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Installation of the computer package: On arrival at the ICU the computer, modems, and 
printers were installed on the unit. 
Basic training: Training to use the computer and the software for basic data collection 
was given. This included computer based training on the reason for and purpose of the 
Study. This training was given in groups of two (preferable) and in no more than three. 
The training was interactive with the users being encouraged to try inputting data to the 
software. 
Training of Audit Managers: It was recommended that there would be two Audit 
Managers, one from the medical team and one from the nursing team. ICUs were 
encouraged to choose senior staff for these roles. The same basic training was followed 
by more intensive training on the management of the Audit software and the rules for· 
collection of the data. It was the r~sponsibility of the AuditManagers to then teach the 
relevant staff on the units. Audit Managers were encouragedib see how the system could 
be used to meet the information needs of the individual ICU s and by so doing it was 
hoped to instil a sense of ownership in the data. The ICU that maintained its existing 
software was also given training in the data collection rules. 
Follow up services: ICUs were encouraged to start collection of data from the day after 
the installation of the computers. The Audit Staff ensured that there was someone 
available by telephone for the two days after training days, to allow any questions to be 
answered. We also provided a phone service throughout the study to answer questions 
about any aspect of the data. This included any software problems that might arise. All 
computers on each of the ICUs had software that allowed a remote connection to be 
made and the ICU's computer could be viewed by us, allowing further explanation and 
training to be carried out from the central Audit office. As part of a data validation 
programme (see Chapter 4) the Research Nurse returned to each ICU once a quarter to 
allow staff an opportunity to talk about any problems they may have been experiencing. 
Manuals detailing the study protocol and data collection rules for the APACHE III model 
were left on all the wards (Appendix 2). Where issues of ambiguity arose, confirmation 
of the correct procedures or rules was sought from AMS. 
Only data collected from 1995 onwards were used which meant that most ICUs had been 
using the software for a month or more before any of their data were used. 
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3.5 Ward Watcher Software 
Data were collected on 21 ICUs using the Ward Watcher Software, which was provided 
under licence by AMS, with one ICU using PC-based software developed by Dundee 
University, Computing Science department. The Ward Watcher program is a 
comprehensive ICU Audit and clinical data system. The software was commercially 
available and was licensed by AMS for the collection and calculation of the APACHE III 
model. The software was considerably altered to collect information on all the models in 
the study, except the UK APACHE II model which was calculated retrospectively. On 
the one unit retaining their., own software, data were downloaded from the system once 
every quarter. The data were imported into a Ward Watcher database at the central Audit 
office where the probabilities for all of the models were calculated. 
There were certain advantages of all but one of the units using the Ward Watcher 
software. These were as follows: 
• ICU s recorded the data in the same format and under the same data entry criteria 
which gave a consistency not available if all units collected on different software. 
• Supporting the data collection was less problematic as ICUs were using the same 
computer set up. 
• All rules for data collection were included within the software at the particular data 
entry point. When in a data entry area, users could click on a question mark to show 
the relevant rules. 
• Range checking asked users to confirm values when they were at the outer limits of 
possible values. 
• The rules for choosing the correct value in the different models are complex, so to 
reduce mistakes users entered the lowest and highest values. The value which was 
used to calculate the probabilities was then chosen by the software. 
• Although primarily for the collection of data for the study, the software was a 
powerful clinical system allowing the users to collect a considerable amount of other 
data which was of specific interest to individual ICUs. 
• The system also included easy-to-use search and report facilities allowing users to 
interrogate their own data. 
• Providing units with a computer, a colour printer and clinical Audit software would, 
it was hoped, help to foster a feeling of ownership in the data and increase the 
possibilities of units collecting good quality data. 
• The software was "user friendly" allowing easy to follow data entry (Ward Watcher 
screens can be seen in Appendix 3). This it was hoped would reduce the time it would 
take to learn how to use the software and reduce the amount of data entry errors. 
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3.6 Model calculation 
Data were collected to generate scores and predictions for APACHE II, APACHE III, 
SAPS II, MPMo and MPM24. Data collected for APACHE II and APACHE III used the 
original published protocols (5,6). Protocols and procedures were published in a data 
collection manual (Appendix 2) and in help screens on the Ward Watcher software 
(Critical Audit Ltd). SAPS II and MPM II were collected in accordance with the 
originally published papers (3,4). 
APACHE II diagnoses were generated from APACHE III diagnoses using mapping 
provided by AMS (Appendix 4). APACHE il mortality predictions were derived using 
both the original coefficients and those generated by the UK APACHE II study (13). This 
required the author to map original APACHE II diagnostic groups to UK AP ~CHE II 
diagnostic groups (Appendix 4). Predictions for all models were calculated using th~ 
" , 
Ward Watcher software. 
3.7 Subjects 
Data were collected on consecutive patient admissions from Ist January 1995 to 31 st 
December 1996 in all ICUs and, as previously described, for ICUIHDUs (3.1). However, 
patients with burn injuries, patients under 16 years of age, patients who died in the first 
hour after ICU admission, patients admitted to die and who died in the first four hours, 
and patients in full cardio-pulmonary arrest who died in the first four hours were 
excluded from the study. The criteria for these exclusions were determined by similar 
exclusions used in the development of the original models (3-6). 
3.8 Outcome measure 
In keeping with the original studies the outcome used was hospital mortality, defined by 
the patient's status when discharged from hospital. 
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3.9 Data Analysis. 
3.9.1 Discrimination 
Discrimination is defined as the ability of a model to identify survivors and non-survivors 
(163). One measure of discrimination is the area under the Receiver Operating 
Characteristic (ROC) curve (164). The ROC curve is constructed by calculating 
sensitivity and specificity for a discrete number of cut-off points. Sensitivity is then 
plotted against I-specificity and the resulting points, when joined, form the curve. The 
higher the number of cut off points the more accurately it is possible to draw the curve. 
The better the discrimination then the closer the area und~r the curve gets to 1. An area 
under the curve of 1.00 would indic~te perfect discrimination with an area of 0.50 
. representing random chance (Fig 3.1). The most intuitive description of what the area 
under the curve represents would be, if you·:randomlY chose a survivor and non survivor 
then the area under the curve represents the probability of the non survivor having a 
higher probability of mortality than the survivor. (4,13). ROC curves are only a measure 
of discrimination and give no sense as to how accurate the probabilities generated by the 
different models are (165,166). ROC curves in this thesis have been calculated using a 
100 cut off points. The DeLong method for comparisons of the areas under the different 
ROC curves was used. The DeLong method is a non-parametric method for comparing 
the areas under the curves· of two or more correlated samples (167). All ROC curves and 
comparisons of the areas under the curves were calculated using AccuRoc Non-
parametric Receiver Operating Characteristic Analysis Version 3.0 (Dr S.Vida, McGill 
University). 
Another means of measuring discrimination is by use of a classification table (168). This 
is generated by counting the numbers of survivors and non-survivors above and below a 
certain cut off point of estimated mortality. The sensitivity, specificity and correct 
classification rate can be compared in different models. Sensitivity is the proportion of 
observed deaths predicted to die, the specificity is the proportion of observed survivors 
predicted to survive and the overall classification rate is the proportion of patients 
correctly classified as survivors or non survivors (Table 3.2). Although this is a means of 
testing discrimination, and the value of it can be extended using different cut off points, 
the weakness in this approach is that it is possible to have good discrimination but for this 
not to be reflected in the classification table depending on which cut off point is used. It 
is also difficult to see what information is gained from classification tables that is not 
already described by an ROC curve. Hosmer and Lemeshow give a good description of 
the classification table and its weakness (168). 
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Figure 3.1 ROC curve for APACHE II model 
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Table 3.2 APACHE II Classification table 
Decision Predicted Alive Predicted Dead Total 
Criterion 
50% 
Observed alive 6288 740 7028 
Observed dead 1440 1380 2820 
Total 7728 2120 9848 
Overall correct classification: 77.86 
3.9.2 Calibration 
The other area of assessing a model's performance, as previously mentioned, is 
calibration. Calibration is used here as·an evaluation of the degree of correspondence 
between"estimated mortalities and observed mortalities. There are a: number of different 
ways of assessing the calibration of a model but the following are the most commonly 
used in the assessment of Intensive Care scoring models. 
Hosmer-Lemeshow Goodness Of Fit (GOF) test: The Hosmer-Lemeshow GOF test 
creates 'bins' of increasing risk. There is no set number of bins but the number is usually 
10. With large numbers it is possible to increase the threshold for obtaining a significant 
result by increasing the number of bins. Both the observed number of survivors and non-
survivors and the predicted number of survivors and non-survivors are calculated for 
each mortality risk group. The Chi Squared statistic which compares the observed with 
the expected frequencies is calculated for each of the bins both for survivors and non-
survivors using the following equation: 
Where o = Observed number of patients 
E = Predicted number of patients 
A P-value can then be obtained from a one-sided Chi Squared distribution table (169). 
There are two approaches to the Hosmer-Lemeshow test. One approach (H) is to group 
the patients by a cut-off point of risk, i.e. all patients with a probability less than 10% and 
then all patients with a probability greater than 10% and a probability less than 20% and 
so on. The alternative approach (C) is to create equal size bins with increasing risk. So, 
for a sample size of 100, the 10 patients with the lowest risk would be in the first bin, the 
10 patients with the next lowest risk would be in the second bin and so on. Hosmer and 
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Lemeshow have validated both these approaches but have reported their preferred use of 
the C statistic. (169) (personal communication). In this study, the C statistic has been 
used, as grouping the patients into equal bins of equal numbers would appear to be the 
most legitimate method. The probabilities from these models produce a distribution with 
relatively low numbers of patients who have high probabiities of death and smaller 
numbers in the higher bins. The H statistic gives equal weight to each of these bins. Any 
differences in the probabilities at the higher end of severity will mean that a relatively 
small number of patients have a disproportionate effect on the test. 
Calibration curves: Calibration curves give a graphical representation of calibration. 
They are produced by grouping patients into bins of predicted mortality of equal width, 
plottillg the observed mortality for each decile and comparing this plot to the line of 
equality. A frequency distributiqn plot should be 'included which allows, areas of 
. discrepancy, between observed"and p~edicted mortality, to be related to the distribution of 
illness severity within a study population. Confidence Intervals (CI) for the observed 
mortality should be included to allow statistical assessment of the level of discrepancy. 
This has been done rarely in the intensive care literature but without CIs it is hard to 
make any real assessment of differences between observed mortality and that estimated 
by the model. This method has been criticised by Lemeshow because of the unequal 
distribution of patients in the different bins overestimating the importance of patients 
with high probabilities in the model (137) (personal communication). While this may be 
true, calibration curves offer a graphical representation of these data and the frequency 
distribution and the CIs allow the viewer to assess the imbalance in distribution. It is also 
the most intuitive way to view these data as you see the full range of severity in a regular 
scale (0-100). CIs for observed mortality are calculated using the following equations 
(170): 
where 
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p = the percentage of observed mortality 
SE= standard error ofp. 
n= sample size 
SE= ...J(p(lOO-p)/n) 
p-(1.96*SE) to p+(1.96*SE) 
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3.9.3 Mortality ratios 
Mortality ratios (observed mortality/expected mortality) have been used to assess 
differences between units and different subgroups in severity models. However, there are 
a number of statistical issues around the use of mortality ratios and it has been 
recommended that caution should be used in drawing conclusions from apparent 
differences (171). To assess differences using mortality ratios, comparisons have only 
been made between ICUs/Subgroups and the whole cohort rather than between separate 
ICUs/Subgroups. Also, statistical significance was accepted only when CIs for the 
ICU/Subgroup lay outside the CIs for the whole population. Although there is no stated 
numbers above which mortality ratios can be legitimately used, comparisons have only 
been made when the numbers were greater than 300. 
Another problem in using mortality ratios is calculating CIs. As most studies do not 
publish the variance from the logistic regression analysis it is not possible to use the 
variance of the model to calculate CIs. However, Hosmer and Lemeshow ·have suggested 
a method for calculating mortality ratios (172). They have shown that this method is 
. . 
comparable to other methods which use information taken from the output of the logistic 
regression model. This method has been used in practice by Rapoport et al (125) and the 
equation is as follows: 
CI=(O ± 1.96*--JVar)/E 
Where 0 = observed number of hospital deaths 
E = expected number of deaths 
Var = I(Pi*(1-pj)) where Pi is the estimated probability for patient i 
3.9.4 Subgroups. 
The proposed use of these models is to adjust for case mix. It is important that different 
subgroups of 'patients representing different case mix should show comparable 
performance. When comparing the performance of models in subgroups it would not be 
appropriate to use ROC curves or the Hosmer-Lemeshow GOF tests. ROC curves will 
quite legitimately demonstrate differing discrimination as subgroups may represent 
different levels of severity of illness. Hosmer-Lemeshow GOF tests are sensitive to the 
numbers involved in the test, with a significant test more likely if the numbers are large 
(142). Therefore, it would be inappropriate to compare performance in subgroups as the 
numbers in different groups would be different. It seems more appropriate to compare 
subgroups using other methods. This study has chosen mortality ratios and their CIs, the 
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CIs for observed mortality, and Chi Squared tests to assess performance in subgroups. 
The Chi Squared tests have been calculated using the following equation (173) 
Where o = Observed number of deaths 
E = Predicted number of deaths 
3.9.5 Statistical Packages 
The above analysis was carried out using a number of statistical packages. All ROC 
analysis were carried out using AccuRoc Non-parametric Receiver Operating 
Characteristic Analysis Version 3.0 (Dr SVida,McGill University). 
HoSmer-Lemeshow GOF tests, mortality ratios, all CIs and Chi Squared values were 
calculated ,on Microsoft Excel version 4 .. 
Bland Altman plots were graphed using Minitab version 10. All other graphs were 
generated using Microsoft Excel version 4. 
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CHAPTER 4-Data Variability and Quality 
Aims: To measure the quality of the data collected in the study, assessing it is fit for 
use in these models 
To discuss possible factors that may affect both the quality and the variability 
within the data. 
Contents: 
4.1 Introduction 
4.2 Validation study 
4.2.1 Methods 
4.2.l.1 Data analysis 
4.2.2 Results 
4.2.3 Discussion 
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4.1 Introduction 
The accuracy of the probabilities generated by the scoring models depends on the 
quality of data collected. The study attempted to ensure that data were both accurate 
and complete. These measures have already been described in chapter 3. In an effort 
to minimise on data errors, the study: 
• collected high and low values 
• had range checking in the software 
• would not allow patients to be discharged from the system until the minimum 
dataset was complete 
• spent a day on each ward installing the computer and explaining data collection 
• a comprehensive data collection manual was supplied to all units 
• answered questions by telephone on data collection on a nine-to-five basis and 
provided a 24 hour answering machine for questions outside those hours 
, ' 
• collected hospital outcome every three months, units being reminded about 
missing data until information was correct. 
• re-scored 10% of all records in the first year and 5% of all records in subsequent 
years. 
• provided feedback to units about where errors were occurring 
However, it is clear there are a wide number of issues regarding scoring models and 
data quality. Some of these issues the study has attempted to address, others it was 
not possible for this study to tackle. 
4.2 Validation Study 
Aims: To monitor the effect of errors on the quality of data. 
Sample: A 10% systematic sample of all records from each unit was re-scored by the 
Research Nurse. 
4.2.1 Methods 
Patients were selected by taking the first patient in every three month period and then 
every tenth patient thereafter. In addition to the 10% sample a further 5% was 
requested in the event that the original case notes were unavailable. These were 
selected by choosing the 18th patient admitted in the quarter and every 18th patient 
thereafter until the required number of extra notes had been identified. 
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A database was designed and constructed using the Ward Watcher data screens 
(Appendix 3). This allowed the Research Nurse to enter the variable values in similar 
conditions to the original scorer. Values from the original scorer were withheld from 
the Research Nurse to allow re-scoring without bias. For variables contributing to the 
APACHE III, II and SAPS II physiology scores, the effect of the value entered by the 
Research Nurse on the score was calculated by the software and then compared to 
that of the original scorer. When changes in any of the three physiology scores 
(APACHE III, APACHE II and SAPS II) were detected an error screen was then 
produced. The screen informed the nurse of the differences and the original scorer's 
value whereupon she would re-check the value and re-enter what she believed to be 
the correct value. Differences in values entered into the MPM II fields and all other 
fields for other models were compared directly which prompted the nurse to check 
the value when differences were found. Forcing the Research Nurse to re-check when 
differences were found, allowed her to correct any mistakes she may have<made, and 
made her as close to a "Gold Standard" as was possible. 
Data were exported from the validation data base into a 'dummy' Ward Watcher and 
probabilities (%) generated for both the original and the re-scored data. 
4.2.1.1 Data analysis 
Student t-tests were used to test for any significant bias in the differences between the 
probabilities (%) generated by the original scorer and the Research Nurse (174). The 
t-tests allowed for any significant over or underscoring to be highlighted by testing if 
the mean differences are significantly different from zero. The differences in the 
probabilities (%) were also plotted against the mean of the two scorers' probabilities 
(%), with the lines representing ± two standard deviations (SO) also being plotted. 
This plot allows the assessment of the relationship between the differences and the 
mean. Ideally, for high and low probabilities (%), there should be no.pattern of under 
or overscoring. We would expect that 95% of the observations will fall within ±2SD 
(175). 
4.2.2 Results 
Over the first nine months of the study 3,390 patients were admitted to the study and 
of these patients, 339 were re-scored by the Research Nurse. Of those patients re-
scored, 54% were male and 46% were female. 
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All models except MPMO showed no significant difference from an expected mean of 
zero (APACHE III, P=0.12; APACHE II, P=0.69; MPM24, P=0.23; SAPS, 
P=0.0.91). MPMO had a mean difference of 2.16 which showed a significant 
overscoring (p=0.014) (Table 4.1). 
Table 4.1 Comparison of original scorer and Research Nurse for each model 
Mean difference Significance of + 2 SO - 2 S 0 
APACHE III 
APACHE \I 
SAPS \I 
MPM 24 
MPM.O 
(Original Scorer- t-tests 
Reseach Nurse) P = 
-1.29 0.12 
-0.31 0.69 
-0.09 0.91 
0.70 0.23 
2.16 0.01 
28.87 
27.69 
27.31 
22.24 
34.22 
-31.45 
-28.31 
-27.49 
-20.86 
-29.32 
SO, Standard Deviation; APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, 
. . . 
Simplifi,ed Acute Physiology Score; MPM, Mortality Probability Model. 
Plots of the differences versus the mean of the two probabilities (%) show no signs of 
over or underscoring (Figure 4.1 - Figure 4.3). There would appear to be no 
relationship between the level of probability and any over or underscoring. Using 
±2SD, 95% of the differences are expected to fall between 34.22 and -29.32 at worst 
(MPMO) and between 22.24and 20.86 at best (MPM24) (Table 4.1). 
4.2.3 Discussion 
The results from the re-scoring of 10% of all records in the first nine months showed 
that there was no significant over or underscoring, except with the MPMO model, 
when the original probabilities (%) were compared to those generated by the 
Research Nurse. Although the Research Nurse returned to the ICUs as soon as 
possible, it was typically 3-4 months after the patient's admission. This may have 
meant that the information in the notes was different to that available the original 
scorer. 
It was believed that those involved in the data collection would not attempt to inflate 
the predictions by deliberately inputting incorrect data ("gaming"). The results seem 
to support this belief with no perceptible overscoring except in the MPMO model. 
The overscoring in the MPMO model appears to be as a result of the incorrect choice 
of the coma variable. This is believed to be the result of a looser interpretation by the 
scorers of the term "coma" than was originally defined in MPM IT paper (4). 
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Figure 4.1 Plots of differences (Original Scorer - Research Nurse) against the mean of 
the two probabilities (%) for the APACHE III and APACHE II models. Each cross 
represents one patient (n=339). Broken lines, ±2SD. 
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Figure 4.2 Plots for the SAPS IT and MPM24 models of differences (Original Scorer-
Research Nurse) against the mean of the two probabilities (%). Each cross represents one 
patient (n=339). Broken lines, ±2SD. 
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Figure 4.3 Plot of differences (Original Scorer - Research Nurse) against the mean of the 
two probabilities (%) for the MPMo model. Each cross represents one patient (n=339). 
Broken lines, ±2SD. 
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With the exception of MPMO the size of the differences between the original scorers 
and the Research Nurse are largest in those models with the most variables i.e. 
APACHE ITI (SD ± 15.08), and smallest for those with fewest variables i.e. MPM24. 
It is clear that the more variables a model has, then the more opportunity for errors 
there are, and as MPM24 has only 13 boolean variables with all but age requiring 
only yes or no answers it is not surprising that the standard deviation is smallest in 
this model (SD± 10.78). 
How small the differences between the Research Nurse and the original scorers 
should be, is not a question of statistical significance but one of judgement (173). 
There would appear to be quite considerable variation in the differences with 95% of 
the differences falling within +34.22 to -29.32 for the MPMO model. Although this 
model is the worst, all the models have considerable variation. Differences of 20-30% 
on the estimated mortality could make a considerable difference to calibration if 
concentrated in a certain group of patients. To assess the effect that errors made to the 
overall performance of the models, it would be important to look at the differences 
they made to the measures of the performance, like ROC curves and Hosmer-
Lemeshow tests. The numbers in this sample were too small to allow these tests to be 
carried out accurately. 
Whilst the study found no significant over or underscoring in the overall population, 
it was possible that some ICUs made more errors than others. It was not possible to 
test whether this was the case as the numbers of re-scored records in the individual 
ICUs were too small (mean = 15.4). However, the evidence from the overall sample 
would suggest there is nothing to support the hypothesis that errors were making the 
estimated mortality of individual ICU's significantly higher or lower. There are no 
data at the moment that would allow this study to determine where these errors 
predominantly occurred, which ICUs made most errors, and in which variables errors 
were most common. 
Although an attempt was made to ensure that data were collected in a uniform and 
accurate way, there were areas where it was uncertain if there were any significant 
effects in the data. As part of the re-scoring process ICUs were informed of the errors 
they had made and the possible effect these errors may have had. It is unclear whether 
this information had any effect on the practice of recording data. It was not possible 
to determine how data were collected as this would have been seen as infringing on 
the autonomy of the clinicians. Where ICU treatment was begun, how often data were 
recorded, what patients were admitted to ICU or selected for entry into the study by 
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the 4 HDUs, were only a few of the decisions that clinicians determined individually. 
However, the knowledge that errors made in scoring cause no significant over or 
underscoring is reassuring and given a lack of data to answer other questions in this 
area it is presumed that the data were accurate enough to be used and were "fit for 
purpose". 
Although for this study we have accepted that the data we have is "fit for purpose", 
there are still a number of areas where we have no information and further work is 
needed. There is no record of the number of case notes not available from different 
units. This could be a bias in the validation study as it would have been possible for 
units to withhold case notes on patients where it was known there was a problem. At 
present the study has no i!lformation on missing case notes, however, it is thought 
unlikely that any case notes were deliberately withheld. It also has to be 
acknowledged that it would have been a simple process to have monitored the 
unavailability of case notes and any future'work should do thi~. 
As has already been stated, there were not enough patients involved in the validation 
study to look at the difference in the error rates in the ICUs. Data from the validation 
study shows us that there is potential for considerable differences in probabilities 
caused by errors. If poor data collection or recording of the data for the models is 
concentrated on certain units, then errors might affect the apparent performance of a 
unit. Although it was hoped that by informing each unit of the effect of their errors 
this would improve their data quality, there is no evidence that this was the case. Any 
future work in this area should involve the collection of enough patient data to allow 
the assessment of errors on the different units and assessment of the effect of 
reporting errors to the units. 
These models, especially those that are physiologically based CAP ACHE II and III, 
and SAPS II), have a considerable number of variables. It is probable that some 
variables are more susceptible to errors than others. The reason for the significant 
overscoring seen in the MPMO model has, anecdotally at lt~ast, been blamed on the 
inaccuracies of the Coma variable. As variables in the models have unequal weight, 
the effect of errors in the collection of some variables will be larger than others. Any 
future validation should be able to analyse if specific variables were more prone to 
errors and also their effect on the probabilities generated by the models. 
Data collection rules: The study attempted to ensure that the same rules for data 
collection were applied by all the units and scorers. After the computers were 
installed on each of the ICUs, a day was also spent explaining the rules for data 
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collection and some of the issues surrounding them. The rules and definitions for the 
data collection of APACHE III were provided in a manual (Appendix 2). Rules and 
definitions for the other models in the study were also available through help screens 
in the Ward Watcher software. Any ambiguities in the rules or definitions could be 
clarified by phoning the central Audit office. However, it was impossible to force 
staff to use manuals or help screens and it was presumed that time and workload 
pressures on the ward would have some effect on the data quality. 
Data collectors: The staff who collect the data may be an important factor in the 
quality of data. At the beginning of the study there was no apparent evidence to 
suggest who would best collect the data required for the severity models. However, 
Holt et al have since reported that inter observer variability in large patient groups has 
minimal effect on predicted mortality (176). They also reported that significant 
variance may occur at an individual pati~!lt level. They reported that, at this 
individual level, residents scored patients more accurately than nurses. In this study, 
at an anecdotal level, the Research Nurse who re-scored the patients, reported that it 
was nearly always medics who recorded the severity of illness data. She also reported 
that the quality of data was best when recorded by fewer people. It was not possible 
for the Audit to decide who would collect the data on each of the ICUs. Different 
ICUs faced different pressures with regard to the time and the resources they had 
available for collecting the information needed for the Audit. It was therefore left to 
the individual ICUs to make the decision as to who was best able to collect the 
severity of illness information. However, it would have been possible to record who 
was collecting the data on each of the ICUs. This would have allowed some analysis 
of who most accurately collects information and if certain groups of staff are better at 
recording this information than others. 
Amount of data and freguency of sampling: Another potential effect on both the 
quality and variation of data was the amount of data routinely recorded on each of the 
units. Although the study had a minimum data set (Appendix 3) some data were not 
necessarily collected for each patient. Some units may routinely have collected 
certain tests, while other ICUs may have only ordered these tests when they felt they 
were indicated. There was an increased possibility of highlighting extreme values if 
clinical tests were carried out routinely rather than when clinicians felt they were 
indicated. ICUs in this study had differing policy depending both on the clinician's 
views within the unit and budgetary constraints. The study was not in a position to 
recommend when these tests should be done and it was therefore left to each ward to 
determine their own policy. 
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Also, some units may record observations more frequently than others. With the 
increase in computer technology in ICUs some monitoring systems allow the storage 
of continuous data for review at a later point. If data are available for the whole of a 
24 hour period rather than sampling every 15 minutes there is increased potential for 
recording abnormal values (177). 
Any future validation study should profile ICUs, looking at where ICU treatment starts, 
how data were collected, who collects it, and the effects of these processes on the 
accuracy of the data. If data from different units is to be consistently collected then it is 
important to understand the effect, if any, of these factors. 
Page 62 Chapter 4 Data Variability and Quality 
Chapter 5- The models' overall performances. 
Aims: To compare the overall performance of the models in a Scottish setting. 
Contents: 
5.1 Results 
5.1.1 Intensive Care Units 
5.1.2 Patients and exclusions 
5.1.3 Model performance 
5.2 Discussion 
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5.1 Results 
5.1.1 Intensive Care Units 
The ICUs in the study varied in size and patient turnover with a range of patient 
admissions, during the study, of 159 to 956. This represents a range of 1.53 to 9.20% of 
the patients admitted to the study. The ICUs in the study had a mortality range of 
16.97%-42.31% and an APACHE II score (a proxy for severity of illness) range of 
14.34-21.77. The percentage of operative patients on the different ICUs was in the range 
of24.68-73.26 (Table 5.1). 
T bl SIP til fIn a e . ro 1 eo tenslve C U' II are mts co ectmg 
Patientsa % of overall % Mortality 
admissions 
A 389 3.74 17 
B 609 5.86 19 
C 394 3.79 21 
D 456 4.39 22 
E 414 3.98 22 
F* 309 2.97 23 
G 585 5.63 27 
H 390 3.75 28 
I 444 4.27 29 
J 304 2.93 29 
K 814 7.83 29 
L 404 3.89 31 
M 513 4.94 32 
N 672 6.47 33 
0* 268 2.58 33 
P 472 4.54 33 
Q 470 4.52 33 
R 767 7.38 35 
S 396 3.81 35 
T* 159 l.53 36 
U 956 9.20 37 
V* 208 2.00 42 
Total 10,393 100 29.4 
APACHE, Acute Physiology and Chronic Health Evaluation; 
*ICU/HDUs; a. Number of patients in study after exclusions. 
d fi h d ata or t e stu ly. 
Mean % of operative 
APACHE II patients 
Score 
14 .43 
16 52 
16 50 
17 57 
16 67 
16 64 
19 41 
17 36 
18 59 
18 33 
19 39 
19 59 
20 25 
18 68 
19 73 
19 32 
18 63 
20 41 
21 58 
20 47 
20 39 
22 49 
18 48 
Those units identified as ICUslHDUs were analysed to assess the impact of excluding 
HDU type patients from the study. The mortality of HDU patients varied from 3.44%-
9.87%. The mortality in these units for those patients who have been included in the 
study had a range of23.30%-42.31%. This compares with a mean 29.09% in the 
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other ICUs in the study. In three of the HOUslICUs the estimated mortality (APACHE 
III and APACHE II) was higher than that in the ICUs (Table 5.2), with the remaining 
HDU/ICU having the 6th lowest APACHE II score in the study (Table 5.1). 
Table 5.2 Profile of high dependency units mortality and severity of illness. 
HOUslICUs lCUs 
HospID F T V 0 
In study 
Subjects 309 159 208 268 9449 
Deaths 72 57 88 89 2749 
Mortality (%) 23.30 35.85 42.31 33.21 29.09 
APACHE III Score 53.05 66.03 70.30 66.22 60.25 
APACHE III estimated mortality (%) 17.46 28.23 32.76 27.16 23.72 
APACHE II Score 16.33 19.82 2l.77 18.71 18.24 
APACHE II estimated mortality (%) 24.54 36.22 4l.39 3l.41 29.98 
Exclusions 
Subjects 60 324 834 436 
Deaths 5, 32 71 ." 15 
Mortality (%) 8.33 9.87 8.51 3.44 
HOU, High Dependancy Unit; ICU, Intensive Care Unit; APACHE, Acute Physiology and Chronic Health 
Evaluation. 
5.1.2 Patients and exclusions 
Data were collected on 13,291 consecutive admissions to the 22 Scottish ICUs in the 
years 1995/96. Of the 13,291 patients, 2,898 were either HOU patients, and excluded 
under the study's exclusion criteria or excluded for other reasons (Table 5.3) leaving 
10,393 patients for analysis. 
Table 5.3 Study exclusions 
Reason for Exclusion 
Readmissions 
Missing Outcomes 
Prospective study exclusion 
categories 
HDU patients 
Total 
HOU, High Dependancy Unit. 
Number of patients 
498 
114 
632 
1,654 
2,898 
The specific entry criteria for each system were applied to these 10,393 patients. This led 
to further exclusions although the numbers excluded varied because of the different 
criteria. When comparing the models it is important to use a common data set (for 
example, the different entry criteria concerning minimum period of admission will lead 
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to different samples being selected for each scoring system). Diagnostic categories were 
not available for 31 records, therefore, a probability for the APACHE models could not 
be calculated. Three records had the APACHE III diagnosis of "Rule out MI" which has 
no coefficient and therefore no probability of mortality was available for these records. 
Fifty-nine records had incomplete SAPS data and therefore probabilities could not be 
calculated on these patients for the SAPS model. The numbers excluded and the extra 
exclusions from each model can be seen in Table 5.4. 
Table 5.4 Model exclusions 
Model 
APACHEID 
APACHE II 
SAPS II 
MPMO 
MPM24 
Patients 
10,326 
9,848 . 
10,334 
10,393 
7,343 
Other reasons for exclusion Exclusions and 
data mi ssing 
missing diagnosis & rule out MI 67 
Stay < 8 hours & missing diagnosis 545 
Missing Data 59 
Stay < 24 hours 3,045 
UK APACHE II 9,848 Stay < 8 hours & missing diagnosis 545 
APACHE, Acute Physiology and Chronic Health Evaluation; MI, mycardial infan::tion, SAPS, Simplified 
Acute Physiology Score; MpM, Mortality Probability Model. 
Table 5.5 Subject characteristics for (a) survivors, (b) non-survivors, and (c) overall. 
Survivors Non-survivors All Observed 
n=7,338 n=3,055 n=1O,393 Mortality % 
Age(±SD) 56.8±18.7 64.07±14.8 58.9±17.9 
Male (%) 4094 (55.8) 1,661(54.4) 5,755 (55.4) 28.9 
Female(%) 3244 (44.2) 1,394 (45.6) 4,638 (44.6) 30.0 
Non-operative(%) 3205 (43.7) 2,136 (69.9) 5,341(51.4) 40.0 
Operative(%) 4133 (56.3) 919 (30.1) 5,052(48.6) 18.2 
Elective(% ) 1999 ~27.2) 215(7·°2 2,214 (21.32 9.7 
Emer~ency(% ) 2134 (29.1) 704 (23.02 2,838 ~27.32 24.8 
Data given are mean (standard deviation) for age, n (percent for other factors). 
In addition observed mortality (%) is shown. 
Although patients under 18 years of age were excluded from the original SAPS II and 
MPM II studies, all patients between 16-18 were scored and included in the study. 
Hospital mortality in our study population was 29.4%, with an ICU mortality of 20.5%. 
Fifty one percent of patients were non-operative and 48.6% operative. Patients had an 
average length ofICU stay of 4.64 days, with non-operative patients having an average 
length ofICU stay of 5.67 days compared to 3.56 in operative patients. 
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The demographics of the population used for analysis are shown in Table 5.5. A further 
breakdown of this population can be found in Table 5.6.1 and Table 5.6.2 which show 
the 20 most common operative and non operative APACHE III diagnoses. 
Table 5.6.1 List of twenty most frequently chosen APACHE III operative diagnoses 
Diagnosis 
GI Neoplasm(not perforation/rupture) 
GI perforation/rupture 
GI obstruction(any cause) 
Other Miscellaneous 
Aortic aneurysm: pre-leak/dissection 
Aortic aneurysm: Rupture 
Other GI Surgery 
-Aortic-fernoral,fem-fem bypass graft 
Bleeding-ulcer 
Peritonitis 
Cholangitis/cholecystitis 
Trauma - extremities 
GI vascular insufficiency/embolism/infarction . 
Renal neoplasm 
GI inflammatory disease 
Other renal surgery 
Neoplasm-mouth/sinuses 
Other cardiovascular surgery 
Localised GI abscess/cyst 
Peripheral ischaemia 
All 
GI, Gastrointestinal 
Number of 
patients 
703 
522 
390 
357 
265 
229 
214 
162 
134 
115 
109 
108 
97 
82 
80 
74 
72 
69 
63 
63 
5,052 
% Operative 
Patients 
13.95 
10.33 
7.72 
7.07 
5.25 
4.53 
4.24 
3.21 
2.65 
2.28 
·2.15 
2.14 
1.92 
1.62 
1.58 
1.46 
1.43 
1.37 
1.24 
1.24 
100 
Table 5.6.2 List of twenty most frequently chosen APACHE III non operative diagnoses 
Diagnosis Number of % Non-operative 
GI neoplasm (not perforation) 
Aortic aneurysm 
GI perforation/rupture 
GI obstruction (any cause) 
Other Miscellaneous 
Other GI disorder 
Other respiratory disorder 
Peripheral ischaemia 
Peritonitis 
Other cadiovascular disorder 
Bleeding - ulcer 
GI vascular insufficiency/embolism/infarction 
Septic shock - gastrointestinal tract 
GI inflammatory disease 
Cholangitis/cholecystitis 
Renal neoplasm 
Congestive heart failure 
Other renal disorder 
Trauma - multiple site without headlbrain 
Localised airway obstruction/oedema (mechanical) 
All 
GI, Gastrointestinal 
patients patients 
564 10.56 
507 9.49 
369 6.90 
297 5.56 
241 4.51 
-163 3.05 
159 2.98 
153 2.86 
135 2.53 
128 2.40 
106 1.98 
85 1.59 
76 1.42 
72 1.34 
71 1.32 
67 1.25 
60 1.12 
59 1.10 
59 1.10 
55 1.03 
5,341 100 
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5.l.3 Model perfonnance 
The results for each model are summarised in Tables 5.7 and 5.8. APACHE III 
demonstrated the best discrimination for the area under the ROC curves (0.845), whereas 
MPMO had the poorest discrimination with an area under the ROC curve of 0.785. 
Statistically valid comparisons can only be made for models that include the same 
patients. Thus, only comparisons of APACHE II and UK APACHE II can be made. The 
area under the ROC curve for UK APACHE II was not significantly greater than that for 
APACHE II (APACHE II = 0.805 and UK APACHE II = 0.809) . 
. All the models had Hosmer-Lemeshow goodness of fit tests, which were statistically 
significant (P<O.OOl). This indicates statistical significance .between observ;ed and 
predicted mortality in all models .. This may not be surprising, given that small differences 
o '"'
can achieve significance with large sample sizes. Although there is no formal way of 
comparing Chi Squared statistics, it would appear that there was a considerable 
difference between the APACHE II Chi Squared value (x2=36.39, p<O.OOl) and the 
APACHE ITI Chi Squared value (x2=33l.65, p<O.OOl). 
Table 5.7 ROC values and Hosmer-Lemeshow goodness of fit tests using each model's 
exclusion criteria and for common subset 
Patients using each model's exclusion criteria Patients in common subset 
Model N= ROC Area Hosmer N= ROC Area Hosmer 
under the Lemeshow under the Lemeshow 
curve GOF curve GOF 
Chi Squared Chi Squared 
APACHE III 10,326 0.845 331.7* 7,338 0.795 365.7* 
APACHE II 9,848 0.805 36.4* 7,338 0.763 67.4* 
SAPS II 10,334 0.843 57.8* 7,338 0.784 142.0* 
MPMO 10,393 0.785 307.5* 7,338 0.741 451.9* 
MPM24 7,343 0.799 101.9* 7,338 0.791 100.8* 
UK 9,848 0.809 307.5* 7,338 0.756 236.6* 
APACHE II 
APACHE, Acute PhysIOlogy and Chromc Health Evaluation; SAPS, Simplified Acute PhysIOlogy Score; 
MPM, Mortality Probability Model; ROC, Receiver Operating Characteristic; GOF, Goodness of fit; * 
P<O.OOI. 
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T bl 58H a e . L h d f fit tati ti fi II osmer- emes ow goo ness-o - 1 S S cs ora mo d I es 
Decilesof Observed Expected Observed Expected GOF 
Predicted swvivors swvivors deaths deaths statistic 
Mortality (%) &df 
APACHE IT 0<4 958 959.63 27 25.37 
4<8 919 925.57 66 59.43 
8<12 887 889.95 98 95.05 
12<17 847 846.67 138 138.33 
17<23 796 792.41 189 192.59 
23<31 710 722.93 275 262.07 
31<40 658 637.11 327 347.89 
40<52 599 532.13 386 452.87 
52<69 451 396.72 534 588.28 df=8 
69<100 203 186.50 780 7%.50 36.39· 
APACHE lIT 0<2 1010 1023.32 23 9.68 
2<3 986 1009.26 47 23.74 
3<5 952 992.35 81 40.65 
5<8 913 966.27 120 66.73 
8<13 856 927.62 177 105.38 
13<20 791 869.41 242 163.59 
20<30 678 779.37 355 253.63 
30<45 575 649.89 458 383.11 
45<68 384 454.68 649 578.32 df=8 
68<100 141 173.18 888 855.82 331.65· 
UKAPACHEII 0<8 952 933.29 33 51.71 
8<13 938 875.75 47 109.25 
13<18 880 829.17 105 155.83 
18<24 839 m.24 146 207.76 
24<31 813 714.64 172 270.36 
31<39 720 645.39 265 339.61 
3948 670 565.16 315 419.84 
48<59 574 466.89 411 518.11 
59<3 424 343.37 561 641.63 df=8 
73<100 218 163.55 765 819.45 307.51· 
SAPS IT 0<3 1011 1018.09 22 14.91 
3<5 992 994.20 41 38.80 
5<9 958 ·962.54 75 70.46 
9<14 897 919.84 136 113.16 
14<20 841 862.12 192 170.88 
20<29 792 784.72 241 248.28 
29<41 681 676.18 352 356.82 
41<58 559 534.23 474 498.77 
58<80 415 333.42 618 699.58 df=8 
80-<00 145 108.92 892 928.08 57.75· 
MPMO 0<3 991 1013.51 48 25.49 
3<6 950 991.01 89 47.99 
6<9 923 960.37 116 78.63 
9<14 856 920.19 183 118.81 
14<20 819 863.52 220 175.48 
20<26 761 803.75 278 235.25 
26<37 695 718.79 344 320.21 
37<53 636 570.85 403 468.15 
53<75 457 377.37 582 66l.63 df=8 
75<100 250 131.27 792 910.73 307.47· 
MPM24 0<4 715 714.19 19 19.81 
4<7 675 694.97 59 39.03 
7<11 662 670.26 72 63.74 
11<16 590 636.51 144 97.49 
16<22 568 5%.65 166 137.35 
22<30 500 545.46 234 188.54 
30<40 495 479.72 239 254.28 
40<53 397 395.13 337 338.87 
53<71 310 278.27 424 455.73 df=8 
71<100 179 119.80 558 617.20 1Ol.87· 
GOF, Goodness of fit; df, degrees offreedom; APACHE, Acute Physiology and Chronic Health 
Evaluation; SAPS, Simplified Acute Physiology Score; MPM, Mortality Probability Model; ... P<O.OOI 
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The impact of these differences in calibration can be seen in the calibration curves and 
goodness of fit tables (Figures 5.1-5.3 and Table 5.8). APACHE II was seen to provide 
agreement between observed and predicted mortality across the full range of severity of 
illness, with the confidence intervals for observed mortality predominantly including the 
line of equality. Conversely, the observed mortality was consistently higher than that 
predicted by the APACHE III model with the line of equality lying outside the 95% 
confidence intervals. The confidence intervals for observed mortality for the UK 
APACHE II model were predominantly below the line of equality indicating that the 
mortality predicted by the model exceeds the observed mortality (Figure 5.2). These 
differences in calibration were reflected in the different frequency distribution plots of 
mortality prediction (Figures 5.1-5.3). Thus, while,more than 40% of patients have a 
predicted mo~ity of 0 to 1.9% with APACHE IlL UK APACHE II gives a figure of just 
over 20~ for the same population. A similar pattern of observations was evident in .the 
. g()~dness of fit table (fable 5.8).· , 
All the models, with the obvious exception of MPM24, showed poorer discrimination 
after excluding patients discharged in the first 24 hours (Table 5.7). Thus, the rank order· 
of performance changes with MPM24's performance relatively improved. Overall 
APACHE III, SAPS II and MPM24 have sIgnificantly superior discrimination compared 
with APACH,E I~, UK APACHE II and MPMO (Table 5.9). UK APACHE II and 
APACHE II were significantly superior to MPMo. 
Table 5.9 Comparison of ROC values in common dataset (showing P values) 
N=7,338 
ROC Values 
APACHE III 
APACHE II 
SAPS II 
MPM24 
MPMo 
UK APACHE II 
APACHE III 
P= 
0.795 
APACHE II 
P= 
0.763 
0.0000 
SAPS II 
P= 
0.784 
0.9921 
0.0000 
MPM24 
P= 
0.791 
0.3369 
0.0000 
0.2298 
MPMo 
P= 
0.741 
0.0000 
0.0006 
0.0000 
0.0000 
UK APACHE II 
P= 
0.756 
0.0000 
0.5003 
0.0000 
0.0000 
0.0002 
APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology; MPM, . 
Mortality Probability Model. 
Significance tested using the DeLong method. 
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Figure 5.1 Calibration curves for APACHE III and APACHE II models. 
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Figure 5.2 Calibration cUlves for the SAPS II and MPMo models. 
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Figure 5.3 Calibration curves for MPM24 and UKAP ACHE II models. 
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The explanation for the deterioration in the ROC values of all models, with the exception 
ofMPM24,was evident from the ROC curves of the excluded population (APACHE III, 
0.931; APACHE II, 0.908; UK APACHE 11,0.9132; SAPS 11,0.925; MPMO, 0.875). 
This demonstrated high predictive ability of all models when restricted to patients 
discharged within 24 hours. 
Model calibrations, which exclude patients discharged in the first 24 hours, were little 
changed from calibrations derived from the total study population with no consistent 
effect (Table 5.7 and 5.8). All produce significant differences with the Hosmer-
Lemeshow goodness of fit test. UK APACHE II has improved calibration with a reduced 
Chi Squared value, while SAPS II, APACHE II, APACHE III, and MPMO have 
increased Chi Squared val.~es. 
5.2 Discussion 
Within each prognostic scoring system the development and validation cohort were 
generated by randomly splitting the overall cohort. There have been several studies 
assessing the performance of scoring systems outside the ICU populations in which they 
were developed (53,73,~3,84,102,1l0,1l5). A study of APACHE II in the UK showed 
similar discrimination (ROC Area) and calibration to that of the original model (73). 
However new diagnostic coefficients derived from the UK database showed improved 
discrimination and calibration when tested on that database (13). 
Unlike other scoring systems, the weights needed to generate probabilities from the 
AP ACHE III model are not within the public domain. There has, therefore, been limited 
assessment of its performance outside the United States. A small study in a single UK 
ICU (83) showed APACHE III to have better discrimination than APACHE II (0.847 and 
0.806 respectively) with both systems underestimating the mortality rate. A large study in 
the UK assessed the ability of APACHE III to adjust for case mix in 17 ICUs (84). 
AP ACHE III considerably underestimated mortality in this population, however 
discrimination, as judged by the ROC area, was similar to that in the original validation 
population. 
A European study, taking data from the original multi-centre database used to validate 
SAPS II and MPM II, compared the performances of these new models with the original 
versions of these scoring systems (SAPS and MPM) and with that of APACHE II and 
APACHE III (score but not prediction as the latter was not available) (21). All three 
scoring systems demonstrated improved performance of the newer versions with no 
individual model being clearly superior. 
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When assessing the relative performance of severity of illness scoring systems it is 
important to appreciate that the most relevant assessment of their performance will 
depend on the proposed application. If models are to be employed to assess quality of 
care, by derivation of standardised mortality ratios, then calibration is the more 
significant measure of performance with discrimination being secondary to this. Wagner 
said, 
"When you talk about performance evaluation you are fundamentally talking 
about calibration issues of the model. You are not as concerned about 
discrimination or ROC areas. Higher ROC areas are always better ... " (9th 
European Congress ofIntensi~e Care Medicine and personal communication). 
Indeed it has been argued by Castella et al that a model must have appropriate calibration 
. before it can be applied to a population outside its' original development population and 
only then can the model's discrimination be analysed (21). 
Model calibration, as indicated by the Hosmer-Lemeshow goodness of fit test, 
demonstrat~d that for all systems there was a significant difference between the observed 
and predicted mortality. As the number of patients increases, the magnitude of the 
difference between observed and predicted mortality, required to generate a significant 
difference, decreases. This sensitivity to larger patient numbers was demonstrated by Zhu 
et al (142). Given the size of our study population, it may not be surprising that the 
goodness of fit tests were significant. However, the original studies for both the MPM II 
and SAPS II models demonstrated no statistical significance for the Hosmer-Lemeshow 
test (MPMO P=0.327; MPM24 P=0.231; SAPS II P=0.104) despite large numbers. The 
poor calibration may be in part due to higher average mortality in our cohort of patients 
(29.4 %) compared to that of the original studies (MPM 11,20.8%; APACHE III, 17.3%; 
APACHE II, 19.7%; SAPS II, 21.9%). This difference reflects differing admission 
criteria which presumably derived from a lower number of available ICU beds per head 
of the Scottish population. 
Although there are no formal means of directly comparing the Chi Squared values 
derived from the goodness of fit tests, it would appear that there were large differences 
between some of the models. Thus, the calibration characteristics were best for APACHE 
II (36.4) and SAPS II (57.8) and poorest for APACHE III (331.7), MPMo (307.5) and, 
most surprisingly, for the UK derived version of APACHE II (307.5). Given that 
Scotland has a similar health care system to the UK as a whole and that four of the units 
contributed data both to this study and the UK APACHE II study, from which this model 
was derived, the poor performance of the UK APACHE II is difficult to explain. 
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While goodness of fit statistics allow statistical evaluation of relative performance it is 
possible that meaningful information on a given model's limitations can be visualised by 
examination of calibration curves. In particular, they demonstrate the extent to which the 
model predicts accurately across the full range of severity of illness. Consequently, 
whenever a given model is to be used there should be evaluation of this aspect of its 
performance within the population, prior to derivation of standardised mortality ratios. 
The low Chi Squared value for APACHE II appears to be associated with a close 
relationship between observed and predicted mortality across the full range of illness 
severity. The plots of the frequency distribution of predicted mortality demonstrate why 
the APACHE III prediction of mortality is lower than the observed rates, with a far 
higher proportion of patients predicted to have a mortality of 10% or less, compared with 
APACHE II. The reverse is seen with the UK APACHE II model. 
While discrimination and calibration are both important characteristics of performance, 
calibration is the more important where it is to be used to predict mortality rate for 
populations. However, it remains important that it should demonstrate adequate 
discriminant characteristics. Statistical evaluation of the models required that patients 
who were discharged, alive or dead, within the first 24 hours were excluded from 
analysis, as suggested by Lemeshow et al (4). The performance of models which 
normally include such patients, all deteriorated when these patients were excluded. This 
results from the ability of the models to discriminate maximally for the excluded group. 
Other studies have also demonstrated this deterioration in model performance over time 
(92,109,178). When this approach was taken a statistical superiority in discrimination 
was demonstrated for APACHE III, SAPS II and MPM24 when differences were tested 
using the Delong method. 
Using the models own exclusion criteria, when the results of both methods of evaluation 
were taken together it appears that the performance of SAPS II, was perhaps best overall. 
The SAPS II model had the second best rank order performance in terms of calibration 
and was one of the three best models in terms of discrimination. However, APACHE II, 
due to its superior calibration would, perhaps, be the most appropriate model from which 
to derive standardised mortality ratios in Scotland. The APACHE III model, which 
includes additional weightings for aspects such as source of admission, may be more 
health care system specific. The only other comparable study of its performance in the 
UK (83) demonstrated a similar pattern of relatively poor calibration associated with an 
underestimate of mortality, but with very good discrimination. The performance of the 
MPMO model was relatively poor in terms of discrimination and calibration. The 
performance of MPM24 was good in terms of discrimination and had comparable 
Page 76 Chapter 5 The Models' overall perfonnance 
calibration. Although the UK APACHE II model had comparable discrimination to that 
of the original APACHE II model, it had poorer calibration. This is surprising and not 
easily explained given that this study shares the same health care system. 
A possible explanation for the underestimation of mortality by the APACHE III model 
and the better calibration demonstrated by the APACHE II system could reflect an 
increase in the standard of care required in ICUs by the APACHE III model. This might 
be the case, reflecting APACHE Ill's development from more recent data collection when 
compared with APACHE II. However, the data used to develop the SAPS II and MPM II 
models were drawn from a similar period and show no such underestimate of mortality. 
Furthermore, Beck et al (83) showed in a UK ICU that both APACHE II and APACHE 
III underestimated mortality in: its population. 
" Another possible explanation, for at least some of the underestimation of mortality in the 
AP ACHE III model and the poor fit irt general of the other models, may be the effect of 
deprivation in the Scottish population. There is a lot of recent evidence to suggest that 
deprivation affects the outcome of a number of diseases and surgical procedures (179-
181). If the Scottish population is a more deprived than the populations represented in the 
original models databases then it is possible that this may have a considerable effect on 
the performance of the models. However, the ICUs involved in collecting data for the 
development of these models may have had considerable deprivation within their 
catchment area. 
One possible criticism of the study is the inclusion of patients from the HDU/ICUs. This 
is because the inclusion of these patients is decided by clinical judgement of the 
Consultant on the different units. It is possible that this will lead to bias when included 
with ICUs who include all patients in the study. However, clinicians on ICUs make the 
same judgement about the inclusion of their patient~ in the study by deeming them an 
"Intensive Care type patient" when they admit them to an ICU. Also, it was important for 
the Audit not to exclude "Intensive Care type" patients from HDU/ICUs as they 
represented ~9. 08% of Intensive care patients in the Study. The mortality rate in three of 
the units is higher than the mortality rate in the ICUs, with five ICUs having a lower 
mortality rate than the remaining HDU/ICU. The mortality estimated by the APACHE II 
model and the mean APACHE II score for three of the HDU/ICUs is higher than the 
average estimated APACHE II mortality and score for the ICUs (Table 5.4). The 
remaining HDU/ICU has an APACHE II score that is higher than 6 of the ICUs (Table 
5.5) . These results would suggest that patients from HDU/ICUs were included 
appropriately. Analysis of those patients not included in the study by the HDU/ICUs 
shows a mortality rate with a range of 3.4 to 9.87 which is considerably lower than the 
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mortality rate in those patients included in the study. It is unlikely that the HDU/ICUs 
were excluding patients who have a poor prognosis as this would be reflected in the 
mortality rate of the excluded patients (Table 5.4). 
While it appears that APACHE II and SAPS II perform best in comparison to other 
models, it is not clear how accurate that performance is. Significant Hosmer-Lemeshow 
GOF tests in the models, especially those which would appear to have better calibration 
(APACHE II and SAPS II), may be a result of the large numbers in the study. These 
differences may be of no clinical significance, with the numbers in the study making the 
sensitivity test reveal differences that have no impact on the clinical application of the 
study. Nevertheless it is important, given the lack of any other evidence, not to dismiss 
the significant GOF tests. As all the statistics used in measuring calibration are 
necessarily a result of averaging (as the outcome variable is a dichotomous one), it is 
possible, given the large numbers, that smaller groups of patients over and underestimate 
the mortality but appear to have good calibration when combined. 
There are considerable differences in the performances of all the models used in this 
study compared with the original published data for both discrimination and calibration. 
It would therefore seem appropriate that before these models are used for comparing 
different ICUs further analysis is carried out on their accuracy in different groups of 
patients. 
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Chapter 6-Uniformity of fit 
Aim: To assess the uniformity of fit of the severity of illness models. 
Contents: 
6.1 Introduction 
6.2 Methods 
6.3 Data analysis 
6.4 Results 
6.4.1 APACHEn 
6.4.2 APACHE ill 
6.4.3 SAPSn 
6.4.4MPMO 
6.4.5 MPM24 
6.5 Discussion 
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6.1 Introduction 
As well as having good calibration and discrimination, a model must have adequate case 
mix adjustment for large subgroups of patients (Uniformity of Fit) (73,115,129). If a 
model does not adequately adjust for case mix in a subgroup, an ICU admitting a large 
number of patients from this subgroup will appear to have poor performance. For 
example, if the APACHE II model underestimates the risk of mortality in medical 
patients, a unit that admits mainly this type of patient will appear to perform poorly. 
The profile of each of the 22 units will be different in some way. Some of the units are 
based in large teaching hospitals others in smaller more general hospitals. Some of the 
units admit mainly operative patients with others receiving mainly medical patients. It is 
because of this imbalance in the type of patients being admitted that case mix adjusted 
. . 
outcomes are so important. 
6.2 Methods 
To test uniformity of fit patients were grouped into mutually exclusive subgroups by both 
the APACHE II system and source of admission. The APACHE III admitting diagnosis is 
categorised by nine systems (cardiovascular, respiratory, neurological, gastrointestinal, 
renal, metabolic/endocrine, haematological, trauma, and general). Source of admission 
was recorded as part of the APACHE III data set and grouped by Accident and 
Emergency (A&E), recovery/theatre, ward in this hospital, other ICU in this hospital, 
ICU in another hospital, other area in another hospital, and home/clinic. Given the poor 
performance and the incompatibility of the diagnosis, the UK APACHE II model has 
been dropped from any further analysis. 
6.3 Data analysis 
In the previous analysis, goodness of fit tests and ROC curves were used to assess the 
performance of the different models. However, these tests are not appropriate in the 
analysis of subgroups. As the numbers of patients increase so the margins for finding 
significant results in the Hosmer and Lemeshow GOF test will narrow. As the numbers in 
each group (system and source) were different, and were smaller than the overall 
database, it was not appropriate to use GOF tests to compare calibration in the different 
sub groups (142,163). 
Comparing ROC values in different subgroups as a measure of performance would also 
not be appropriate as discrimination in different subgroups will naturally produce 
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different types of patients. Patients within some groups may represent the middle range 
of severity of illness making discrimination more difficult i.e. patients remaining in the 
ICU longer than 24 hours (Table 5.7). It is more important that a model's calibration in 
groups is adequate. 
CIs (95%) were calculated for the observed mortality in each subgroup to assess the 
difference between the mean observed mortality and the mean estimated by each of the 
models (see Chapter 3.9.2). The mean estimated mortality was considered to be 
significant ifit lay outside the confidence intervals for the observed mortality. 
P-values from the Chi Squared test were calculated to assess the significant differences 
between the observed survivors and non survivors and those estimated by the models 
(see Chapter3.9.4). 
Mortality ratios were calculated with their confidence intervals (see Chapter 3.9.3). 
Ratios whose confidence intervals lay outside the confidence intervals for the overall 
population were treated as significantly different to the overall population mortality ratio 
for a particular model. This allows the prediction of subgroups to be related to the 
overall estimated mortality generated by a model. 
6.4 Results 
6.4.1 APACHE II 
Within the source of admission category the estimated mortality lay outside the observed 
mortality CIs for the A&E, recovery/theatre category, ward and other area in another 
hospital (Table 6.1). Of the APACHE system categories the estimated mortality lay 
outside the CIs for the cardiovascular, neurological, gastrointestinal and general groups 
(Table 6.2). With the model underestimating mortality in the cardiovascular and 
neurological groups and overestimating the mortality in the gastrointestinal and general 
. groups. These results were confirmed by the Chi Squared test. The mortality ratio CIs 
(observed/expected) lay outside the mortality ratios CIs for the overall population in 
those patients admitted from A&E, recovery/theatre, ward and another area in another 
hospital. 
Page 81 Chapter 6 Uniformity of fit 
Table 6.1 Patients b~ source of admission for the APACHE II model 
APACHE Source n Mortality Expected Observed x2 
ratios mortality mortality % P= 
{C!2 % {CI} 
A&E 1,183 1.09* 30.8* 33.6 0.080 
(1.03-1.16) (31.0-36.3) 
Recovery/theatre 4,909 0.79* 22.8* 17.9 0.001 
(0.74-0.83) (16.9-19.0) 
Ward in this hospital 2,703 1.08* 41.7* 45.0 0.008 
(1.04-1.12) (43.1-46.8) 
Other ICU in this 168 1.01 37.0 37.5 0.920 
hospital (0.85-1.18) (30.2-44.8) 
leu in another 315 1.08 34.3 37.1 0.380 
hospital (0.95-1.22) (31.8-42.5) 
Other area in 560 0.81* 31.2* 25.4 0.014 
another hospital (0.71-0.92) (21.8-29.0) 
Home/clinic 10 1.45 27.6 40.0 0.458 
~0.60-2.3°l ~9.6-70.4l 
Overall patients 9,848 0.95 30.0* 28.6 0.011 
~0.93-O.98l ~27.7-29.5l 
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; A&E, Accident and 
Emergency, ICU, Intensive Care Unit; "'Significance as indicated by confidence intervals 
Table 6.2 Patients b~ APACHE III diaS!!ostic s~stem for the APACHE II model 
APACHE System n Mortality Expected Observed X2 
ratios mortality mortality % P= 
(C!2 % {C!2 
Cardiovascular 2,131 1.09* 37.7* 41.2 0.009 
(1.05-1.14) (39.1-43.2) 
Respiratory 1,846 1.04 30.6 31.7 0.377 
(0.98-1.10) (29.6-33.9) 
Neurological 850 1.35* 21.7* 29.3 0.001 
(1.25-1.45) (26.2-32.4) 
Gastrointestinal 3,276 0.77* 34.1* 26.3 0.001 
(0.73-0.81) (24.7-27.8) 
Renal 299 0.81 22.8 18.4 0.114 
(0.62-0.99) (14.0-22.8) 
Metabolic! 126 1.04 27.4 28.6 0.806 
Endocrine (0.80-1.29) (20.7-36.5) 
Haematological 48 1.08 42.3 45.8 0.708 
(0.80-1.37) (31.7-59.9) 
Trauma 697 1.18* 11.0 13.1 0.110 
(0.99-1.37) (10.6-15.6) 
General 575 0.49* 15.7* 7.7 0.001 
~0.32-O.66l ~5.5-9.8l 
Overall pati ents 9,848 0.93 30.0* 28.6 0.011 
(0.95-0.98) (27.7-29.5) 
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; A&E, Accident and 
Emergency, ICU, Intensive Care Unit; "'Significance as indicated by confidence intervals 
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Patients admitted with cardiovascular, neurological, gastrointestinal, trauma and general 
diagnosis had mortality ratios that fell outside the confidence intervals for the overall 
groups and also had significant Chi Squared tests. 
6.4.2 APACHE III 
The estimated mortality of those patients who were admitted from A&E, 
recovery/theatre, ward and ICU in another hospital lay outside the CIs for observed 
mortality (Table 6.3). Those patients with a cardiovascular, respiratory, neurological, 
gastrointestinal, haematological or trauma diagnosis had an estimated mortality which 
fell outside the CIs for observed mortality (Table 6.4). All significant groups 
underestimated mortality. The analysis of the expected mortality compared with the 
observed mortality was confirmed by the significance in the Chi Squared test. Only those 
admitted from other leu in this hospital and another area in another hospital or with a 
neurological haematological or general diagnosis had a mortality ratio whose CIs fell 
outside the CIs for the overali model. 
6.4.3 SAPS II 
Patients admitted from A&E, recovery/theatre, the ward (the three largest groups) and 
another area in another hospital had an estimated mortality which fell outside the CIs for 
observed mortality in these groups (Table 6.5). The model overestimated mortality in the 
A&E, other area in another hospital and recovery/theatre groups and underestimated 
mortality in patients admitted from the Ward. Those with neurological, trauma, renal and 
general diagnosis also had estimated mortality ratios that fell outside the CIs for observed 
mortality, with all significant groups overestimating mortality (Table 6.6). These results 
were again confirmed by the significance of the Chi Squared test in both the source of 
admission and the diagnoses, with the exception of a non-significant result in the other 
area in another hospital group. Patients admitted from A&E, recovery/theatre and the 
ward as well those with a diagnosis that fell in the respiratory, neurological, renal, 
general and trauma groups all had mortality ratios whose CIs fell outside those for the 
overall patients. 
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Table 6.3 Patients by source of admission for the APACHE III model 
APACHE Source n Mortality Expected Observed .x2 
A&E 
Recovery/theatre 
Ward in this 
hospital 
Other ICU in this 
hospital 
ICU in another 
hospital 
Other area in 
another' hospital 
Home/clinic 
Overall patients 
1,300 
5,030 
2,917 
175 
321 
572 
11 
10,326 
ratios mortality mortality % p= 
(Cn % (CI) 
1.27 26.6* 33.8 0.001 
(1.21-1.34) (31.3-36.4) 
1.23 14.9* 18.2 0.001 
(1.17-1.28) (17.2-19.3) 
1.24 37.1 * 46.0 0.001 
(1.20-l.28) (44.2-47.8) 
1.02* 37.7 38.3 0.888 
(0.86-1.17) (31.1-45.5) 
1.29 29.1 * 37.7 0.005 
(1.15-1.43) (32.4-43.0) 
1.02* 25.3 25.9 0.791 
(0.91-1.13) (22.3-29.5) 
1.86 19.6 36.4 0.209 
(0.87-2.85) (7.9-64.8) 
1.23 24.0* 29.4 " 0.001 
(1.20-l.25) (28.6-30.3) 
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; A&E, Accidentand 
Emergency, ICU, Intensive Care Unit; *Significance as indicated by confidence intervals 
Table 6.4 Patients b~ APACHE III diagnostic s~stem for the APACHE III model 
APACHE n Mortality Expected Observed .x2 
System ratios mortality mortality % p= 
{C!2 % {C!2 
Cardiovascular 2,281 1.25 34.8* 43.6 0.001 
( 1.21-1.30) (41.6-45.7) 
Respiratory 1,918 1.20 26.6* 32.0 0.001 
(1.14-1.26) (29.9-34.1) 
Neurological 926 1.44* 19.6* 28.2 0.001 
(1.34-1.53) , (25.3-31.1) 
Gastrointestinal 3,368 1.17 23.0* 27.0 0.001 
( 1.12-1.22) (25.5-28.5) 
Renal 312 1.14 16.4 18.6 0.330 
(0.94-1.33) (14.3-22.9) 
Metabolic/ 130 1.25 22.8 28.5 0.174 
Endocrine (1.02-1.48) (20.7-36.2) 
Haematological 53 1.88* 22.0* 41.5 0.003 
(1.50-2.27) (28.2-54.8) 
Trauma 738 1.34 10.0* 13.4 0.003 
(1.17-1.52) (11.0-15.9) 
General 600 0.85* 9.0 7.7 ,0.286 
{0.63-1.08l {5.5-9.8l 
Overall patients 10,326 1.23 24.0 29.4 0.001 
p.20-1.25l ~28.6-30.3~ 
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; ICU, Intensive Care 
Unit; *Significance as indicated by confidence intervals 
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Table 6.5 Patients by source of admission for the SAPS II model 
AP ACHE Source n Mortality Expected Observed 
A&E 
Recovery/theatre 
Ward in this 
hospital 
Other ICU in 
this hospital 
ICU in another 
hospital 
Other area in 
another hospital 
Home/ciinic . 
Overall patients 
1,301 
5,031 
2,922 
175 
321 
573 
11 
10,334 
ratios mortality mortality % 
(CI) % (CI) 
0.83* 40.6* 33.9 
(0.78-0.88) (31.3-36.5) 
0.88* 20.6* 18.2 
(0.84-0.93) (17.2-19.3) 
1.11 * 41.3* 46.0 
(1.08-1.15) (44.2-47.8) 
0.95 40.2 38.3 
(0.81-1.10) (31.1-45.5) 
1.00 37.5 37.7 
(0.89-1.12) (32.4-43.0) 
0.86 30.2* 25.8 
. (0.76-0.96) (222-29.4) 
1.16 3t4 . 36.4 
(0.56-1.75) (7.9-64~8) 
0.97 30.4* 29.4 
(0.95-0.99) (28.6-30.3) 
P= 
0.001 
0.001 
0.001 
0.689 
1.000 
0.057 
0.76;4 
0.084 
SAPS, Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation; 
CI, confidence interval; A&E, Accident and Emergency, ICU, Intensive Care Unit; *Significance as 
indicated by confidence intervals 
Table 6.6 Patients by APACHE III diagnostic system for the SAPS II model 
APACHE. n Mortality Expected Observed Jt2 
System ratios mortality mortality % p= 
(CI) % (CI) 
Cardiovascular 2,283 1.03 42.4 43.7 0.337 
Respiratory 
Neurological 
Gastrointestinal 
Renal 
Metabolic/ 
Endocrine 
Haematological 
Trauma 
General 
1,918 
927 
3,368 
312 
130 
53 
738 
600 
(0.99-1.07) 
1.06* 
(1.01-1.12) 
0.79* 
(0.72-0.86) 
0.99 
(0.95-1.04) 
0.77* 
30.2 
35.7* 
27.2 
24.1* 
(41.6-45.7) 
32.0 
(29.9-34.1) 
28.2 
(25.3-31.1) 
27.0 
(25.5-28.5) 
18.6 
(0.62-0.93) (14.3-22.9) 
0.80 35.7 28.5 
(0.63-0.96) (20.7-36.2) 
1.22 33.9 41.5 
(0.92-1.53) (28.2-54.8) 
0.74* 18.2* 13.4 
(0.61-0.86) (11.0-15.9) 
0.63* 12.2* 7.7 
(0.45-0.81) (5.5-9.8) 
0.140 
0.001 
0.806 
0.048 
0.167 
0.343 
0.002 
0.002 
Overall patients 10,334 0.97 30.4* 29.4 0.084 
(0.95-0.99) (28.6-30.3) 
SAPS, Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation; 
CI, confidence interval; A&E, Accident and Emergency, ICU, Intensive Care Unit; *Significance as 
indicated by confidence intervals 
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,-----------------------------------------------------------------------------
6.4.4 MPMO 
The mean estimated mortality from the MPMO model fell outside the CIs for the 
observed mortality for patients admitted from A&E, recovery/theatre, and the wards 
(Table 6.7). Patients with a cardiovascular, respiratory, neurological, haematological, 
trauma and general diagnosis also had mean estimated mortalities lying outside the CIs 
for the observed mortalities (Table 6.8). The model overestimated mortality in the 
trauma, neurological, general, A&E and recovery/theatre groups and underestimated 
mortality in the cardiovascular, respiratory and ward groups. These results from both the 
source of admission and the diagnoses are confirmed by the significance in the Chi 
Squared value. Patients admitted from A&E, recovery/theatre and the ward, and patients 
with a cardiovascular, <respiratory, neurological, trauma, general and haematological 
diagnosis allhad mortality ratio CIs that lay outside the CIs for the overall patients. 
6.4.5 MPM24 
Patients admitted from A&E, recovery/theatre, wardin this hospital, and another area in 
another hospital and with a cardiovascular, respiratory, renal and trauma diagnosis had a 
significantly different expected mortality to that observed using CIs. All but those 
admitted from another area in another hospital and those with a cardiovascular diagnosis 
had a significant chi squared test. The model overestimated the mortality in the groups 
recovery/theatre, other area in another hospital, renal and trauma and underestimated 
mortality in patients admitted from the wards and with a respiratory and cardiovascular 
diagnoses. The mortality ratio CIs from the MPM24 model lay outside the CIs for the 
overall patients for patients admitted from A&E, recoveryltheatre, the wards, other area 
in another hospital and patients with an admitting diagnosis from the respiratory, renal 
and trauma groups (Table 6.10). 
Subgroups showing significance using the CIs for observed mortality for all models can 
be seen in Table 6.11. 
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Table 6.7 Patients by source of admission for the MPMo model 
APACHE Source n Mortality Expected Observed 
A&E 
Recovery/theatre 
Ward in this 
hospital 
Other ICUin 
this hospital 
ICU in another 
hospital 
Other area in 
another hospital 
Home/clinic 
Overall patients 
1,313 
5,052 
2,940 
178 
322 
575 
13 
10,393 
ratios mortality mortality % 
(CI) % (CI) 
0.84* 40.6* 34.0 
(0.78-0.89) (31.4-36.5) 
0.90* 20.2* 18.2 
(0.85-0.95) (17.1-19.3) 
1.20* 38.3* 45.8 
(1.16-1.23) (44.0-47.6) 
0.99 38.6 38.2 
(0.84-1.14) (31.1-45.3) 
0.98 38.4 37.6 
(0.86-1.09) (32.3-42.9) 
0.90 28.9 25.9 
(0.79-1.01) (22.3-29.5) . 
1.59 24.3 38.5 
(0.80-2.38) (12.0-64.9) 
1.00 29.3 29.4 
(0.98-1.03) (28.5-30.3) 
P= 
0.001 
0.001 
0.001 
0.920 
0.806 
0.190 
0.299 
0.819 
MPM, Mortality Probability Model; APACHE, Acute Physiology and Chronic Health Evaluation; CI, 
confidence interval; A&E, Accident and Emergency, ICU, Intensive Care Unit; *Significance as indicated 
by confidence intervals 
Table 6.8 Patients by APACHE III diagnostic system for the MPMO model 
APACHE System n Mortality Expected Observed ){2 
ratios mortality mortality % p= 
(CI) % (CI) 
Cardiovascular 2,291 1.10* 39.7* 43.6 0.003 
(1.06-1.14) (41.5-45.6) 
Respiratory 1,923 1.13* 28.4* 31.9 0.003 
(1.07-1.18) (29.8-34) 
Neurological 933 0.72* 38.9* 28.2 0.001 
(0.66-0.79) (25.3-31.1) 
Gastrointestinal 3,377 1.03 26.0 26.9 0.303 
(0.99-1.08) (25.4-28.4) 
Renal 315 0.83 22.6 18.7 0.153 
(0.66-1.00) (14.4-23) 
Metabolic/ 130 0.83 34.3 28.5 0.260 
Endocrine (0.66-1.00) (20.7-36.2) 
Haematological 53 1.57* 26.5* 41.5 0.034 
(1.18-1.96) (28.2-54.8) 
Trauma 739 0.72* 18.6* 13.4 0.001 
(0.59-0.85) (10.9-15.9) 
General 604 0.60* 12.7* 7.6 0.001 
(0.42-0.78) (5.5-9.7) 
Overall patients 10,393 1.00 29.3 29.4 0.819 
(0.98-1.03) (28.5-30.3) 
MPM, Mortality Probability Model; APACHE, Acute Physiology and Chronic Health Evaluation; CI, 
confidence interval; ICU, Intensive Care Unit; *Significance as indicated by confidence intervals 
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Table 6.9 Patients by source of admission for the MPM24 model 
AP ACHE Source n Mortality Expected Observed 
A&E 781 
Recovery/theatre 3,445 
Ward in this hospital 2,223 
OtherlCU in 
this hospital 
ICU in another 
hospital 
Other area in 
another hospital 
Home/clinic 
139 
291 
455 
9 
ratios mortality mortality % p= 
(Cn % (Cn 
l.16* 32.3* 37.5 0.011 
(1.08-1.24) (34.1-41.3) 
0.86* 24.1 * 20.8 0.001 
(0.81-0.91) (19.5-22.0) 
l.17* 37.5* 43.8 0.001 
(1.12-1.21) (41.8-46.0) 
0.96 36.1 34.5 0.752 
(0.77-1.14) (26.6-42.3) 
0.95 38.4 36.4 0.584 
(0.83-1.07) (30.9-42.5) 
0.84* 28.5* 24.0 0.069 
(0.72-0.96) , '(20.0-27.3) 
. l.74 25.644.4 0.262 
(0.76-2.72) (12.0-80.7) 
Overall patients 7,343 l.02 30.1 30.7 0.396 
(0.99-1.05) (29.6-31.9) 
MPM, Mortality .Probability Model; APACHE, Acute Physiology and Chronic Health Evaluation; CI, 
confidence interval; A&E, Accident and Emergency, ICU, Intensive Care Unit; *Significance as indicated 
by confidence intervals 
Table 6.10 Patients by APACHE III diagnostic system for the MPM24 model 
APACHE System n Mortality Expected Observed X2 
Cardiovascular 
Respiratory 
Neurological 
Gastrointestinal 
Renal 
Metabolic! 
Endocrine 
Haematological 
Trauma 
General 
Overall patients 
1,599 
1,519 
574 
2,482 
213 
83 
37 
507 
325 
7,343 
ratios mortality mortality % p= 
(Cn % (Cn 
l. 06 39. 1 * 41. 7 0.104 
(1.01-1.12) (39.2-44.1) 
l.20* 28.2* 33.8 0.001 
(1.13-1.27) (31.5-36.2) 
0.95 33.6 31.9 0.475 
(0.85-1.04) (28.1-35.7) 
0.96 29.3 28.0 0.240 
(0.91-1.01) (26.3-29.8) 
0.72* 27.5* 19.7 0.030 
(0.54-0.89) (14.4-25.1) 
0.93 32.5 30.1 0.699 
(0.69-1.16) (20.3-40.0) 
1.33 36.5 48.6 0.221 
(0.98-1.69) (32.5~4.8) 
0.77* 18.3* 14.0 0.025 
(0.61-0.93) (11.0-17.0) 
0.80 13.8 11.1 0.180 
(0.57-1.03) (7.7-14.5) 
1.02 30.1 30.7 0.396 
(0.99-1.05) (29.6-31.9) 
MPM, Mortality Probability Model; APACHE, Acute Physiology and Chronic Health Evaluation; CI, 
confidence interval; ICU, Intensive Care Unit; *Significance as indicated by confidence intervals 
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Figure 6.1 Mortality ratios for ICUs for the APACHE II, APACHE III and SAPS II 
models. Open circles, APACHE II. Open triangles, APACHE III. Open squares, SAPS II. 
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Figure 6.2 Mortality ratios for ICUs for the APACHE II, MPMQ, and MPM24 models. 
Open circles, APACHE II. Asterix, MPMO. Open diamonds, MPM24. 
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Table 6.11 Subgroupsa where estimated mortality is significantlyb different than that 
observed 
APACHE II A&E, ward, cardiovascular, 
neurological 
APACHE A&E, Recovery/theatre, ward 
ill in this hospital, ICU in another 
hospital, cardiovascular, 
respiratory, neurological, 
gastrointestinal, trauma 
SAPsn 
MPMO 
MPM24 
ward in this hospit,al 
ward in this hospital, 
cardiovascular, respiratory 
A&E, ward in this hospital, 
cardiovascular 
recovery/theatre, other area in 
another hospital, 
gastrointestinal, general 
A&E, recoveryltheatre, Other 
area in another hospital, 
neurological, renal, trauma, 
general 
A&E, recovery/theatre, 
trauma, general, neurological 
recovery/theatre, other area in 
another trauma 
r\.\...-.o..o.:.. Acute PhySiology and Chronic Health Evaluation; A&E, Accident and Emergency; SAPS, 
Simplified Acute Physiology Score; MPM, Mortality Probability Model. 
a. Only subgroups with more than 300 patients are shown 
b. Significance as tested by observed mortality CIs 
When mortality ratios for each of the units from each model are plotted together and 
ordered by APACHE II there appears to be no pattern of increasing mortality ratios for 
each of the models. (Figures 6.1-6.2). 
6.5 Discussion 
If these models are to be accurately used to assess an ICU's performance, then they must 
adequately adjust for case mix in large subgroups. If a model is sensitive to where a 
patient is admitted from or the patient's underlying disease then the profile of an ICU will 
profoundly affect the unit's mortality ratio and apparent performance (115,129). 
ICUs in the study could arguably be seen as a homogeneous group, with much more in 
common with each other than the ICUs contributing data to these models' development. 
However, the ICUs (Table 5.1) in the study all have different profiles. As already stated, 
36% of the ICUs are within teaching hospitals and 64% in non teaching hospitals. Some 
ICUs take mostly surgical patients others mostly medical patients. There are also high 
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concentrations of diagnoses within certain ICDs. It is important for any model to have 
good accuracy and calibration within subgroups otherwise case mix adjusted 
comparisons between units will only reflect failures within a model and not ICDs. 
The study has used three statistics for assessing uniformity of fit. 
1. The estimated mortality compared to the CIs of the proportions of the observed 
mortality. 
2. The Chi Squared statistic. 
3. The CIs for the mortality ratio in subgroups compared to the CIs for the overall 
population 
Comparing the actual mortality to that estimated by the model using the Chi Squared 
statistic and the CIs for the observed mortality is a measure of calibration within a 
particular group. The mortality ratio in each group, on the other hand, is related to the 
overall mortality ratio for each model. If there is a systematic bias and the probaQilities 
from a model are consistently low compared to the actual mortality experience then 
subgroups may not show significance when using mortality ratios. A model showing 
poor calibration in the different subgroups but with no .significant mortality ratios in the 
subgroups may possibly be legitimately used to compare ICDs within the study. 
When grouping patients by their source of admission and their diagnostic systems it is 
important to realise that some of the groups have small numbers and therefore any 
conclusions drawn from these groups may be unreliable. Therefore the focus was on 
subgroups of300 patients or more. Wagner recommended that mortality ratios should not 
be compared until they were over 300 patients in a group (European Congress of 
Intensive Care Medicine). 
All the models have subgroups which either show significant differences between the 
estimated and observed mortality or ratios which are significantly different from the 
overall ratio. It also has to be borne in mind the number of statistical tests carried out in 
this chapter, with each model having 48 tests. It would be expected that a certain number 
of tests would be significant because of random variation. However, the number of 
statistical significant tests found was greater than the number you would expect just from 
random chance. ICUs admitting patients from any of these subgroups may have their 
performance affected by the type of patient they are admitting and from where they are 
admitting them. Not all the subgroups underestimated mortality, in some groups the 
observed mortality was less than that predicted by the different models. It is possible that 
the overall performance of a model appears good but that good calibration in either 
deciles or decades of prediction is a result of averaging. 
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In the assessment of the overall performance of the different models APACHE II and 
SAPS II were the models with the best performance. Although both models had Hosmer-
Lemeshow GOF tests that were significant (P<0.0001), it is possible that this significance 
was due to the large numbers in the study. However, both the APACHE II and SAPS II 
models had large subgroups of patients that were poorly predicted with significant 
differences in all three tests used. Also, those groups demonstrating significance 
contained a large number of patients. 
AP ACHE III had performed relatively poorly compared to the other models in the study 
with a particularly large Chi Squared value (x2=331.65). However, when the 
performance of the model is considered in the subgroups, APACHE III appears to have 
less variation than the. other models. As the overall evaluation of the model shows, the 
estimates of mortality in the APACHE III model are lower than the actual mortality. It is 
therefore not surprising that the estimated mortality is significantly different to that 
actually observed in the largest subgroups using both CIs and the Chi Squared tests.' 
However, when comparing the mortality ratios in the subgroups to the overall mortality 
ratios there is much less variation than in the other models. Patients admitted with a 
neurological and general diagnosis and'patients admitted from an other area in another 
hospital are the only large subgroups (more than 300 patients) with mortality ratios 
significantly different than the overall mortality ratios of the groups. It is possible that 
comparisons of mortality ratios from the ICUs in this study would be more meaningful 
using the APACHE III model than the other models in this study. The consistency in the 
subgroups may be as a consequence of the presence of the diagnosis and source of 
admission as variables in the APACHE III model. The lack of fit in the neurological 
patients may, in part, be due to the rules for the collection of the GCS score. The rules 
state that if a patient is sedated in the first 24 hours then the GCS is presumed to be 
normal. As the GCS has the potential to contribute 19% to the APACHE III score, 
presuming patients who are sedated have a normal GCS could have a profound effect on 
the probabilities of mortality generated by the model. 
There is considerable variation in the performance of these models in estimating the 
mortality in the different subgroups. An ICU's mortality ratio is dependent on the type 
and source of patients admitted to the unit. This seriously questions the ability of these 
models to accurately adjust for case mix. As all the models have been developed in other 
ICU cultures, it is not surprising that the resulting logistic regression models appear not 
to adjust adequately for case mix. There could be any number of differences in the ICU 
culture in Scotland, and the units participating in the original model development. When 
Intensive Care is commenced and admission criteria are just two possibilities where 
differences in ICU culture may have an effect but there are many more. The higher 
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average mortality in patients entering this study, compared to original study, has already 
been highlighted and may indicate that patients are, on average, sicker than those in the 
original studies. In their present form and based on this analysis there would appear to be 
no value in comparing ICU performance based on the output from these models. 
From the apparent differences of the models in predicted mortality in the different 
subgroups it might be expected that the different ICUs in the study would perform 
differently in each model depending on the type and source of patients admitted. This 
would appear to be the case, with different ICUs having very different mortality ratios 
depending on the model (Figures 6.1-6.2). This apparent disparity between the models is 
confirmed by the correlation coefficients when each model is compared to the other. 
, Given the relatively good ROC values in all the scores (0.79-0.85) this would suggest 
that each of the models is measuring a different aspect of severity of illness and accounts 
for a different percentage of variation in mortality 
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Chapter 7-The use of pre-sedation GCS value when calculating 
APACHE scores for sedated patients. 
Aiml To assess the impact of using a pre-sedated GCS value when calculating APACHE 
scores, when the patient has been sedated for the first 24 hours precluding the use of the 
GCS in the APACHE models. 
Contents: 
7.1 Introduction 
7.2 Methods 
7.2.1 Data analysis 
7.3 Results 
7.4 Discussion 
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7.1 Introduction 
The GCS is an important component of both the APACHE II and APACHE III models 
and has the potential to contribute 17% of the theoretical maximum acute physiology 
score in APACHE II, and 19% in APACHE III. This is more than any other single 
variable. It has been shown that there is a significant relationship between GCS and. 
outcome in general ICU patients and that the overall predictive capability of APACHE 
III is improved by incorporating the GCS (182). 
In view of the importance of the GCS, it is unfortunate that there are a significant number 
of Intensive Care patients in whom the use of sedation prevents its accurate assessment. 
In APACHE II and APACHE III a normal GCS value (83) is assigned to all such 
patients. An alternative approach in such cases, as used in the SAPS II model, is to 
. substitute the GCS recorded before the patient was sedated (3). There are theoretical 
arguments as to the better approach but there is no published evidence to support one 
methodology in preference to the other, and certainly no direct comparison within the 
same system. We hypothesised that the choice might have a significant effect on the 
performance of scoring systems, particularly if the number of sedated patients was large. 
In this study 50% of patients were sedated, preventing the use of the GCS score in the 
APACHE model (Table 7.1). The impact would be different in each of the ICUs with the 
percentage of sedated patients varying considerably in individual units in the study (10-
70%). 
Analysis from Chapter 5 showed that patients with a neurological diagnosis had an 
estimated mortality that was significantly lower than that observed. As already stated, the 
GCS is an important factor in the APACHE models. It is even more important for 
neurological patients that some assessmenfoftheir neurological status is available in the 
score. It may be that the use of a pre-sedated GCS might make an important difference to 
the estimation of mortality for these patients. 
This chapter presents the effect of either assigning a normal GCS value or adopting the 
pre-sedation value on the performance of both APACHE II and APACHE III in the data 
collected for this study. 
7.2 Methods 
Data from the study, described in chapter 3-5, were used for the analysis in this chapter. 
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Where the use of sedative drugs precluded accurate assessment of the GCS during the 
first 24 hours of Intensive Care, the pre-sedation GCS was recorded, based on clinical 
observation, communication with referring staff or the clinical notes. The APACHE II 
and III score and prediction were calculated for these patients in two ways. Firstly this 
was done in the usual way, assuming that the GCS was 15 (normal GCS), producing 
database A. The calculations were then repeated using the pre-sedation value of GCS, 
producing an alternative database, B. 
7.2.1 Data analysis 
The performance of the two databases was then compared. Discrimination was again 
assessed using the area under the ROC curve (164) and the DeLong method was used for 
statistical assessment of the differences (167). The goodness of fit of the actual and 
predicted data was assessed using calibration curves and the Hosmer-Lemeshow statistic 
(163,169). In addition to an assessment of the overall effects, an analysis was made of the 
performance within the sub-group of patients with altered scores. The pattern within 
different primary APACHE diagnostic categories was also studied. 
As there are differences in the sample sizes of different groups within this analysis, when 
assessing the differences in database A and B, comparisons have only been made where 
the sample sizes are the same. This is particularly important with the Hosmer -Lemeshow 
test as it is particularly sensitive to sample size (as previously discussed in Chapter 3). 
7.3 Results 
A total of 13,291 patients were admitted to the participating units during the study period. 
The 1,654 patients classed as HDU or CCU admissions were excluded, as were 498 re-
admissions and 114 patients for whom outcome data was not available. The specific 
exclusion criteria for APACHE II and III were also applied. These criteria differ slightly, 
so scores and predictions were available for 9,848 patients using APACHE II and for 
10,326 using APACHE III. The demographic details of the patients are shown in Table 
7.1. 
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Table 7.1 Demographics of the study populations 
Age range (yrs) (mean) 
Male (%) 
Non-operative (%) 
Sedated, GCS not recorded (%) 
Sedated patients with pre-
sedation GCS < 15 (%) 
APACHE IT 
group (n=9,848) 
16-99 (59) 
5,457 (55%) 
4,939 (50%) 
4,965 (50%) 
2,066 (21%) 
APACHEID 
group (n=10,326) 
16-99 (59) 
5,714 (55%) 
5,030 (49%) 
5,124 (50%) 
2,281 (22%) 
APACHE, Acute Physiology and ChronicHealthEvaluatio~ GCS, Glasgow Coma Score. 
Of the 9,848 patients with APACHE IT predictions, 4,965 were recorded.as sedated and 
2,066 of these had a pre-sedation GCS less than 15. The APACHE IT scores of21% of all 
patients were therefore altered when the pre-sedation GCS (Method B) was used. The 
effects of this are summarised in Table 7.2. In the APACHE III database, 2,281 (22%) of 
10,326 patients had their scores altered and the effects are summarised in Table 7.3. The 
increase in the mean APACHE scores is inevitable, since incorporating ~ pre-sedation 
GCS ofless than 15 into an APACHE score must increase it. It follows that the predicted 
mortality will increase and that the mortality ratio, the ratio of observed to predicted 
mortality, must therefore be reduced. 
Table 7.2 The effect on APACHE II score and performance 
APACHE IT Mortality Hosmer- Area under 
score (mean) ratio Lemeshow ROC curve 
GOF 
All patients (n=9,848) 
Method A 18.3 0.953 36.39 0.805a 
MethodB 19.4 0.874 132.97 0.816a 
Patients with altered scores (n=2,066) 
Method A 19 1.26 144 0.764b 
MethodB 25 0.89 65 0.771b 
APACHE, Acute Physiology and Chronic Health Evaluation; GOF, Goodness of fit; ROC, Receiver 
Operaing Characteristic. 
a P<O.OOO9 for difference between method A and method B 
b P=O.13 not significant between method A and method B 
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Table 7.3 The effect on APACHE III score and Eerfonnance 
APACHE ill Mortality Hosmer- Area under 
score (mean) ratio Lemeshow ROC curve 
GOF 
All patients (n=10,326) 
Method A 60.8 1.23 331.65 0.845a 
MethodB 64.3 1.09 126.89 0.852a 
Patients with altered scores (n=2,281) 
Method A 64 1.51 518 0.809b 
MethodB 81 1.00 47 0.805b 
APACHE, Acute Physiology and Chronic Health Evaluation; GOF, Goodness of fit; ROC, Receiver 
Operaing Characteristic. . 
a p<O.OOOI for difference between method A arid method B 
b p=O.55 not significant between method A and method B 
There is a significant increase in the area under the ROC curve for APACHE II (Method 
B) compared to the original model (Method A), indicating improved discrimination 
(Table 7.2, Figure 7.1). The value of the Hosmer-Lemeshow statistic in database is 
increased in APACHE II (Method B) compared with the original model (Method A) 
suggesting that the fit of the data is poorer. The calibration curves (Figure 7.2) confinn 
this. The curve for APACHE II lies significantly below the line of equality (which 
represents the situation where actual mortality and estimated mortality are equal) when 
the estimated mortality is between 30% and 70%. This indicates that actual mortality is 
less than estimated. Since using the pre-sedation GCS increased estimated mortality, it 
must also increase this difference. Examination of the perfonnance in the patients with 
altered scores however (Table 7.2) shows that for these patients there is an improvement 
in both the Hosmer-Lemeshow statistic and the calibration curve (Figure 7.3) although 
the increase in area under the ROC curve is not statistically significant. 
The discrimination of APACHE III was also improved (Table 7.3, Figure 7.4), as was the 
Hosmer-Lemeshow statistic and the calibration curve. The calibration curve for 
APACHE III for the entire population (Figure 7.5) lies significantly above the line of 
equality for most of its length i.e. it underestimates mortality. The use of pre-sedation 
GCS moves the calibration curve closer to the diagonal, and for an estimated mortality of 
greater than 50% it is within the 95% confidence limits. If the calibration and goodness 
offit are again analysed for the patients with altered scores (Figure 7.6, Table 7.3) an 
improvement in this group is confinned. 
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Figure 7.1 ROC curves for APACHE II (all patients) for Database (a) and Database (b) 
and APACHE II (patients with altered scores) for Database (a) and Database (b) 
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Figure 7.2 Calibration curves for APACHE II (a) assuming a normal GCS in sedated 
patients and APACHE II (b) using the pre-sedation GCS value for sedated patients. 
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Figure 7.3 Calibration curves for APACHE II (a) (patients with altered scores) assuming 
a nonnal GCS in sedated patients and APACHE II (b) (patients with altered scores) using 
the pre-sedation GCS value for sedated patients. 
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Figure 7.4 ROC curves for APACHE III (all patients) for Database (a) and Database (b) 
and APACHE III (patients with altered scores) for Database (a) and Database (b). 
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Figure 7.5 Calibration curves for APACHE III (a) assuming a normal GCS in sedated 
patients and APACHE III (b) using the pre-sedation GCS value for sedated patients. 
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Figure 7.6 Calibration curves for APACHE ITI (a) (patients with altered scores) 
assuming a normal GCS in sedated patients and APACHE ITI (b) (patients with altered 
scores) using the pre-sedation GCS value for sedated patients. 
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Table 7.4 Patients sedated and with altered scores in APACHE III database 
APACHE diagnostic No. of No. sedated No. with score 
s~stem category Eatients {%} changed {%} 
Cardiovascular 2,281 1,123 (49) 490 (21) 
Respiratory 1,918 1,022 (53) 534 (28) 
Neurological 926 466 (50) 395 (43) 
Gastrointestinal 3368 1,735 (52) 522 (15) 
Renal 312 109 (35) 31 (10) 
Metabolic/endocrine 130 46 (35) 25 (19) 
Haematological 53 22 (42) 13 (25) 
Trauma 738 399 (54) 219 (30) 
General 600 202 (34) 52 (9) 
Overall 10,326 . 5,124 (50) 2,281 (22) 
APACHE; Acute Physiology and Chronic Health Evaluation. 
Table 7.5 The effect on actual and Eredicted mortality, APACHE II 
APACHE diagnostic No. of Mortality ratio 
system category 
Cardiovascular 
Respiratory 
Neurological 
Gastrointestinal 
Renal 
Metabolic/endocrine 
Haematological 
patients 
2,131 
1,846 
850 
3,276 
299 
126 
48 
Method A 
1.09 (1.05-1.14) 
1.04 (0.98-1.10) 
1.35 (1.25-1.45) 
0.77 (0.73-0.81) 
0.81 (0.62-0.99) 
1.04 (0.80-1.29) 
1.08 (0.80-1.37) 
Trauma 697 1.18 (0.99-1.37) 
General 575 0.49 (0.32-0.66) 
APACHE, Acute Physiology and Chronic Health Evaluation. 
·Cls for Method A and Method B that don't overlap 
MethodB 
1.01 (0.97-1.05) 
0.93 (0.88-0.99) 
1.01 (0.92-1.09)* 
0.75 (0.71-0.79) 
0.78 (0.60-0.96) 
0.94 (0.72-1.16) 
1.05 (0.75-1.33) 
0.89 (0.73-1.05) 
0.46 (0.29-0.62) 
The effects of these changes were not confined to any particular diagnostic group. 
Although those patients whose primary APACHE diagnostic category was neurological 
or trauma were particularly likely to be affected, they accounted for only 27% of all 
altered scores. The number of patients sedated and with altered scores for each of the 
primary APACHE diagnostic categories are shown in Table 7.4 for APACHE III. The 
figures for APACHE II are almost identical. The effects on the ratio of actual to observed 
mortality for each category are shown in Tables 7.5 and 7.6. The proportion of patients 
who were sedated (10-69%) and who had their APACHE scores altered (5-47%) varied 
markedly amongst the participating units (Figure 7.7). 
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Table 7.6 The effect on actual and Eredicted mortality, APACHE III 
AP ACHE diagnostic No. of Mortality ratio 
s~stem cateso!l. Eatients 
Method A MethodB 
Cardiovascular 2281 1.25 (1.21-1.30) 1.14 (1.11-1.18)* 
Respiratory 1918 1.20 (1.14-1.26) 1.07 (1.02-1.13)* 
Neurological 926 1.44 (1.34-1.53) 1.04 (0.96-1.12)* 
Gastrointestinal 3368 1.17 (1.12-1.22) 1.13 (1.08-1.18) 
Renal 312 1.14 (0.94-1.33) 1.11 (0.92-1.31) 
Metabolic/endocrine 130 1.25 (1.02-1.48) 1.12 (0.90-1.34) 
Haematological 53 1.88 (1.50-2.27) 1.84 (1.46-2.22) 
Trauma 738 1.34 (1.17-1.52) 1.00 (0.85-1.14)* 
General 600 0.85 {0.63-1.08} 0.80 {0.58-1.02} 
APACHE, Acute Physiology and Chronic Health EvaluatiOIl 
·CIs for Method A and Method B that don't overlap 
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Figure 7.7 Percentage of patients sedated and with altered APACHE III scores for each 
ICU. 
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7.4 Discussion 
The association between an impaired conscious level and mortality in Intensive Care is 
well recognised (183). Although the validity of using the GCS in general ICU patients 
has been questioned (77), there is a significant relationship between the GCS and 
outcome in such patients and the overall predictive capability of the APACHE III system 
is improved by incorporating the GCS (182). As already mentioned, the GCS is 
potentially the largest single contributor to the acute physiology score. There is no doubt 
that the GCS should be assessed directly whenever possible. 
The purpose of the development of GCS was to facilitate consistent and reliable 
recording 'of level of consciousness, but difficulties do arise in practice. Ideally the GCS 
should be recorded in a patient who is fully resuscitated and is not sedated. Concern has 
been expressed about inconsistency of approach in patients with head injuries presenting 
to A&E (46) since modem practice emphasises early intubation and sedation. Similar 
problems clearly occur in the ICU where sedation and paralysis are commonly employed. 
In this study population, almost 50% of admissions were classed as being sedated for the 
first 24 hours. 
There are four possible approaches to scoring an ICU patient who is sedated and in 
whom it is not possible to stop sedation. The first approach is to record the GCS 
observed. This is likely to result in an artificially low score, which is at least partly 
attributable to the sedative drugs rather than the underlying physiological disturbance. 
The second is to make a best guess at the underlying GCS with clear potential for 
systematic or random error. The third is to assume that the GCS is normal and the fourth 
is to assume that the GCS is unchanged from the pre-sedation value. 
There is little support for either of the first two approaches and they have not been 
considered here. The third approach, used in APACHE II and III, is consistent with the 
general practice that missing values are recorded as normal. The reason for this is if there 
is no measurement of the PaD2 then it is likely that the clinician was not concerned about 
it and it probably was normal. The same assumption cannot be made when the GCS is 
absent, indeed it may well be that the patient is kept sedated because of concern about 
their neurological condition. The main argument in favour of this approach is that 
although it runs counter to many clinicians' instincts and may underestimate the risk of 
death for an individual patient, it is, at least, consistent (49). When the number of sedated 
patients is large, however, there may be a considerable overall effect, which may not be 
equally distributed across different ICUs or diagnostic groups. The proportion of patients 
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sedated between units can vary considerably (0-26% in APACHE III (182)), 10% to 70% 
in the present study. This may hinder any comparisons between units. 
The fourth approach, adopted in SAPS II, allows account to be taken of a previously 
documented abnormal level of consciousness but this has its own deficiencies. It assumes 
that the GCS has not changed since sedation was begun. The value ascribed to the pre-
sedation GCS may be unreliable due to observer error or incomplete resuscitation. It is a 
single point measurement, whereas the principle of recording the worst in first 24 hours 
has gained general acceptance. Finally, it may have been recorded some time prior to 
ICU admission. 
The choice <:>f method is an important issue. In the present study 50% ofpatients were 
sedated, and 40% of these sedated patients had their APACHE scores changed. This had 
a significant effect on the performance of both APACHE II and III. . 
Ideally a severity scoring system would nave both good discrimination and calibration. 
AP ACHE III was improved by the adoption of pre-sedation values of GCS rather than 
assuming a normal value. The calibration of APACHE III was also improved but the 
calibration of APACHE II was poorer. The difference here is related to the initial 
calibration of the two systems to the Scottish database. Since APACHE II overestimates 
mortality even when the GCS in sedated patients is taken as normal and using the pre-
sedation GCS increases predicted mortality, this deterioration is inevitable. It does 
however require explanation since it suggests use of the pre-sedation GCS may be 
i~appropriate. A clear improvement in the calibration seen when the patients with altered 
scores are analysed separately confirms the benefit of using pre-sedation GCS. It is 
probable that there are other limitations in the applicability of the existing APACHE II 
model in this data, normally concealed, that are exposed by the improvement seen in this 
group. The patients with a neurological or trauma primary diagnosis were most likely to 
have their scores affected, and the greatest changes in mortality ratios were also seen in 
these groups. It is noteworthy that it is in precisely these groups that the performance of 
both APACHE II and APACHE III has been least satisfactory in previous studies in the 
UK (20,83). It seems that the balance for these data favours the use of the pre-sedation 
value. It has the further advantage of reducing the spread of actual to observed mortality 
between diagnostic groups which will tend to reduce the effect of differing case mix on 
performance. 
No previous published studies, as far as the author is aware, have examined this issue, 
and it is always difficult to generalise from a single study. The database is a large one, 
encompassing almost all general Intensive Care admissions in Scotland over this period 
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and the distribution of diagnoses was broadly similar to that of the UK APACHE II study 
(20,73). The population is probably representative of UK practice. The fact that the 
clinicians felt unable to assess the GCS in almost 50% of the patients was surprising, but 
it is difficult to know if this is an atypical figure. In the UK APACHE II study 52% of 
patients were sedated when the lowest GCS was estimated and 26% were sedated for all 
GCS measurements (K Rowan, personal communication). The great majority of the 
patients in the present study (70%) were ventilated and this may represent, 
unintentionally, a form of case selection compared to the original APACHE II and III 
databases. Despite the trend to lighter sedation in current practice it is not always 
possible to assess the GCS in such patients. If the pre-sedation values for these patients 
were nearly allIS then the approach taken would have little practical impact, but in fact 
40% of the sedated patients had a GCS less than 15 and using these values had a 
significant effect on scores, mortality pred~cti()n and performance. 
Whilst it is important to re-emphasise the importance of recording the GCS accurately 
whenever possible, when sedation prevents this then the pre-sedation GCS, it would 
appear, should be used to calculate APACHE scores and mortality predictions. This 
approach improves the performance of the system and reduces one possible source of 
error in the mortality ratios for individual units. 
It is clear that if any customisation or remodelling is to be done in this population then it 
should consider the use of a pre-sedated GCS where a normal GCS is not available. 
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Chapter 8- Customisation of Models. 
Aims: To improve the perfonnance of the existing models in the Scottish setting 
To assess the ability of customisation to improve the perfonnance of different 
severity of illness models 
Contents: 
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8.2 Materials and Methods 
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8.1 Introduction 
The models in this study have been tested and evaluated in several countries with varying 
results (53,73,83,84,102,110,184). The probabilities generated by all these models are 
based on logistic regression coefficients from their original data cohorts and therefore 
represent the weights for the variables in those data. These weights may not be 
representative of all ICU cultures and there is widespread agreement that these models 
must first be validated before being applied in different ICUs (21,22,83). 
Results from previous chapters (Chapters 4-6) demonstrated significant differences 
between the predicted and observed mortality (Hosmer- Lemeshow goodness of fit test) 
in all models. The conclusions drawn from analysis of these data, confirms that before 
any valid comparisons of outcome on different ICUs in Scotland could take place, the 
models needed to be customised to better reflect the mortality experience in Scottish 
ICUs. There are a number of studies where customisation has been shown to improve the 
accuracy of the MPMo part of the MPM II model (139,142). In a large study of over 
11,000 patients after a process of customisation both the MPM24 and the SAPS II 
models had improved goodness offit (141). 
In an attempt to improve the accuracy and validity of four of the scoring models 
(APACHE II, SAPS II, MPMO and MPM24) analysed in Chapters 4-6, the data from this 
study have been used to customise these models. 
8.2 Materials and Methods 
8.2.1 Added data 
Data from a further six m<:>,nths of the study were added to the two years of data already 
collected. The same data protocols and conditions applied to these six months as in the 
first two years of data collection. It was hoped that by adding a further six months data 
this would help to generate more representative models with the extra observations. As 
some diagnostic categories and variables represent small numbers of patients, it was 
hoped that by adding a further six months data this would help to produce coefficients 
that were a true reflection of these patients. 
8.2.2 Outcome measures 
Patient status on hospital discharge was the outcome used in the original development of 
all models. However, patients being transferred to other ICUs would be recorded as 
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having survived, though these patients may not have survived after treatment in the 
second ICU. In the original analysis (Chapter 4-6) it was important to test the models 
using the original rules and outcome measures. However, the customisation process did 
not constrain the study to a particular outcome and the use of patient status at the end of 
hospital stay, being defined as one continuous stay in any hospital, was a possible 
alternative outcome measure. 
The Information and Statistics Division's Scottish Morbidity Record (SMR) database 
routinely links all mortality data and all hospital admission records. All acute admissions 
to hospitals in Scotland require an SMRI return to be generated on discharge. SMRI 
records and the Registrar General's Office (RGO) mortality records are linked together 
for individual patients using probability matching. The accuracy of the linkage of these 
records to each other and to the GRO's death records is at least 99% (185). 
Patients for the first year were linked to the Information and Statistics Division's linked 
database to extract status at the end of hospital stay. Of 669 patients transferred to other 
hospitals in 1995, 97 patients (14.5%) died before hospital discharge. This represents 
1.96% of all patients entered in to the study in 1995, and 6.8% of the deaths in 1995. 
Record linkage was not available past 1995. An attempt was made to obtain status at the 
end of hospital stay but the data were difficult and time consuming 'to collect. The 
numbers suggest that the impact on the overall population was small but the size of the 
error may be larger for individual units. However, as end of hospital stay was not 
available for all patients, status on hospital discharge was chosen as the dependent 
variable in the customisation process. Status was defined as dead or alive on discharge 
from hospital. 
8.2.3 Development and validation cohorts 
All patients were allocated a random number between 1 and 100. The data were then 
divided approximately in half by allocating all patients with a random number of 50 or 
less (development cohort) into one group and the remaining patients forming the other 
(validation cohort). The development cohort was used to generate the new models and 
the validation cohort was used to test these new models. The data were grouped in a ratio 
of 50:50 to ensure that analysis was not weighted in favour of either the model building 
or validation exercise. This also allowed valid comparisons when using goodness of fit 
tests, which are sensitive to sample size, as it created cohorts of roughly equal size. 
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8.2.4. Data analysis 
Models were customised using forward stepwise logistic regression. Variables in the 
regression that were not significant were not included in the final models. All regression 
was carried out using the SPSS software (SPSS Inc, Chicago, Illinois, US). Comparisons 
were then made between the performance of the original models and performance of the 
new customised models. Discrimination was assessed using the area under the ROC 
curve (164,186) with the DeLong method (167) being used to test for significant 
differences between areas under the curves. Calibration was assessed using the Hosmer-
Lemeshow GOF C statistic (169) and calibration curves (see Chapter 3.9.2). As discussed 
in Chapter 5, it is important that the accuracy of the severity of illness models is 
maintained inlar:ge sub groups (115,129). Mortality ratios with their CIs were used to 
assess this uniformity of fit (See Chapter 3.9.3). cis that did not overlap with the CIs for 
the whole population in the relevant models were treated as demonstrating significant 
differences. The Chi Squared test was used to· test differences between estimated 
mortality and observed mortality in subgroups (see Chapter 3.9.4). 
To convert the Logit (g(x» to hospital mortality the following calculation was used: 
Pr(Ho~pital mortality )=[ ~(x)/1 +~(x)] 
8.2.4.1 APACHE IT 
Two new APACHE IT models were created in the process of customisation. The first 
model used the APACHE IT score as originally reported (New APACHE (A». A second 
model was created using an adapted score which incorporated a pre-sedated GCS if the 
patient was sedated for the first 24 hours (New APACHE (B». Analysis from Chapter 7 
shows that using a pre-sedated GCS improves the APACHE IT model. Three variables 
were entered into the regression to produce the new model, the APACHE II score, 
admitting diagnosis, and emergency operative status. The original APACHE II model 
was not calculated unless the patient stayed for longer than eight hours, ~his exclusion 
was not applied in the customisation study, and patients staying longer than an hour were 
included in the study if fulfilling all other criteria. 
The study did not collect the APACHE IT diagnosis as described in the original paper. 
The APACHE III list of diagnoses (230 separate diagnoses) was used to collect admitting 
diagnosis. Only diagnoses chosen for more than twenty patients were entered into the 
new models, remaining diagnoses with less than twenty patients were allocated to the 
general diagnostic groups (i.e. other respiratory). 
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The logistic regression equations for the two new APACHE models were as follows: 
New APACHE II (A) = Logit=f30+(APACHE II score*B)+(Diagnostic B) 
+(post-emergency surgery B). 
New APACHE II (B) = Logit=BO+(APACHE II score(GCS amended)*B) 
+(Diagnostic B). 
8.2.4.2 SAPS II 
The SAPS II score, post-emergency surgery, and, as in the original published paper, a log 
of the score were included in the regression to generate the New SAPS II model (new 
SAPS II (A». 
The logistic regression equation for the new SAPS II (A) model was as follows: 
Logit=f3Q+(SAPS IIscore*Bl)+(Log(SAPS IIscore+l) *132) +(post-emergency surgery 
B3). 
8.2.4.3 MPM II 
To generate a New MPMo model (New MPMO(A» all the variables, collected on 
admission to the ICU, from the original paper were entered into the regression. As in the 
published methodology all the variables collected on admission and those entered after 
24 hours were entered into the regression for the New MPM24 model (New MPM24(A». 
The logistic regression equations for the new MPMO (A) and the new MPM24 (A) 
models were as follows: 
Logit g(x)=f3Q-tI31xl+B2x2+ .......... BkXk 
where no is the constant and Bixi is the estimated coefficient for the ith variable times the value of the ith 
variable, with i taking the values 1 to k and k being the number of variables in the model. 
Previous studies customising the MPM model had also used a simpler method entering 
only the logit from the original model (139,142). To allow comparisons with these 
studies a second model was calculated for both MPMO (New MPMo (B» and MPM24 
(New MPM24 (B» by entering the logit from the original score as the only independent 
variable. 
The logistic regression equations for the new MPMo (B) and the new MPM24 (B) 
models was as follows: 
Logit: =BO+(B* [Study ]MPMLogit) 
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8.2.4.4 Selection check 
A further random 50:50 split was carried out to check the robustness of the customisation 
process and to test the presumed stability of the models. The second random selection 
was used to calculate new coefficients for the APACHE II model incorporating a pre-
sedated GCS. The same methods were used as in 8.2.4.1 with Hosmer-Lemeshow tests 
and ROC curves used to test the performance of the new APACHE II (check) model. 
8.3.1 Patients 
A total of 16,701 patients were admitted to the ICUs participating in the study. Study 
exclusions, readmissions, HOU and patients with missing data, amounted to 3,693 
leaving 13,008 patients for analysis (Table 8.1). Demographic details for the overall 
population, the development and validation cohorts can be seen in Table 8.2. Both the 
development cohort and the validation cohort had similar characteristics to the overall 
population. Importantly the severity of illness when measured by the SAPS II score and 
APACHE II score remained of a similar magnitude to the overall population. 
8.3.2. APACHE II Models 
Analysis for the APACHE II models used 12,936 patients, 6,422 in the development 
cohort and 6,514 in the validation cohort, with 72 patients excluded because of missing 
information. 
Table 8.1 Study exclusions 
Reason for Exclusion 
Readmissions 
Missing outcomes 
Prospective study exclusion 
categories 
HOU patients 
Total 
HDU, High Dependency Unit. 
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Number of patients 
637 
150 
817 
2,089 
3,693 
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Table 8.2 DemograEhics 
All Patients Model Group Validation Group 
n=13,008 n=6,458 n=6,550 
Age range (yrs) (mean) 16-99 (59) 16-99 (59) 16-99 (59) 
Male(%) 7,163 (55) 3,548 (55) 3,615 (55) 
Mean SAPS II score 39.58 39.51 39.66 
Mean APACHE II score 18.38 18.32 18.44 
SAPS, Simplified Acute Physiology Score; APACHE, Acute Physiology and Chronic Health Evaluation. 
In the model New APACHE II (B) the variable "emergency surgery" was not 
significantly associated with the dependent variable (hospital mortality) and was 
therefore not included in the model. 
The coefficients for the new APACHE II models are as follows (Table 8.3): 
New APACHE II (A) 
New APACHE II (A) constant (130) 
APACHE II (A) score 
Emergency Operative 
New APACHE II (B) 
New APACHE II (B) constant (130) 
APACHE II (B) Score 
-3.8822 
+0.1587 
0.3984 
-4.2952 
+0.1694 
Table 8.3 Diagnostic coefficients for new APACHE II models 
Diagnostic codes op- PtNo New New 
nonop· APACHE II APACHE II 
(A) (B) 
Respiratory 
230 Respiratory arrest N 88 0.0856 ~.2089 
I Neoplasm-mouth/sinuses 0 47 ~.8437 ~.5324 
2 Neoplasm-larynx/trachea 0 33 -1.0666 ~.8253 
3 Neoplasm-lung parenchyma 0 23 ~.2835 ~.065 
8 Other respiratory surgery 0 50 -1.3997 -1.1845 
9 ARDS (non cardiogenic pulmonary oedema) N 52 0.619 0.6001 
to Pneumonia-viral N 24 0.4298 0.4754 
12 Pneumonia-bacterial N 375 0 0 
14 Pneumonia-aspiration/toxic N 73 0.2492 0.1162 
18 Pulmonary embolus N 24 0.111 0.1343 
20 Localised airway obstruction/oedema N 36 ~.4347 ~.4774 
(mechanical) 
21 Emphysema N 67 ~.4549 ~.4649 
22 Asthma N 134 -1.5623 -1.4618 
23 Smoke inhalation N 28 ~.3391 ~.3757 
25 Other respiratory disorder N 187 ~.0459 0.0207 
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Cardiovascular 
27 Aorto-femoral, fern-fern bypass graft 0 97 .Q.3581 .Q.0992 
29 Aortic anewysm: pre-leak/dissection 0 143 .Q.8961 .Q.6899 
30 Aortic anewysm: dissection 0 20 -1.0327 .Q.5151 
31 Aortic anewysm: rupture 0 141 .Q.6262 .Q.l34 
32 Peripheral ischaemia 0 38 -1.2287 .Q.8971 
51. Other cardiovascular surgery 0 119 .Q.555 ~.2688 
53 Aortic anewysm N 30 0.0462 0.0374 
57 Rhythm distwbance N 29 .Q.2835 .Q.5435 
58 Acute myocardial infarction N 23 0.6536 0.495 
60 Congestive heart failure N 126 .Q.6489 .Q.6403 
61 Cardiogenic shock N 117 1.0993 1.0758 
64 Septic shock - lungs (pneumonia) N 49 0.4502 0.2772 
65 Septic shock - urinary tract infection N 24 0.0372 0.0737 
66 Septic shock - gastrointestinal tract N 57 0.5327 0.4791 
67 Septic shock - unknown origin N 66 0.0427 .Q.0252 
69 Post cardiac arrest (± respiratory arrest) N 260 1.1342 0.7538 
73 Other cardiovascular disorder N·· 84 .Q.6772 . .Q.6816 
Neurological 
74 Subarachnoid haemorrhage/intracranial 0 29 0.8665 0.5716 
anewysm 
75 Subdural/epidural haematoma 0 28 0.0729 .Q.8359 
82 Other neurosurgery 0 44 .Q.3672 .Q.5464 
83 Subarachnoid haemorrhage/intracranial N 58 1.4534 1.0298 
anewysm 
85 Intracerebral haemorrhage/haematoma N 29 1.3838 0.8867 
86 Cerebrovascular accident (CV A)/stroke N 22 1.8432 1.6839 
88 Seizures N 74 -1.2772 -1.6031 
92 Self-inflicted overdose N 171 -2.2551 -2.2793 
98 Non traumatic coma - cause unknown N 22 .Q.8737 -1.0917 
99 Other neurological disorder N 119 0.0299 .Q.3233 
Gastrointestinal 
110 Bleeding - ulcer 0 97 .Q.17 0.3667 
III Bleeding - laceration/tear 0 25 -1.525 -1.3084 
115 GI perforation/rupture 0 323 .Q.5469 .Q.1226 
116 GI obstruction (any cause) 0 222 .Q.7943 .{).3069 
117 GI neoplasm (not perforation/obstruction) 0 439 .Q.4572 .Q.1434 
118 Localised GI abscess/cyst 0 41 .Q.7188 .Q.2258 
119 Peritonitis 0 70 .Q.686 .Q.1452 
121 CholangitiS/cholecystitis 0 75 -1.5658 -1.1786 
123 GI vascular 0 69 0.5431 1.0942 
insufficiency/embolism/infarction 
124 GI inflammatory disease 0 53 -1.6879 -1.3188 
125 Liver transplant 0 29 -1.8185 -1.7582 
128 Other GI surgery 0 193 .Q.3567 0.0171 
129 Bleeding - ulcer N 28 0.635 0.6855 
131 Bleeding - varices N 32 0.9495 0.6385 
134 GI perforation/rupture N 62 0.3575 0.4233 
135 GI obstruction (any cause) N 46 0.4924 0.5994 
136 GI neoplasm (not perforation/obstruction) N 39 .Q.5951 .Q.4306 
138 Peritonitis N 28 1.6085 1.6305 
139 Pancreatitis N 73 0.3084 0.3512 
148 Hepatic failure - drug overdose N 26 1.4763 0.7312 
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150 Other GI disorder N 112 0.1852 0.1072 
Renal 
157 Renal neoplasm 0 53 -0.5892 -0.3499 
163 Other renal surgery 0 76 -0.9171 -0.6446 
172 Other renal disorder N 60 -0.3938 -0.4102 
Metabolic/endocrine 
175 Other metabolic/endocrine surgery 0 26 -5.6774 -5.2667 
187 Other metabolic endocrine disorder N 51 -0.1379 -0.2333 
Baematologicai 
190 Other haernatological surgery 0 5 0.5649 0.8382 
196 Other haernatological disorder N 31 0.5242 0.6359 
Trauma 
199 Ttauma - face 0 24 -0.6509 -0.1606 
203 Trauma - extremities 0 72 -1.3135 -0.8928 
204 Trauma - multiple sites plus headlbrain 0 25 -0.5806 -0.3094 
205 Trauma - multiple site without headlbrain 0 39 -2.5173 -2.1282 
.' 
209 Trauma - headlbrain N 47 -0.4306 -0.9344 
212 Trauma - chest N 45 -0.6287 -0.4448 
216 Trauma - multiple sites plus headlbrain N 78 -0,0137 -0.5668 
217 Trauma - mul~ple site without headlbrain N 45 ' -0.3644 -0.1725 
General 
Obs and gynae 
222 Pre-eclampsialeclampsia 21 -5.9244 -5.548 
223 Hysterectomy 26 -5.6133 -5.1656 
Elderly 
226 Other elderly disorder 43 -0.8461 -0.6574 
Miscellaneous 
229 Other miscellaneous 393 -1.3054 -1.1199 
APACHE, Acute Physiology and Chronic Health Evaluation;*N, Non-operative, 0, Operative 
GI, Gastrointestinal. 
In the development cohort, the New APACHE II (A) showed poorer calibration than the 
original APACHE II model using the Hosmer-Lemeshow GOF test. The New APACHE 
II (A) had a significant GOF test (P< 0.001). The New APACHE II (B) had improved 
calibration, with the Hosmer-Lemeshow GOF test not significant (Table 8.4). Both new 
models showed significantly higher areas under the ROC curve when compared to the 
original score (Table 8.4). 
In the validation cohort, the New APACHE IT (A) model had poorer calibration than both 
the original model and the New APACHE IT (B) model and all had significant Hosmer-
Lemeshow tests but the New APACHE II (A) model had a much larger Chi Squared 
value (x2=136.S2). This difference between the New APACHE (A) and the other 
APACHE II models was reflected in the calibration curves (Figure 8.1). Both new 
models showed significantly increased areas under the ROC curve when compared to the 
original model. 
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Table 8.4 GOF tests and Area under the ROC curves for APACHE II 
GOF P< ROC P< Mortality 
Ratios 
APACHE II Development 16.53 0.035 0.820 0.97 
(0.94-1.00) 
Validation 34.12 0.001 0.807 0.94 
(0.91-0.97) 
NEW APACHE II (A) Development 45.48 0.001 0.862 0.001 * 0.92 
(0.89-0.94) 
Validation 136.52 0.001 0.838 0.001* 0.88 
(0.85-0.91) 
NEW APACHE IT (B) Development 12.99 0.112 0.858 0.001* 1.00 
(0.97-1.03) 
Validation 44.86 0.001 0.835 0.001* 0.97 
(0.94-1.00} 
GOF, Goodness of Fit; ROC, Reciever Operating Characteristic; APACHE, Acute Physiology and Chronic 
Health Evaluation; • P-value of area under the ROC curve when compared to the original model. 
Table 8.5 Source of admission mortality ratios and P values for APACHE II 
Source of IF Original X2 New X2 New X2 
Admission APACHE p= APACHE p= APACHE p= 
II ll(A) ll(B} 
A&E 810 1.06* 0.345 0.84 0.003 0.93 0.224 
(0.98-1.13) (0.78-0.90) (0.86-1.00) 
Recovery/theatre 3,135 0.79* 0.001 0.92 0.051 1.00 1.000 
(0.73-0.85) (0.86-0.98) (0.94-1.07) 
Ward in this 1,877 1.05* 0.167 0.91 0.007 0.99 0.740 
hospital (1.00-1.09) (0:87-0.95) (0.95-1.03) 
Other ICU in this 117 1.00 1.000 0.83 0.203 0.92 0.572 
hospital (0.80-1.20) (0.67-0.98) (0.75-1.09) 
ICU in another 207 1.04 0.708 0.81 0.077 0.92 0.458 
hospital (0.88-1.21 ) (0.69-0.94) (0.78-1.06) 
Other area in 363 0.80 0.034 0.66* 0.001 0.75* 0.007 
another hospital (0.66-0.93) (0.55-0.78) (0.62-0.87) 
Home/clinic 5 1.70 0.450 1.12 0.888 1.15 0.841 
~0.34-3.05} ~0.19-2·042 ~0.30-2.002 
Overall patients 6,514 0.94 0.009 0.88 0.001 0.97 0.121 
(0.91-0.97} (0.85-0.91} (0.94-0.99} 
APACHE, Acute Physiology and Chronic Health Evaluation; A&E, Accident and Emergency; ICU, 
Intensive Care Unit; ·Significance as indicated by 95% CIs. 
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Variations in the model's ability to predict in large sub groups were seen in the mortality 
ratios for both source of admission and the APACHE System category in the validation 
cohort (Table 8.5 and 8.6). The CIs for the mortality ratios for patients admitted from 
A&E, Recovery/theatre, and Ward in this hospital all lay outside the CIs for the overall 
population in the original APACHE II model. 
Table 8.6 APACHE S~stem mortality ratios for APACHE II 
AP ACHE System N Original X2 New X2 New X2 
APACHE p= APACHE p= APACHE II p= 
II II {A} (B} 
Cardiovascular 1,406 1.07* 0.086 0.91 0.016 0.97 0.406 
. (1.02-1.12) (0.87-0.95) (0.92-1.01 ) 
Respiratory 1,241 1.01 0)91 0.87 0.005 0.95 0.313 
(0~94-1.08) (0.81-0.93) , (0.88- 1.02) 
Neurological 573 1.27* 0.002 0.75* 0.001 0.95. 0.493 
(1.15-1.40) (0.67-0.83) , (0.85-1.05) 
Gastrointestinal 2,149 0.77* 0.001 0.92 0.042 0.97 0.532 
(0.72-0.83) (0.86-0.97) (0.92-1.03) 
Renal' 200 0.75 0.090 0.74 0.070 0.77 0.118 
(0.54-0.97) (0.54-0.94) . (0.56-0.98) 
Metabolic/ 73 1.02 0.920 0.75 0.198 0.82 0.365 
Endocrine (0.70-1.34) (0.54-0.96) (0.59-1.05) 
Haematological 32 1.12 0.655 1.01 1.000 1.08 0.764 
(0.77-1.47) (0.72-1.31 ) (0.76-1.40) 
Trauma 461 1.13 0.351 0.80 0.092 1.03 0.806 
(0.89-1.37) (0.61-0.99) (0.81-1.26) 
General 379 0.58* 0.001 1.20 0.275 1.34* 0.080 
{0.37-0.782 {O .88-1.52 2 ~1.00-1.682 
Overall 6,514 0.94 0.009 0.88 0.000 0.97 0.121 
~0.91-0.972 ~0.85-0. 912 ~0.94-0.992 
APACHE, Acute Physiology and Chronic Health Evaluation; 
*Significance as indicated by 95 % CIs 
These were the areas admitting the bulk of patients to ICUs. The CIs for the mortality 
ratios for patients admitted from an "Other area in another hospital" lay outside the CIs 
for the overall population for both the New APACHE II models (New APACHE II (A & 
B)). However, the numbers in this group of patients were small. In the system categories, 
of cardiovascular, neurological, gastrointestinal and general, the CIs for the mortality 
ratios lay outside the CIs for the overall population in the original APACHE II model. 
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Figure 8.1. Calibration curve for APACHE II models in the validation cohort. 
..... 
.... 1It 
l1li ..... 
..... 
... c:: 
.... ! 
- -. t':i 
o A. 
z::~ 
......... 
!lillie 
......... 
... c:: 
.. . ;;:; 
..... 
.. . 
o A. I:cf 
........ 
III! III! 
......... 
~I: _ 0 
.- ... 
'G. 
--
~ ::I 
o A. 
J:l 
Page 123 
100 
90 
80 
70 
60 
50 
40 
30 
20 
10 
0 
APACHE II (Validation set) 
Predicted Hospital Mortality 
(96 ) 
• POpUation ci&lribUion 
----Oba!rved Mortality 
=Precic:t.d Mortality 
CI 
n Oba!rved Mortality 
••• ---- CI 
New APACHE II (A) (validation set) 
100 
90 
80 
70 
60 
SO 
40 
30 
20 
10 
0 
lIlU)lI')lI) UlUlll) Lt')LI')LI) 
-Nt<lVII)'l)r''-OO(7) 
Predicted Hospital Mortality 
(96 ) 
• Popualion diotribUion 
____ Ob ..... d Mortality 
=Predict.d Mortally 
••• __ • __ CI 
--G--Ob ..... d Mortality 
••• --.-- CI 
New APACHE II (8) (validation set) 
100 
90 
80 
60 
SO 
40 
30 
20 
10 
0 
I/) 1/)11) It) It) It) It) It) It) It) 
-Nt<l.rIt)..o .... m(7) 
Predicted Hospital Mortality 
(96 ) 
• PopuI3ion distrilution 
Observed Mortally 
=Ptedicted Mortally 
_ •••. _ .• a 
[] Observed Mortally 
- •••. - .• a 
Chapter 8 Customisation of Models 
In the New APACHE II(A) model the neurological system category was the only 
category with mortality ratio CIs falling outside the overall CIs. In the New APACHE 
II(B) model the general system category was the only category with mortality ratio CIs 
falling outside the overall CIs, representing a small amount of patients. 
T4e original APACHE II model showed significant differences in the Chi Squared value 
between the expected mortality and that observed for patients admitted from Recovery/ 
theatre, Other area in another hospital, and the patients with a neurological, 
gastrointestinal and general diagnosis (Table 8.5-8.6). The New APACHE II (A) showed 
significance using the Chi Squared test in patients admitted from A&E, Ward in this 
hospital, or Other area in another hospital and in patients with a cardiovascular, 
respiratory, neurological or gastrointestinal diagnosis (Table 8.5-8.5). The New 
APACHE (B) showed no significance in patients grouped by diagnosis only for patients 
. -."
admitted from Another area in another hospital: which had arelatively small amount of 
patients (Table 8.5). 
8.3.3 SAPS II Models 
Analysis for the SAPS II models used 12,944 patients, 6,426 in the development cohort 
and 6,518 in the validation cohort, with 64 patients excluded because of missing 
information. 
The Chi Squared values for the Hosmer-Lemeshow GOF test in both cohorts were highly 
significant for the original SAPS II model but were not significant for the New SAPS II 
(A) model (Table 8.7). The New SAPS model showed improved calibration using the 
Hosmer-Lemeshow GOF test with the changes reflected in the calibration curves (Figure. 
8.2). Discrimination was improved for the New SAPS II (A) model with slightly 
increased areas under the ROC curves for both the development and validation cohorts. 
Despite the slight change in the area under the ROC curves these changes· were 
significant. 
The coefficients for the new SAPS II (A) model were as follows: 
New SAPS II constant (Bo) -8.3937 
SAPS II score (3t) +0.0518 
Log of SAPS II score + 1 (32) + 1.4439 
Emergency Operative (33) -0.4544 
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Table 8.7 GOF tests and Area under the ROC curves for SAPS II 
GOF P ROC P Mortality Cis 
Ratios 
SAPS II Development 40.14 0.001 0.843 0.96 0.94-1.00 
Validation 56.04 0.001 0.837 0.95 0.92-0.98 
New SAPS II (A) Development 10.09 0.258 0.846 0.001* 1.00 0.97-1.03 
Validation 7.55 0.479 0.839 0.001* 0.98 0.95-1.01 
GOF, Goodness of Fit, ROC, Receiver Operating Characteristic; CI, Confidence IntelVal; SAPS, 
Simplified Acute Physiology Score; * P-value of area under the ROC CUlVe when compared to the original 
model. 
-
The uniformity of fit did not seem to have been significantly improved with the New 
SAPS model (Table 8.8 and 8.9). The CIs for the mortality ratios; for patients gro~ped by 
source of admission, showed the same significance in the original model and the New 
SAPS IT (A) model with admissions from A&E, Ward in this Hospital, Other area in 
another Hospital lying outside the overall CIs. Although not significant the original 
SAPS II mortality ratio for the group "Recovery/theatre" was low with a CI that does not 
include one. The New SAPS II (A) model had a mortality ratio of 1.00 in this group 
which suggests there had been an improvement. As this was the largest group of patients 
this may be important to the accuracy of the model. 
When grouped by the APACHE diagnostic system, patients' CIs in the neurological, renal 
and trauma systems did not overlap with the CIs for all patients in both models with the 
general category falling outside the CIs for the New SAPS model. 
Using the Chi Squared test patients admitted from A&E, Recovery/theatre, Ward in this 
hospital or Other area in another hospital, and patients admitted with a neurological, renal 
and trauma diagnosis showed significance for the original SAPS II model (Table 8.8 and 
8.9). However, the renal category was small and represents only 200 patients. Using the 
same test for the New SAPS II (A) model, patients admitted from A&E, Ward in this 
hospital, or Other area in another hospital, and patients admitted with a neurological, 
renal, trauma and general diagnosis showed significant differences between observed and 
estimated mortality. 
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Table 8.8 Source of admission mortality ratios for SAPS II 
Source of Admission N Original X2 
SAPS II p= 
New SAPS 
II (A) , 
X2 
p= 
A&E 810 0.83* 0.002 0.82* 0.001 
(0.76~.89) (0.76~.89) 
Recoveryltheatre 3,135 0.88 0.002 1.00 1.000 
(0.82~.94) (0.93-1.06) 
Ward in this hospital 1,880 1.09* 0.017 1.08* 0.036 
(1.04-1.13) (1.03-1.12) 
Other ICU in this hospital 117 0.98 0.888 0.96 0.806 
(0.80-1.16) (0.78-1.15) 
IOU in another hospital 207 1.01 1.000 0.98 0.862 
(0.86-1.16) (0.83-1.13) 
Other area in another hospital 364 0.78* 0.020 0.75* 0.008 
(0.65~.91) (0.62~.88) 
Home/clinic 5 1.93 0.345 1.88 0.365 
(0.79-3.06) (0.66-3.10) 
Overall patients . 6,518 0.95 0.035 0.98 0.488 
(0.92~.98) (0.95-1.01) 
SAPS, Simplified Acute Physiology Score; A&E, Accident and Emergency; ICU, Intensive Care Unit; 
*Significance as indicated by 95% CIs 
Table 8.9 APACHE System mortality ratios for SAPS II 
APACHE System n Original X2 New SAPS II (A) 
SAPS II p= 
Cardiovascular 1,406 1.00 0.920 1.03 
(0.95-1.04) (0.98-1.08) 
Respiratory 1,241 1.05 0.359 1.02 
(0.98-1.12) (0.95-1.09) 
Neurological 573 0.80* 0.005 0.80* 
(0.71 ~.89) (0.71 ~.90) 
Gastrointestinal 2,149 0.98 0.603 1.07 
(0.92-1.03) (1.01-1.13) 
0.68* 0.018 0.68* 
(0.50~.85) (0.49~.86) 
0.79 0.303 0)9 
Renal 200 
Metabolic/Endocrine 73 
(0.57-1.02) (0.56-1.03) 
Haematological 32 1.20 0.471 1.19 
(0.87-1.54) (0.85-1.54) 
Trauma 461 0.69* 0.006 0.71 * 
(0.53~.85) (0.54-0.88) 
General 379 0.73 0.059 0.70* 
(0.50~.95) (0.48~.93) 
Overall patients 6,518 0.95 0.035 0.98 
(0.92-0.98) (0.95-1.01) 
X2 
P= 
0.431 
0.718 
0.006 
0.093 
0.020 
0.299 
0.488 
0.010 
0.035 
0.488 
APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; 
*Significance as indicated by 95% CIs 
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Figure 8.2. Calibration curves for SAPS II models in the validation cohort. 
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8.3.4 MPMO Models 
The MPMO model used all 13,008 patients for the analysis, with 6,458 patients in the 
development cohort and 6,550 patients in the validation cohort. 
The coefficients for the new MPMO models are as follows (Table 8.10): 
Table 8.10 Coefficients for the NewMPMo (A) model. 
Variable B 
Constant 
Physiology 
Coma or deep stupor 
Heart Rate >= 150 
Systolic blood pressure 
Chronic diagnosis 
Chronic renal insufficiency . 
Cirrhosis 
Metastatic neoplasm 
Acute diagnosis 
Acute renal failure 
Cardiac dysrhythmia 
Cerbrovascular incident 
Gastrointestinal bleeding 
Intracranial mass effect 
Other 
Age 
Cardiopulmonary 
resuscitation prior to 
admission 
-4.9072 
0.5531 
* 
* 
0.5539 
0.7652 
0.466 
1.2697 
0.2983 
0.9335 
0.5208 
0.4515 
0.034 
1.2781 
Mechanical ventilation 0.3341 
Non-elective surgery 1.2483 
MPM, Mortality Probability Model; SE, Standard Error; CI, Confidence Intervals; 
*Variable not significant and not included model. 
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NewMPMo(B) 
Constant (130) 
MPMLogit 
-0.3938 
0.6387 
Table 8.11 GOF tests and Area under the ROC curves for MPMO 
GOF P ROC P Mortality CIs 
Ratios 
MPMO Development 209.56 0.001 0.787 1.00 0.97-1.02 
Validation 229.46 0.001 0.779 0.98 0.96-1.01 
NEW MPMO (A) Development 17.74 0.023 0.809 0.001* 1.00 0.96-1.03 
Validation 18.19 0.020 . 0.787 0.001* 0.98 0.94-1.01 
New MPMo(B) Development. 20.59 0.008 0.786 o:oof* 1.00 0.97-1.03 
Validation 17.70 0.024 0.780 0.001* 0.98 0.96-1.01 
GOF, Goodness of Fit; ROC, RecjeverOperating Characteristics; MPM, Mortality Probability Model; 
CI, Confidence Interval 
• P-value of area under the ROC curve when compared to the original model. 
Table 8.12 Source of admission mortality ratios for MPMO 
Source of Admission N= Original Xl New X~ New X2 
MPMO P= MPMO P= MPMo P= 
(A) (B) 
A&E 815 0.81* 0.001 0.94 0.332 0.90* 0.07 
(0.77-0.85) (0.87-1.02) (0.84-0.95) 
Recovery/theatre 3,147 0.89* 0.004 0.84* 0.001 0.85* 0.001 
(0.84-0.94) (0.78-0.90) (0.80-0.90) 
Ward in this hospital 1,891 1.17* 0.001 1.15* 0.001 1.17* 0.001 
( 1.14-1.19) (1.10-1.20) (1.13-1.22) 
Other ICU in this 118 1.08 0.610 0.98 0.888 1.04 0.78 
hospital (0.87-1.28) (0.78-1.18) (0.86-1.22) 
ICU in another 207 0.97 0.806 0.93 0.517 1.01 1.00 
hospital (0.88-1.06) (0.77-1.08) (0.86-1.15) 
Other area in another 365 0.83* 0.076 0.77* 0.018 0.78* 0.02 
hospital (0.70-0.95) (0.63-0.91 ) (0.66-0.91) 
Home/clinic 7 2.12 0.182 1.85 0.277 2.21 * 0.16 
~0.74-3.51l ~0.71-3.ool ~1.22-3.20l 
Overall patients 6,550 0.98 0.454 0.98 0.301 0.98 0.46 
{0.96-1.01l {0.94-1.01l {0.96-1.01l 
MPM, Mortality Probability Model; A&E, Accident and Emergency; ICU, Intensive Care Unit 
*Significance as indicated by 95% CIs 
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Figure 8.3. Calibration curves for the MPMO models in the validation cohort. 
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The calibration of the New MPMO models (A & B) improved with the Chi Squared value 
for the GOF test in both the development and validation cohorts reduced compared to 
that of the original model (Table 8.11). Although the Chi Squared value was reduced for 
both new models the P-values remain significant for both. The calibration for all the 
MPMO models can be seen in Figure 8.3. Discrimination was increased in the New 
MPMO (A) model with a significant increase in the ROC values in both the 
developmental cohort and the validation cohort (Table 8.11). Discrimination was also 
improved in the validation cohort for the New MPMo (B) model, but, although there 
were significant differences, the differences were small. 
Table 8.13 APACHE System mortality ratios for MPMO 
APACHE System N= Original Xl New X2 New Xl 
MPMO P= MPMO P= :MPMO P= 
(A) (B) 
Cardiovascular 1,408 l.04 0.348 l.05 0.258 l.07* 0.08 
(0.99-1.09) (0.99-1.10) (1.03-1.12) 
Respiratory 1,247 l.12* 0.022 l.1O* 0.056 l.08 0.13 
(1.05-1.19) (1.02-1.18) (1.01-1.15) 
Neurological 577 0.71* 0.000 0.82* 0.012 0.84* 0.03 
(0.63-0.80) (0.72-0.92) (0.76-0.92) 
Gastrointestinal 2,157 l.03 0.532 0.96 0.365 l.00 0.92 
(0.97-1.09) (0.90-1.02) (0.95-1.06) 
Renal 202 0.77 0.106 0.70* 0.030 0.70* 0.03 
(0.57-0.97) (0.50-0.90) (0.53-0.87) 
Metab01 ic/ 73 0.82 0.380 0.98 0.920 0.83 0.41 
Endocrine (0.59-1.06) (0.68-1.27) (0.63-1.03) 
Haematological 32 1.47* 0.132 1.49* 0.121 1.49* 0.12 
(1.07-1.88) (1.02-1.95) (1.12-1.86) 
Trauma 462 0.66* 0;002 0.67* 0.003 0.60* 0.001 
(0.49-0.82) (0.50-0.85) (0.47-0.73 ) 
General 381 0.71* 0.046 0.68* 0.024 0.58* 0.001 
(0.49-0.94 ) (0.45-0.92) (0.43-0.73) 
Overall patients 6,550 0.98 0.454 0.98 0.301 0.98 0.46 
(0.95-1.01) (0.94-1.01) (0.96-1.01) 
APACHE, Acute Physiology and Chronic Health Evaluation; MPM, Mortality Probability Model; 
*Significance as indicated by 95% CIs 
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Despite the marked improvement in the calibration and the small but significant 
discrimination for the New MPMO models the uniformity of fit was very similar in all 
models for both source of admission and system category (Table S.12 andS.13). In the 
validation cohort, CIs for the groups of patients admitted from Recovery/theatre, Ward in 
this hospital, and Other area in another hospital all lay outside the overall CIs in all 
models. In the original model and the New MPMO (B) model the CIs for the group of 
patients admitted from A&E also lay outside the overall CIs. The same pattern was seen 
when the patients were broken down by the APACHE system category. Patients with an 
admitting diagnosis that fell in the respiratory, neurological, trauma, general or 
haematological system categories all had CIs that fall outside the overall CIs for the 
original MPMO model and the New MPMO (A) model: In the New MPMo(A) model the 
CIs for the renal system category fall outside the overall CIs. Patients admitted with 
neurological, trauma, renal, general or haematological diagnoses all had CIs that fall 
outside the overall CIs for the New MPMo (B) model. 
The Chi Squared test for the original MPMO model showed significant differences 
between estimated and observed mortality for patients admitted from A&E, 
Recovery/theatre, or Ward in this hospital and for patients admitted \.vith a 
cardiovascular, neurological, gastrointestinal or general diagnosis. There were significant 
differences for patients admitted from Recovery/theatre, Ward in this hospital, Other area 
in another hospital and patients with a neurological, renal trauma and general diagnoses 
in both New MPMO models using the Chi Squared test. 
S.3.5 MPM24 Models 
As the MPM24 models exclude patients discharged in the first 24 hours, this left 9,212 
patients for the analysis, with 4,549 patients in the development cohort and 4663 patients 
in the validation cohort. 
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New coefficients for the MPM24 models are as follows (Table 8.14): 
Table 8.14 Coefficients for new MPM24(A) 
Variable B 
Constant 
Variables ascertained at 
admission 
Chronic renal insufficiency 
Cirrhosis 
Metastatic neoplasm 
Cerabralvascular incident 
Gastrointestinal bleeding 
Intracranial mass effect 
Age 
Cardiopulmonary resuscitation 
prior to admission 
Non-elective surgery 
24 hour assessments 
Coma or deep stupor at 24 hour 
Creatinine >176.8mmollL 
Confirmed infection 
Mechanical ventilation 
Partial pressure of oxygen(p02) 
• c <7.98 Kilopascal (60 mm Hg) 
Prothrombin time> 3 sec above 
standard. 
Urine output <150 ml in 8 h 
Vasoactve drugs2: 1 h 
intravenously 
-5.0243 
0.4415 
0.6915 
0.7541 
0.7114 
0.5204 
* 
0.0315 
l.0152 
0.7913 
l.4195 
0.325 
0.3021 
0.5525 
0.5555 
-0.0012 
l.0694 
0.6331 
MPM, Mortality Probability Model; SE, Standard Error; CI, Confidence Intervals; 
*Variable not significant and not included model. 
New MPM24(B) 
Constant (30) 
MPMLogit 
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Table 8.15 GOF tests and Area under the ROC curves for MPM24 
GOF P< ROC P< Mortality Cis 
Ratios 
MPM24 Development 53.22 0.001 0.799 1.04 1.00-1.07 
Validation 106.07 0.001 0.782 0.99 0.95-1.02 
NEW MPM24 (A) Development 169.34 0.001 0.816 0.009* 1.28 1.24-1.32 
Validation 134.54 0.001 0.795 0.001* 1.22 1.18-1.27 
NEW MPM24 (8) Development 15.11 0.057 0.807 0.003* 1.02 0.98-1.06 
Validation 30.22 0.001 0.793 0.001* 0.98 0.94-1.02 
GOF, Goodness of Fit; ROC, Receiver Operating Chamcteristic; MPM, Mortality Probability Model; CI, 
Confidence Interval; * P-value of area under the ROC curve when compared to the original model. 
The New MPM24 (A) model had significantly improved discrimination with increases in 
the area under the ROC curve for both the development andvalidation cohort (Table. 
8.15). However, the calibration for New MPM24 (A) had deteriorated and although both 
the original and new models had significant GOF tests the Chi Squared value was 
considerably increased for the new model. This calibration was reflected in the 
calibration curves and mortality ratios where New MPM24 (A) was clearly 
underestimating mortality (Figure 8.4). 
New MPM24 (B) (logit only model) had significantly improved areas under the ROC 
curve for both the development and validation cohort (Table 8.15). In contrast to the New 
MPM24 (A) (development from original MPM variables), calibration was improved 
when compared to the original model with reduced Chi Squared values in the GOF tests 
for both the developmental and validation cohort (Table 8.15). 
Table 8.16 Source of admission mortality ratios for MPM24 
Source of Admission N Original X2 . New X2 New X2 
MPM24 P= MPM24 (A) P= MPM24 (8) P= 
A&E 510 1.08 0.292 1.19 0.020 1.01 0.888 
(0.98-1.19) (1.08-1.30) (0.91-1.11 ) 
Recoveryltheatre 2,132 0.86* 0.002 1.20 0.000 0.89 0.015 
(0.80-0.93) (1.11-1.28) (0.82-0.96) 
Ward in this hospital 1,448 1.11* 0.008 1.29 0.000 1.08 0.063 
(1.06-1.17) (1.22-1.35) (1.02-1.14) 
Other ICU in this 95 1.06 0.740 1.23 0.242 1.02 0.888 
hospital (0.82-1.30) (0.95-1.50) (0.78-1.26) 
ICU in another hospital 180 0.91 0.475 1.14 0.292 0.92 0.502 
(0.76-1.07) (0.95-1.34) (0.76-1.08) 
Other area in another 295 0.81 0.083 1.03 0.806 0.79 0.049 
hospital (0.67-0.96) (0.85-1.21 ) (0.64-0.94) 
Home/clinic 3 2.26 0.237 2.11 0.279 2.09 0.288 
{0.68-3.84! {0.75-3.47! {0.68-3.49! 
Overall patients 4,663 0.99 0.671 1.22 0.000 0.98 0.410 
(0.95-1.02) {1.18-1.27l (0.94-1.02) 
MPM, Mortality Probibility Mortality; A&E, Accident and Emergency; ICU, Intensive Care 
Unit;*Significance as indicated by 95% CIs 
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Figure 8.4. Calibration curves for the MPM24 models 10 the validation cohort. 
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However, the Chi Squared value was still significant in the validation cohort. These 
changes were reflected in the calibration curves, with more of the line of equality lying 
within the CIs for observed mortality (Figure 8.4). 
The New MPM24 models (A & B) had less variation in the mortality ratios for source of 
admission than the original model, with none of the CIs for patients admitted from the 
various areas lying outside their respective overall CIs (Table 8.16). In the onginal model 
CIs for patients admitted from Recovery/theatre and Ward in this hospital, the areas 
admitting the majority of patients, lay outside the CIs for the overall cohort. 
Table 8.17 APACHE System mortality ratios for MPM24 
IF MPM24 x2 New x2 NEW x2 
p:: MPM24 P= MPM24 P= 
(Al (Bl 
Cardiovascular 971 1.05 0.145 1.18 0.001 1.00 1.000 
(1.01-1.10) (1.10-1.25) (0.94-1.07) 
Respimtory 993 1.20* 0.001 1.42* 0.001 1.16* 0.006 
( 1.14-1.26) (1.32-1.52) (1.08-1.25) 
Neurological 370 0.90 0.137 1.10 0.303 0.86 0.108 
(0.82-0.99) (0.96-1.25) (0.74-0.98) 
Gastrointestinal 1,598 0.95 0.160 1.24 0.001 0.95 0.262 
(0.91-1.00) (1.15-1.32) (0.88-1.02) 
Renal 138 0.75* 0.036 0.82* 0.322 0.65* 0.025 
(0.59-0.91) (0.56-1.09) (0.42-0.87) 
Metabolic/ 49 0.95 0.777 1.01 1.000 0.84 0.554 
Endocrine (0.73-1.17) (0.64-1.38) (0.51-1.18) 
Haematological 21 1.35 0.154 2.04* 0.009 1.57* 0.101 
(1.04-1.67) (1.48-2.60) (1.12-2.02) 
Tmuma 317 0.73* 0.004 0.97 0.823 0.68* 0.015 
(0.58-0.87) (0.71-1.23) (0.47-0.89) 
General 203 0.80 0.133 1.09 0.663 0.81 0.277 
~0.6°-1.oo2 ~0.74-1.442 ~0.51-1.1°2 
Overall patients 4,663 1.01 0.538 1.22 0.001 0.98 0.410 
~0.99-1.042 ~ 1.18-1.272 ~0.94-1.022 
APACHE, Acute Physiology and Chronic Health Evaluation; MPM, Mortality Probability Mortality; 
*Significance as indicated by 95% CIs 
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The Chi Squared value was, however, significant for the New MPM 24 (A) model for 
patients admitted from A&E, Recovery/theatre, Ward in this hospital (the three largest 
groups) (Table 8.16). The New MPM24 (B) model had a significant Chi Squared value 
for patients admitted from Recovery/theatre and Other area in another hospital. The 
original model had significant Chi Squared values in patients admitted from 
Recovery/theatre and Ward in this hospital (the two largest groups). 
Using the APACHE system category to group patients the New MPM24 model did not 
appear to improve the uniformity of fit (Table 8.17). The CIs for the categories of 
respiratory, and renal, lay outside their respective overall CIs for all MPM24 models . 
. The CIs for the trauma category lay outside the pverall CIs for the original MPM24 and 
the new MPM24 (B) model. ~he CIs for the haematological group also lay outside the 
overall CIs for both newMPM24 models. ~henumbers in this group were very small and 
probably had little influence on the performance of the model. 
The New MPM24 (A) had significant Chi Squared values 10 patients with a 
cardiovascular, respiratory, gastrointestinal or haematological diagnosis (Table 8.17). 
The New MPM 24 (B) and original MPM24 has significant Chi Squared values in 
patients admitted with a respiratory, renal or trauma diagnosis, although the renal group 
represented a small number of patients. 
All the models had demonstrated some improvement in at least one of the areas 
measured. All the models, apart from the New MPMO (B), had shown improved 
discrimination. As reported in Chapter 4-6 the APACHE II model had the superior 
calibration of all the models previously tested in the Scottish data. The New APACHE II 
(B) model had maintained this calibration(Table 8.18) but more importantly the model 
had improved its uniformity of fit when patients were grouped by APACHE system and 
source of admission (Table 8.19, 8.20). The New SAPS II (A) model was the only model 
that had improved its calibration to the extent that the Hosmer-Lemeshow test was no 
longer significant in the validation cohort. The New MPMO models had improved 
calibration as measured by the Hosmer-Lemeshow test. The New MPM24 (B) 
demonstrated improved calibration using the Chi Squared statistic and both new models 
showed improvement in uniformity of fit when grouped by source of admission. 
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Table 8.18 Results for new models in validation cohort 
New APACHE II (A) 
New APACHE II (B) 
New SAPS 
New MPMO(A) 
New MPMO(B) 
New MPM24 (A) 
GOF P= ROC 
136.52 0.001 0.838 
44.86 
7.55 
18.19 
17.14 
134.54 
0.001 0.835 
0.479 0.839 
0.020 0.787 
0.024 0.7801 
0.001 0.795 
P= 
0.001* 
0.001* 
0.001* 
0.001* 
0.001* 
Mortality 
Ratios 
0.88 
0.97 
0.98 
0.98 
0.98 
1.22 
Cis 
0.94-1.00 
0.94-1.00 
0.95-1.01 
0.94-1.01 
0.96-1.01 
1.18-1.27 
New MPM24 (B) 30.22 0.001 0.793 0.001* 0.98 0.94-1.02 
GOF, Goodness of Fit; ROC, Receiver Operating Characteristic; CI, Confidence Interval; APACHE, Acute 
Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; MPM, Mortality 
Probability Model; * Significance when cOmpared to the original model. 
Table 8.19 Uniformity of fit by source for new models in validation cohort 
A&E Cis RecoveIY 
theatre 
Cis Ward CIs Overall CIs 
New APACHE II (A) 0.84 0.78~.90 0.92 0.86~.98 0.91 0.87~.95 0.88 0.85~.91 
New APACHE II (B) 0.93 0.86-l.00 1.00 0.94-l.07 0.99 0.95-l.03 0.97 0.94~.99 
New SAPS 0.82* 0.76~.89 1.00 0.93-l.06 1.08* l.03-1.12 0.98 0.95-l.01 
New MPMo (A) 0.94 0.87-l.02 0.84* 0.78~.90 1.15* 1.10-l.20 0.98 0.94-1.01 
New MPMo (B) 0.90 0.84~.95 0.85 0.80~.90 1.17* 1.13-l.22 0.98 0.96-1.01 
New MPM24 (A) 1.19 l.08-1.30 1.20 1.11-l.28 1.29 l.22-1.35 l.22 1.18-l.27 
New MPM24 (B) 1.01 0.91-1.11 0.89 0.82~.96 1.08 l.02-1.14 0.98 0.94-l.02 
A&E, Accident and Emergency; CI, Confidence Intervals; APACHE, Acute Physiology and Chronic 
Health Evaluation; SAPS, Simplified Acute Physiology Score; MPM, Mortality Probibility Model; 
* Mortality ratios whose CIs fall outside the Cis for the whole population. 
Table 8.20 Uniformity offit by APACHE system for new models in validation cohort 
New APACHE II (A) 
New APACHE II (B) 
New SAPS 
NewMPMo(A) 
NewMPMQ(B) 
New MPM24 (A) 
Cardio- Cis 
vascular 
0.91 0.87-0.95 
0.97 0.92-1.01 
1.03 0.98-1.08 
1.05 0.99-1.l0 
1.07* 1.03-1.l2 
1.l8 1.l 0-1.2 5 
Respiratory 
0.87 
0.95 
1.02 
1.l0* 
1.08 
1.42* 
CIs Gastro- CIs Overall CIs 
intestinal 
0.81-0.93 0.92 0.86-0.97 0.88 0.85-0.91 
0.88- 1.02 0.97 0.92-1.03 0.97 0.94-0.99 
0.95-1.09 1.07 1.01-1.l3 0.98 0.95-1.01 
1.02-1.l8 0.96 0.90-1.02 0.98 0.94-1.01 
1.01-1.l5 1.00 0.95-1.06 0.98 0.96-1.01 
1.32-1.52 1.24 1.l5-1.32 1.22 1.l8-1.27 
New MPM24 (B) 1.00 0.94-1.07 1.l6* 1.08-1.25 0.95 0.88-1.02 0.98 0.94-1.02 
APACHE, Acute Physiology and Chronic Health Evaluation; CI, Confidence Intervals; SAPS, Simplified 
Acute Physiology Score; MPM, Mortality Probibility Model; 
* Mortality ratios whose CIs fall outside the Cis for the whole population. 
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8.3.6 Selection check 
Analysis for the extra random selection used 12,936 patients, 6461 patients in the 
developmental cohort and 6475 patients in the validation cohort. Discrimination in the 
APACHE II (check) model is little different compared to the new APACHE II (B) in the 
both the development and validation cohort (Table 8.21). However, the new APACHE II 
(check) model has better discrimination than the original model in both cohorts. 
The calibration in the new APACHE (Check) in both the development and validation 
cohorts was improved in comparison to the original model (Table 8.21). However the 
differences in the Chi Squared statistic was small in comparison to other differences 
found in this study. In comparison to the new APACHE II (B) model there was little 
difference in calibration. The new APACHE IT (check) model had a non-significant GOF 
. . 
test in the developmtmt cohort (P=0.088) but the same test was significant in the 
. validation set. Although the new APACHE II (B) model was significant in the 
development set the actual Chi Squared values in both validation and development 
cohorts were very similar to those in the new APACHE II (check) model. 
Table 8.21 GOF tests and Area under the ROC curves for APACHE II 
GOF P< ROC P<* Mortality Ratios 
{C!2 
APACHE II Development 23.88 0.002 0.8119 0.97 
(0.94-1.00) 
Validation 27.52 0.001 0.8168 0.94 
(0.91-0.97) 
New APACHE II Development 13.74 0.088 0.8515 0.001* 0.99 
(check) (0.%-1.02) 
Validation 24.43 0.001 0.8516 0.001* . 0.96 
(0.94-1.00) 
New APACHE II Development 19.63 0.012 0.8506 0.001* 0.99 
(B) (0.96-1.02) 
Validation 20.22 0.009 0.8476 0.001 * 0.97 
{0.94-1.00l 
GOF, Goodness of Fit; ROC, Receiver Operating Characteristic; APACHE, Acute Physiology and Chronic 
Health Evaluation; CI, Confedence Intervals; 
* P-value of area under the ROC curve when compared to the original model. 
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8.4 Discussion 
For a logistic regression model to be a useful tool in assessing the differences in ICUs the 
probabilities produced must accurately reflect the mortality experience of the population 
to which the model is to be applied. Analysis from Chapter 5-7 shows that this was not 
the case in the Scottish Intensive Care study where the five models tested showed 
significant differences between observed and predicted mortality. All the models 
described in this paper have been developed on data collected from either an American or 
a mixture of American and European ICUs . The reported mortality rates in these studies 
have been considerably lower than those reported in the Scottish data. There is a general 
acceptance that this represents a difference in admission criteria rather than reflecting 
poorer outcomes and it is therefore not surprising that the" performance of these models 
were not replicated in the Scottish data. Zhu et al suggested that where 
" the level ofICU care results in poor fit of the models, the models could be 
customised to better reflect the mortality experience among those patients" (142). 
Methods for customisation of severity of illness models have recently been demonstrated 
(139,141',142). Zhu et al showed two methods for customising MPMo by using 
bootstrapping methods on data from the original MPM II study. The first method was to 
ta~e the logit from the original MPM II model and enter it into a logistic regression 
analysis. The second method was to re-weight the variables from the original model. The 
study found that using the original variables was more successful when the difference in 
mortality from the original model was highest. A paper using data from the EURICUS 
study showed improved performance of MPMO after customisation of both the logit and 
the original variables. However, the authors did show that some large sub groups of the 
populatio~ had significant differences between the observed and predicted mortality 
suggesting that mortality ratios could be affected by the type of patients being admitted. 
LeGall et al also showed improved performance ofMPM II and SAPS II in patients with 
sepSiS. 
In our customisation of these models some improvement was produced in one or more of 
the tests either in discrimination or calibration. There is no agreed point at which a model 
becomes legitimate to use and the customisation process can be judged to have been 
successful. It is important for a model to have good discrimination, however, if a model 
is to be used to audit differences in different ICUs then there seems to be a general 
agreement that calibration is the more important measure (21). Wagner said, 
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"When you talk about performance evaluation you are fundamentally talking 
about calibration issues of the model. You are not as concerned about 
discrimination or ROC areas. Higher ROC areas are always better ........... " (9th 
European Congress of Intensive Care medicine and personal communication). 
As calibration is a measure of the differences between observed and predicted mortality 
measured across the "severity of illness" range, it is clear that significant differences in 
specific ranges may affect the apparent performance of an ICU, depending on the nature 
of the patients that they admit. More recently it has been argued that, as well as 
traditional goodness of fit tests, models need adequate "uniformity of fit" which can be 
defined as a model that has no significant differences between observed and predicted 
mortality in clinically relevant sub groups (llS). If a model predicts poorly as for 
example neurological patients then this will effect the mortality ratios of those units 
admitting an unusually large number of these patients. However, it was difficult to assess 
the uniformity of fit of the original models as this information was not published. 
Therefore, any differences in the uniformity of fit in the new models may have existed in 
the original models. 
8.4.1 APACHE IT Models 
Both New APACHE II models (A & B) showed improved discrimination when 
compared to the original model (Table 8.3). Calibration was not improved in the 
important validation cohort. The New APACHE II (B) model showed similar calibration 
to that of the original model, though still had a significant Hosmer-Lemeshow test in the 
validation cohort. It would appear that when accuracy in subgroups was analysed there 
was a real improvement in the New APACHE II (B) model (Table 8.4- 8.5). The New 
AP ACHE IT (A) model also had improved performance in subgroups when the CIs from 
the mortality ratios were analysed. However, using the results from the Chi Squared 
value the New APACHE II (A) model performance was less promising (Table 8.4- 8.5). 
The New model (B) had only significant differences between the expected and observed 
mortality in patients admitted from Other area in another hospital and patients with a 
general diagnoses. 
The improvement in the New APACHE II (B) model would seem to have created a 
genuine improvement in the APACHE II model. Athough the calibration results were 
very similar for both models (APACHE II; New APACHE (B» analysis from Chapter 6 
and 7 showed that the original APACHE II model's performance is due to the effect of 
averaging. Improving the performance in those patients with a neurological deficit 
reduces the performance of the model (Chapter 7). As the New APACHE II (B) model 
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had considerably improved performance in subgroups it can be argued that the overall 
calibration was genuine whilst that in the original model was misleading. Analysis in 
Chapter 7 appears to have been confirmed with the use of a pre-sedated OCS, when 
patients were sedated, having led to a superior model. This confirms the finding that the 
GCS is an important prognostic factor in the model. Also, it highlights the fact that the 
method used for collecting the data for a variable can have a profound effect on the 
accuracy of a model. The other main difference between the original APACHE II model 
and the New APACHE II (B) model is the use of the APACHE ill diagnoses in the new 
model as opposed to the APACHE II diagnostic groups. This may have contributed to the 
improvement of the New APACHE II (B) model's performance when analysed in 
subgroups. 
The New APACHE II (~) model still showed significant differences iri the Hosmer-
Lemeshow test although guestions remain about the clinical significance of these results, 
given the large numbers of patients in the study. 
8.4.2 SAPS II Models 
The -New SAPS II (A) model had significantly better discrimination, however, this 
improvement was very small as the large numbers i.n the study allowed for small 
differences to be highlighted (Table 8.6). The differences in the validation cohort would 
be imperceptible if rounded to two decimal places. As the logistic regression model used 
to customise the SAPS II model contained only the SAPS II score and a log of the SAPS 
II score, there was little room for improvement of the ROC curves. This is because the 
ROC test is based on ranking the probabilities from the model and while the probabilities 
may change considerably in the new model their rank will not. It is in the calibration that 
the new SAPS II (A) model shows such a dramatic improvement. It is the only model 
that has a Hosmer-Lemeshow test which did not show significant differences between 
expected and observed mortality- (Table 8.6). What is even more surprising is that the 
improvement in calibration was greatest in the validation cohort rather than the 
development cohort. 
However, results from analysis of the New SAPS II (A) model showed that the 
uniformity of fit had not been improved (Table 8.7-8.8), and a considerable number of 
patients admitted from A&E and from Ward in this hospital showed significant 
differences between expected and observed mortality. When patients were grouped by 
admitting diagnoses and then by system there were also significant differences in some of 
the groups but most patients fell into groups where no significance was detected. These 
apparent failures of the model may be as a result of a lack of diagnostic variable. 
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8.4.3 MPM II Models 
8.4.3.1 MPMO 
There was a significant improvement in discrimination in the new models when 
compared to the original (Table 8.10). However, the areas under the ROC curves in the 
New MPMO (A) and the New MPMO (B) models for the validation cohort was only 
0.7874 and 0.7801 which was considerably lower than other models. Calibration was 
considerably improved with the Hosmer-Lemeshow GOF test going from 229.46 in the 
original model to 18.19 in the New MPMO (A) model and 17.7 in the validation cohort. 
Nevertheless, the GOF statistics still remained significant but without the same certainty 
that was present in the orj.ginal model. The new models have shown little improvement in 
uniformity of fit with significant differences between expected and observed mortality 
still present (Table 8.11-8.12). However, as the only model to use data on admission to 
the ICU, thereby avoiding treatment effect, and given its ease of collection it may still 
remain a useful model to use. There seems to be little to choose between the new models 
with the logit model (New MPMO (B» performing slightly better with small 
improvements in calibration. 
8.4.3.2 MPM24 
Like all the models that have been customised the discrimination had improved for both 
the New MPM24 models (Table 8.12). Although the area under the curve was only 0.79 
in the validation cohort for both new models and this was low in comparison to the other 
models in this study. This was a result of excluding patients discharged in the first 24 
hours as was shown in Chapter 5. Calibration had, surprisingly, deteriorated for the New 
MPM24 (A), model, while the New MPM24 model (logit only) had improved its 
calibration. However, the GOF statistic remained statistically significant for the New 
MPM24 (B) model in the validation cohort. When analysed in subgroups none of the 
MPM24 models had good performance and many of the large sub groups showed 
significant differences between expected and observed mortality (Table 8.13 -8.14). 
It is surprising that the model which used the logit only (New MPM24 (B» was the 
MPM24 model which appeared to have the best performance. This suggest that the 
weights for the variables in the model, once the logit has been re-weighted, was more 
accurate than the weights generated from the variable only model (New MPM24 (A». 
This may be a result of the larger numbers in the original MPM II study, which allowed 
for the generation of more representative weights for the variables. At the moment, the 
accuracy in this model may be too poor to allow it to have any meaningful use. 
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8.4.4 Selection check 
The new APACHE II (check) model has improved discrimination and calibration 
compared to the original model. However, the performance of the model when compared 
to the new APACHE II (B) model is similar with discrimination and calibration little 
changed. The performance of this new model in comparison to the new APACHE II (B) 
model would suggest that this different random split has produced a similar model to that 
in the original random split. This would appear to add weight to the legitimacy of the 
customisation process. As the new APACHE II (check) model produces such similar 
results to the new APACHE II (B) model in a different random sample, this would imply 
that the model is relatively robust and the process has produced a model that is stable in 
different groups of patients 
8.4.5 Overall 
The process of customisation has improved the discrimination of all the new models but 
the changes for most appear to be small. This is not surprising as for example re-
weighting the SAPS II score will not change the ranks of the predictions within an ROC 
curve. Larger changes were seen in the new APACHE II models as the customisation 
process involved re-weighting the diagnostic groups as well as the score. Therefore, 
depending on the changes in weights from the original score there was potential for 
considerable change in the ranks of probability. 
All the new models except the New APACHE II (A) and the New MPM24 (A) had 
gained improved calibration when measured by Chi Squared values. The poor calibration 
in the New APACHE II (A) model is hard to explain but the poor performance in 
neurological patients may indicate that the lack of GCS scores in many of the patients 
had a significant effect on the accuracy of the model. The calibration for the New 
MPM24 (A) had decreased, for which there would appear to be no obvioiJs reason. 
However, the numbers in each of the variables may not be large enough to provide 
adequate weightings. Only the New SAPS II (A) had calibration which did not 
demonstrate significant differences between observed and predicted mortality. Two of 
the reported studies, where customisation was undertaken, have reported non significant 
results for the Hosmer-Lemeshow test in the New MPMO models (139,142). The results 
reported for the New MPMO are consistent with those demonstrated in data published 
from the EURICUS study, with improved calibration but with some questions remaining 
about the "uniformity offit" of the model. 
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As the original studies did not report analysis of the "uniformity of fit" it was hard to 
compare this aspect of performance. The original APACHE II study did not report 
Hosmer-Lemeshow tests and it was therefore difficult to assess if the improved New 
APACHE II (B) model had equivalent performance. All the new models, apart from the 
New APACHE II (A) and the New MPM24 (A), had improved performance when 
compared to the original models. Consequently, if severity of illness models are to be 
used in the continuing Audit of Intensive Care in Scotland, involving the comparison of 
case mix adjusted outcome, then the coefficients generated in the new customised models 
should be used in preference to those used in the original models. If further 
improvements are needed then a more fundamental process of model building needs to ~e 
undertaken. Any future ~odel building would need to look carefully at the process and 
quality of the data collection while ensuring the assumptions of a multiple' logisti~ 
regression model were not violated. If the new models are to be used in the comparison 
of case mix adjusted outcome, even with :the improvements that have been made,· they 
should still be used with caution when applied to the Scottish data: As questions remain 
on the ability of the models to satisfactorily adjust for case mix in the Scottish ICU 
population, it may be that more than one model should be applied to the data. As both the 
New SAPS II (A) and the New APACHE II (B) model demonstrated good areas under 
the ROC curves, and the New SAPS II (A) demonstrated good calibration and APACHE 
. , 
II good "uniformity of fit", the results from one model could be confirmed by the other 
model. 
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Chapter 9- Customisation of Models using cohorts from different time 
periods. 
Aim: To assess the effect on customisation of using a temporal divide in the data. 
Contents: 
9.1 Introduction 
9.2 Methods 
9.2.1 APACHE IT 
9.2.2 SAPS II 
9.2.3 Data analysis 
9.3 Results 
9.3 .1 APACHE IT 
9.3 .2 SAPS II 
9.4 Discussion 
9.4.1 APACHE II 
9.4.2 SAPS II 
9.4.3 Overall 
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9.1 Introduction 
Analysis in Chapter 8 demonstrated that the process of customisation could improve the 
performance of these models. The pace of change in medical science is fast with new 
drugs and treatments being introduced all the time. It is possible that data collected in the 
early part of the study might represent a different level of severity compared to data 
collected in the later part of the study. Lemeshow and Teres argued that the main reason 
for the customisation of models is to account for changes in treatment and provide more 
accurate coefficients (187). 
In the last chapter, the data were divided using a random 50:50 split. However, splitting 
the data by time might highlight the differences in treatment. Coefficients generated in 
the early part'ofthe study would representthe weight. of variables from that time period. 
If outcome has changed over time, a model g'enerated from an earlier cohort would' 
expect to have a significant deterioration in the model's performance when tested on a 
later cohort. Having shown the customisation to be successful in improving the 
performance of these models, it should be possible to improve the accuracy of 
coefficients by using a larger development cohort, creating a more robust and accurate 
model. 
To investigate the possible effect of changes over time during the period of the study and 
to investigate the possibility of improving the accuracy and robustness of the 
probabilities generated by the model, a further customisation of the APACHE II (GCS 
amended) and SAPS II models was undertaken. These models were chosen as they had 
performed best after the process of customisation. They are also the most commonly 
used systems in both the UK and in Europe, and therefore represent the standard models 
in these countries 
9.2 Methods, 
The same data were used as described in Chapter 8. Data were split into a development 
cohort and validation cohort, with the 20 months representing the development cohort 
and the remaining 10 months the validation set. Models were customised using forward 
stepwise regression. Variables in the regression that were not significant were not 
included in the final models. 
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9.2.1 APACHE II 
The development set was used to develop a new APACHE II model (New APACHE IT 
(C» which, like new APACHE II (B), incorporated a pre-sedated GCS if the patient was 
sedated for the first 24 hours. Three variables were entered into the regression to produce 
the new model, the APACHE II score, admitting diagnosis, and emergency operative 
status. The original APACHE II model was not calculated unless the patient stayed for 
longer than eight hours. This exclusion was not applied in the customisation study, and 
patients staying longer than an hour were included in the study if they fulfilled all other 
criteria. 
As in .Chapter 8 the APACHE III list of diagnoses (230 separate diagnoses) was used to 
collect admitting diagnosis. 
" '. 
The'logistic regression equation for the new APACHE (C) model was as follows: 
Logit=80+(APACHE II score(GCS amended)*8)+(Diagnostic 8). 
9.2.2 SAPS IT 
The SAPS IT score, the emergency operative status and as in the original published paper, 
a log of the score were included in the logistic regression to generate the New SAPS II 
(B) model. 
The logistic regression equation for the new SAPS II (B) model was as follows: 
Logit=Bo+(SAPS IIscore*8I)+(Log(SAPS IIscore+ 1) *82) +(Postemergancy surgery 
83). 
9.2.3 Data analysis 
The methods used for measuring discrimination, calibration and GOF have been 
described in Chapter 3. 
All logistic regression was carried out using SPSS software version 6.0 (SPSS Inc, 
Chicago, Illinois, US) 
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9.3 Results 
9.3.1 APACHE II 
Analysis for the APACHE II model used 12,936 patients, 8544 patients in the 
development cohort and 4,392 patients in the validation cohort, with 72 patients excluded 
because of missing data. The variable emergency surgery was not significant in the 
model and was therefore not included. 
The coeffiecients for the new APACHE II (C) model were as follows (Table 9.1): 
New APACHE II(C) constant (130) -3.8746 
APACHE IT (C) score +0.1537 
Table 9.1 Diagnostic coefficients for new APACHE II (C) model 
Diagnostic codes op-nonop· PtNo New APACHE 
n 
(C) 
Respiratory 
230 Respiratory arrest N 106 ~.6584 
1 Neoplasm-mouth/sinuses 0 60 -1.4882 
2 Neoplasm-larynx/trachea 0 43 -1.6317 
3 Neoplasm-lung parenchyma 0 39 0.4156 
8 Other respiratory surgery 0 64 -1.2346 
9 ARDS (non cardiogenic pulmonary oedema) N 77 0.0913 
10 Pneumonia-viral N 29 0.1238 
12 Pneumonia-bacterial N 471 0 
14 Pneumonia-aspiration/toxic N 92 0.0277 
18 Pulmonary embolus N 28 ~.7427 
20 Localised airway obstruction/oedema N 41 -1.1188 
(mechanical) 
21· Emphysema N 75 ~.925 
22 Asthma N 165 -1.7201 
23 Smoke inhalation N 40 ~.7065 
25 Other respiratory disorder N 268 0.0846 
Cardiovascular 
27 Aorto-femoral, fern-fern bypass graft 0 142 -1.0238 
28 Fern-popliteal bypass graft 0 32 0.6142 
29 Aortic aneurysm: pre-leak/dissection 0 231 ~.8126 
30 Aortic aneurysm: dissection 0 27 ~.885 
31 Aortic aneurysm: rupture 0 186 ~.425 
32 Peripheral ischaemia 0 52 ~.6949 
51 Other cardiovascular surgery 0 121 ~.5509 
53 Aortic aneurysm N 39 ~.046 
57 Rhythm distwbance N 38 0.0232 
58 Acute myocardial infarction N 38 ~.2279 
60 Congestive heart failure N 151 ~.6949 
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61 Cardiogenic shock N 150 1.255 
64 Septic shock - lungs (pneumonia) N 62 0.6608 
65 Septic shock - urinary tract infection N 27 -0.5128 
66 Septic shock - gastrointestinal tract N 86 0.4628 
67 Septic shock - unknown origin N 83 -0.0392 
69 Post cardiac arrest (± respiratory arrest) N 320 0.7736 
73 Other cardiovascular disorder N 109 -0.3502 
Neurological 
74 Subarachnoid haemorrhage/intracranial 0 38 0.931 
aneurysm 
75 Subdural/epidural haematoma 0 39 -0.%36 
82 Other neurosurgery 0 54 -0.5111 
83 Subarachnoid haemormage/intracranial N 69 0.6211 
aneurysm 
85 Intracerebral haemorrhage/haematoma N 45 0.6773 
86 Cerebrovascular accident (CV A)/stroke N 36 1.027 
88 Seizures N 99 -1.741 
91 Meningitis N 22 -0.338 
92 Self-inflicted overdose N 221 -1.9359 
98 Non traumatic coma - cause unknown· N 25 -0.5654 
99 Other neurological disorder N 126 -0.4551 
Gastrointestinal 
110 Bleeding - ulcer 0 114 0.226 
111 Bleeding - laceration/tear 0 34 -0.4988 
115 GI perforation/rupture 0 426 ~.0437 
116 GI obstruction (any cause) 0 314 -0.2337 
117 GI neoplasm (not perforation/obstruction) 0 595 -0.3111 
118 Localised GI abscess/cyst 0 53 -0.2986 
119 Peritonitis 0 97 0.2387 
120 Pancreatitis 0 22 -1.0131 
121 Cholangitis/cholecystitis 0 98 -1.6821 
122 Diverticulosis 0 29 -0.9312 
123 GI vascular 0 69 0.8642 
insufficiency/embolism/infarction 
124 GI inflammatory disease 0 64 ~.4244 
125 Liver transplant 0 50 -1.4963 
128 Other GI surgery 0 212 -0.5304 
129 Bleeding -1;Ilcer N 37 0.2599 
131 Bleeding - varices N 42 1.0967 
134 GI perforation/rupture N 98 0.2944 
135 GI obstruction (any cause) N 46 -0.5128 
136 GI neoplasm (not perforation/obstruction) N 38 -0.537 
138 Peritonitis N 33 0.8101 
139 Pancreatitis N 99 0.3909 
142 GI vascular insuffieciency/ N 25 -0.1583 
embolism/infarction 
146 Hepatic Failure-toxin N 26 -0.009 
148 Hepatic failure - drug overdose N 30 -0.3099 
150 Other GI disorder N 102 -0.1893 
Renal 
157 Renal neoplasm 0 65 -1.287 
163 Other renal surgery 0 116 -0.7372 
172 Other renal disorder N 87 -0.5613 
Metabolic/endocrine 
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175 Other metabolic/endocrine surgery 
176 Diabetic ketoacidosis 
187 Other metabolic endocrine disorder 
Haematological 
190 Other haematological surgery 
196 Other haematological disorder 
Trauma 
197 Tl3uma- headJbrnin 
o 
N 
N 
o 
N 
199 Tl3uma - face 0 
201 Tl3uma- abdomen 0 
203 Tl3uma - extremities 0 
204 Tl3uma - multiple sites plus head/brnin 0 
205 Tl3uma - multiple site without headJbrnin 0 
209 Tl3uma - head/brnin N 
212 Tl3uma - chest N 
216 Tl3uma - multiple sites plus head/brnin N 
217 TI3tuna" - multiple site without headlbrnin N 
General 
Obs and gynae 
35 -4.3998 
20 -0.7175 
56 -0.5365 
5 0.3585 
39 0.2884 
21 -1.8269 
36 -0.9472 
26 -0.4443 
91 -0.8699 
31 -0.259 
51 -1.8292 
64 -0.4657 
54 -0.4302 
103 -0.7525 
67 -0.6801 
222 Pre-eclampsia/eclampsia 24 -4.6526 
223 Hysterectomy 38 -1.0517 
Elderly 
224 Fracture of hip 20 -1.416 
226 Other elderly disorder 38 -0.3931 
Miscellaneous 
229 Other miscellaneous 438 -0.9152 
APACHE, Acute Physiology and Chronic Health Evaluation;*N, Non-operative; 0, Opel3tive 
GI, Gastrointestinal. 
The new model (New Model APACHE II (C» showed improvement in calibration when 
compared to the original model in both the development cohort and the validation cohort, 
with the Hosmer-Lemeshow GOF test improved and not significant in either cohort 
(Table 9.2). These changes are reflected in the calibration curves (Figure 9.1-9.2). The 
GOF statistic is smaller in the validation cohort than the development cohort with no 
evidence of poorer calibration in the validation cohort. Though it is important to note that 
the two cohorts are very different in size and this may be responsible for the differences 
in the GOF test. The new APACHE II model (C) has improved GOF when compared to 
the original customised model (new APACHE II (B» using the Hosmer-Lemeshow GOF 
test (Table 9.2). The new APACHE II (B) model has significant Hosmer-Lemeshow 
GOF tests in both the validation and development cohorts, with this reflected in the 
calibration curves (Figure 9.2-9.3). 
Discrimination has improved in both the development cohort and validation cohort, with 
significant improvement in the areas under the ROC curve when compared to the original 
model. There are improvements in the discrimination when compared to new APACHE 
II (B) model in both the validation and developmental cohorts. However, the 
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improvements are less marked then those with the original APACHE II model (Table 
9.2) 
Table 9.2 GOF tests and Area under the ROC curves for APACHE II and SAPS II 
Model GOF P< ROC P<* Mortality 
Ratio (Cn 
APACHE II Development 32.7 0.001 0.8068 0.96 (0.94-0.99 
Validation 29.0 0.001 0.8271 0.94 (0.91-0.98) 
New APACHE II (B) Development 29.42 0.001 0.8399 0.001 0.99 (0.96-1.02) 
Validation 13.89 0.08 0.8581 0.006 0.97 (0.91-0.98) 
New APACHE II (C) Development 10.9 0.21 0.8515 0.001 1.00 (0.97-1.02) 
Validation 6.71 0.57 0.8569 0.001 0.98 (0.95-1.0i) 
SAPS Development 69.1 0.001 0.8368 0.96 (0.94-0.99) 
Viilidation 34,.1 0.001 0.8456 0.95 (0.92-0.99) 
" 
NEW SAPS (A) Development 5.22 0.733 0.8395 0.675 1.00 (0.97-1.02) 
Validation 4.54 0.805 0.8478 0.001 0.99 (0.95-1.02) 
New SAPS (B) Development 16.2 0.039 0.8395 0.675 1.00 (0.98-1.03) 
Validation 10.14 0.26 0.8455 0.5106 0.99 (0.96-1.03} 
GOF, Goodness of Fit; ROC, Receiver Operating Characteristics; APACHE, Acute Physiology and 
Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score; CI, Confidence Intervals 
* P-value of area under the ROC curve when compared to the original model. 
Table 9.3 Source of admission mortality ratios and P values for APACHE II for 
validation cohort 
Source of n= Original X2 New X2 New 
.x2 
admission APACHE P= APACHE II P= APACHE P= 
n (B} II {C} 
A&E 599 1.06 0.431 0.94 0.406 0.96 0.527 
(0.97-1.14) (0.87-1.02) (0.88-1.04) 
Recovery/theatre 2012 0.77* 0.000 0.98 0.680 0.98 0.708 
(0.7()"0.84) (0.9()"1.06) (0.9()"1.06) 
Ward in this 1307 1.04* 0.301 1.00 1.000 1.02 0.718 
hospital (0.99-1.10) (0.95~ 1.05) (0.97-1.06) 
Other ICU in this 75 1.19 0.301 1.11 0.538 1.08 0.639 
hospital (0.96-1.42). (0.9()"1.31) (0.88-1.28) 
ICU in another 131 1.05 0.740 0.95 0.740 0.97 0.841 
hospital (0.86-1.24) (0.78-1.13) (0.8()" I. 15) 
Other area in 264 0.84 0.153 0.77* 0.032 0.81 0.078 
another hospital (0.69-0.99) (0.64-0.91 ) (0.67-0.95) 
Home/clinic 4 1.06 0.920 0.89 0.920 0.77 0.791 
(0.0()"2.47) (O.ll-I.71) (0.0()..1.65) 
Overall patients 4392 0.94 0.033 0.97 0.260 0.98 0.522 
(0.91-0.98) (0.93-1.00) (0.95-1.02) 
APACHE,Acute Physiology and Chronic Health Evaluation, A&E, Accident and Emergency; ICU, 
Intensive Care Unit; *Significance as indicated by CIs 
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Figure 9.1 Calibration cUive for original APACHE II model in validation cohort. 
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Figure 9.3 Calibration curve for New APACHE II (C) model in validation cohort. 
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Figure 9.4 Calibration curve for original SAPS II model in validation cohort. 
--lit lit 
--
::::11= _ C 
........ 
--. III III 
--
... :J 
o Q, 2:.f 
Page 154 
SAPS II 
100 .,------------, 
90 
80 
70 
60 
50 
40 
30 
20 
10 
o 
lI)lI)lI)lI)lI)lI)lI)lI)lI)lI) 
NtoVlI)"O ...... COO'> 
Predicted Hospital 
Mortality (%) 
• Population distribution 
----Observed Mortality 
=Predicted Mortality 
- - - - - - - - CI 
--O--Observed Mortality 
- - - - - - - - CI 
Chapter 9- Customisation of models using cohorts from 
different time periods. 
The Uniformity of Fit has also improved when compared to the original model. When 
grouped by source of admission significant differences were found in Recovery/theatre 
and Ward in this hospital for the original model (Table 9.3). Other area in another 
hospital was significant for the New APACHE II (B) model. No significance was found 
for any of the tests in the New APACHE II (C) model. When patients were grouped by 
their APACHE diagnostic system significant differences were found in the 
cardiovascular, neurological, gastrointestinal and general groups for the original model 
(Table 9.4). No significance was found using either the New APACHE II(B) or New 
APACHE II (C) models in any of the groups. 
Table 9.4 AP ACHE S~stem mortality ratios for APACHE II for validation cohort 
APACHE IF Original Xl New Xl New Xl 
System APACHE II P= APACHE II P= APACHE P= 
(B} II{C} 
Cardiovascular 959 1.06* 0.195 0.97 0.480 0.98 0.680 
(1.01-1.12) (0.92-1.02) (0.93-1.03) 
Respiratory 864 1.06 0.354 1.00 1.000 1.01 0.823 
(0.97-1.14) (0.92-1.07) (0.94-1.09) 
Neurological 398 1.18* 0.084 0.92 0.393 0.92 0.427 
(1.04-1.33) (0.80-1.04) (0.80-1.05) 
Gastrointestinal 1427 0.78* 0.001 0.97 0.610 0.99 0.920 
(0.71-0.84) (0.90-1.05) (0.92-1.07) 
Renal 117 ,0.83 0.371 0.85 0.420 0.95 0.806 
(0.54-1.12) (0.57-1.12) (0.65-1.25) 
Metabolic! 51 1.10 0.718 0.98 1.000 1.09 0.764 
Endocrine (0.69-1.51 ) (0.69-1.28) (0.76-1.41) 
Haematological 21 1.49 0.170 1.28 0.377 1.41 0.230 
(1.02-1.94) (0.89-1.69) (0.98-1.84) 
Trauma 286 0.91 0.647 0.80 0.254 0.75 0.145 
(0.60-1.23) (0.52-1.09) (0.48-1.03) 
General 269 0.45* 0.001 1.12 0.603 0.85 0.484 
(0.21-0.70) (0.72-1.53) (0.50-1.21 ) 
Overall patients 4392 0.94 0.033 0.97 0.260 0.98 0.522 
~0.91-0.982 ~0.93-1.002 ~0.95-1.022 
AP ACHE,Acnte Physiology and Chronic Health Evaluation; *Significance as indicated by CIs 
*Significance as indicated by CIs 
9.3.2 SAPS II 
Analysis for the SAPS II model used 12,944 patients, 8,552 in the development cohort 
and 4,392 in the validation cohort with 64 of the original 13,008 patients being excluded 
because of missing data. 
The coeffiecients for the new SAPS II (B) model were as follows: 
New SAPS II constant (Bo) -5.1571 
SAPS II score 
Log of SAPS II score + 1 
Emergancy Operative 
+0.0767 
+0.2796 
-0.3844 
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Calibration has improved in the new SAPS II (B) model when compared to the original 
SAPS II model with reduced Chi Squared values for both the validation and development 
cohort. Significant differences were found using the Hosmer-Lemeshow GOF test in the 
developmental cohort for the new SAPS II (B) model, while the statistic is not significant 
in the validation cohort (p= 0.26) (Table 9.2). This difference may be 4ue to smaller 
numbers in the validation cohort. However, the new SAPS II (B) model has not 
improved when compared to the New SAPS (A) model, with model (A) producing 
smaller and non significant Chi-Squared statistics in both the development and validation 
cohort. These GOF results were reflected in the calibration curves (Figure 9.4-9.6). 
Discrimination has changed little in the new SAPS II (B) model with little difference in 
the area under the ROC curve when compared to the original model or the new SAPS 
(A) model (Table 9.2). 
When uniformity of fit is considered using patients grouped by source of admission, 
significant differences using either the mortality ratios or the Chi Squared test were 
found in the original model for A&E, Recovery theatre and Ward in this hospital and 
Other area in another hospital. The SAPS II (A) model had significant differences in the 
A&E, Ward in this hospital and Other area in another hospital. The SAPS II (B) had 
significant differences in the A&E, Recovery/ theatre and Other area in another hospital 
(Table 9.5). 
Table 9.5 Source of admission mortality ratios and P values for SAPS II for validation 
cohort 
Source of n= Original X2 SAPS II Xl SAPS II Xl 
admission SAPS II P= (A) P= (B) P= 
A&E 599 0.86* 0.026 0.85* 0.022 0.87* 0.037 
(0.78-0.93) (0.78-0.93 ) (0.79-0.94) 
Recovery/theatre 2012 0.85 0.002 0.97 0.590 0.96 0.446 
(0.78-0.92) (0.89-1.05) (0.88-1.04) 
Ward in this 1307 1.09* 0.038 1.08* 0.065 1.10* 0.024 
hospital (1.04-1.14) (1.03-1.13) (1.05-1.15) 
Other ICU in this 75 1.12 0.480 1.12 0.517 1.13 0.458 
hospital (0.92-1.33) (0.90-1.33 ) (0.92-1.35) 
ICU in another 131 1.02 0.888 1.00 1.000 1.02 0.888 
hospital (0.84-1.19) (0.82-1.18) (0.84-1.20) 
Other area in 264 0.81 0.071 0.79* 0.046 0.80* 0.064 
another hospital (0.67-0.94) (0.65-0.93) (0.66-0.94) 
Home/clinic 4 0.72 0.740 0.70 0.740 0.70 0.740 
(0.00-1.67) (0.00-1.75) (0.00-1. 73) 
Overall patients 4392 0.95 0.078 0.99 0.597 0.99 0.823 
~0.92-0.99~ ~0.95-1.02~ ~0.96-1.03~ 
SAPS, Simplified Acute Physiology Score, A&E, Accident and Emergency; ICU, Intensive Care Unit; 
*Significance as indicated by CIs 
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Figure 9.5 Calibration curve for New SAPS II (A) model in validation cohort. 
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Figure 9.6 Calibration curve for New SAPS II (B) model in validation cohort. 
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Table 9.6 APACHE S~stem mortality ratios for SAPS II for validation cohort 
APACHE IF Original Xl New Xl New Xl 
System SAPS II P= SAPS II (A) P= SAPS II P= 
(B} 
Cardiovascular 959 l.00 0.920 l.03 0.507 l.04 0.420 
(0.94-1.05 (0.98-1.09) (0.98-1.09) 
Respiratory 864 l.08* 0.188 l.05 0.393 l.08 0.219 
(1.00-1.16) (0.97-1.13) (0.99-1.16) 
Neurological 398 0.76* 0.004 0.76* 0.005 0.77* 0.008 
(0.65-0.87) (0.64-0.87) (0.66-0.89) 
Gastrointestinal 1427 0.98 0.708 l.08 0.114 l.09 0.103 
(0.91-1.05) (1.01-1.16) (1.01-1.16) 
Renal 117 0.70 0.084 0.71* 0.095 0.71* 0.102 
(0.47-0.92) (0.47-0.94) (0.47-0.95) 
Metabolic! 51 0.86 0.554 0.86 0.554 0.85 0.554 
Endocrine (0.60-1.11) (0.58-1.13) (0.58-1.13) 
lIaematological 21 l.51 * 0.157 l.52* 0.144 l.54* 0.133 
(1.08-1.92) ( 1.08-1.96) (1.09-1.99) 
Trauma 286 0.51* 0.001 0.53* 0.001 0.53 0.001 
(0.31-0.72) (0.32-0.74) . (0.32-0.74) 
General 269 0.65 0.052 0.61* 0.028, 0.60 0.020 
(0.37-0.93) (0.34-0.89) (0.32-0.88) 
Overall patients 4392 0.95 0.078 0.99 0.597 0.99 0.823 
~0.92-0.99~ ~0.95-1.02~ ~0.96-1.03 ~ 
APACHE, Acute Physiology and Chronic Health Evaluation; SAPS, Simplified Acute Physiology Score, 
*Significance as indicated by CIs 
Grouping patients by the APACHE diagnostic system showed significant differences in 
the original model using for at least one of the CI for the mortality ratios or the Chi 
Squared statistic, for the respiratory, neurological and trauma groups. The neurological, 
renal, trauma and general groups were found to have significant tests in the new SAPS 
(A) model and the new SAPS II (B) model (Table 9.6). Regardless of significance the 
parameter estimates are similar. 
9.4 Discussion 
9.4.1 APACHE II 
The new APACHE II (C) model has improved its performance with improved 
calibration, discrimination and uniformity of fit in both cohorts (developmental and 
validation) compared to the original model. There would appear to be no discernible 
change in the model's performance over time between the two time periods analysed 
here. The model has also improved its performance when compared to the customised 
GCS amended model in Chapter 8 (new APACHE II model (B)). This improvement may 
be due to the increased number of subjects in the development set allowing for more 
robust coefficients to be generated. It is important to note that the numbers in the 
validation cohort are considerably smaller than those of the developmental cohort and 
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other data sets in this thesis. Some of the apparent improved performance in the 
validation cohort may be due to the smaller numbers in this cohort. Caution should be 
used if comparing the results in the developmental cohort to those in the validation 
cohort. However, improvement in comparison to the original and new APACHE IT (B) 
model would suggest that these changes are genuine. 
9.4.2 SAPS II 
Compared to the original SAPS II model the new model has improved its calibration and 
maintained its discrimination. Although significant differences between the observed 
mortality and that predicted by the new SAPS (B) model were found in the development 
set using the GOF test, the Chi Squared value is smaller than that of the original model. 
Significant differences are found in the original SAPS IT model in the validation cohort 
but there is no significance. in the observed and estimated mortalities using the GOF test 
in the new SAPS II (B) model. All SAPS models have poor uniformity of fit with many 
of the larger groups being significant. 
The new SAPS II (B) model has improved its performance when compared to the 
original model. However, despite a larger developmental cohort, the model has poor 
performance when compared to the new SAPS II (A) model. This poorer calibration, 
when compared to the original customised model is difficult to explain. Time would not 
appear to be a factor as the performance of the new SAPS II (B) model is poorer than the 
new SAPS II (A) in the developmental set as well. The coefficients generated from the 
random 50:50 split would appear to give a better model than using the larger 
development cohort split temporally. The coefficients produced in the first cohort would 
appear to be less representative in both the first and second cohort than the original 
customised SAPS II model (new SAPS II (A) model). One reason may be a change in 
data collection over time, with data errors in the earlier cohort affecting the ability of the 
model to produce accurate coefficients both in the development cohort and the validation 
cohort. This is however conjecture as it is difficult to understand why this would have an 
effect on the SAPS II model but not the APACHE II model. There may have been either 
a change in practice over the time period or a change in type of patients being admitted. 
However, it would be expected that the performance in the developmental set would be 
good with poor performance in the validation cohort. 
The results from this temporal divide in the data seem to confirm the ability of the 
customisation process to improve the models as both the new APACHE II (C) and new 
SAPS II (B) models showed improved performance when compared to the original 
models. There would appear to be no evidence of deterioration over time but this may be 
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due to the narrow time span which the data cover. It may also be, in part, due to the 
smaller sample size in the validation cohort. 
9.4.3 Overall 
The new APACHE II model appears to have improved performance when also compared 
to the new APACHE II (B) model from Chapter 8, with no significance in Hosmer-
Lemeshow GOF tests and no significant differences found in uniformity of fit in the new 
AP ACHE II (C) model. The new SAPS II (B) model shows similar improvement 
compared with the original model but not in comparison to the new SAPS II (A) model. 
Although no apparent change over time has been noted, this may be a result of the time 
span which the data cover (two and half years). It may be that comparisons over time 
should be made over. a longer time period, allowing the two cohorts to cover non-: 
. . 
adjacent time. periods. As there is an improvement in the performance of the new 
AP ACHE II (C) model then this model should be used in preference to the other 
APACHE models described in this thesis, if case mix adjustments are to be carried out 
in Scottish ICUs. Although the new SAPS II (B) model has improved its performance 
when compared to the original SAPS II model, the GOF has not improved when 
compared to the new SAPS II (A) model. As the new SAPS II (A) model has slightly 
better performance with good GOF it should be used in preference to the otHer SAPS II 
models in this thesis. 
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10.1 Performance of models in Scottish data 
The initial analysis (Chapter 5) would suggest that all the models in this study have poor 
calibration, with all showing significant differences in the Hosmer-Lemeshow test. 
Discrimination would appear to have been maintained in most models. There is no agreed 
point at which these models can be said to have adequate performance, although a 
consensus conference agreed which statistics should be used to assess their performance 
(22). The significance in the Hosmer-Lemeshow test may be a result of the extra 
sensitivity afforded by large numbers (142), with the differences having little clinical 
significance. However, the Hosmer-Lemeshow GOF table (Table 5.8) seems to show 
quite considerable differences in the numbers of observed deaths and those expected by 
the models, especially in the APACHE In and MPMO models. 
These results appear to be confirrbe~ by the uniformitY of fit (Chapter 6). In fact the 
models appearing to have the best fit in Chapter 5 (APACHE II and SAPS II), also had 
significant differences in important subgroups. The better performance of these models 
(AP ACHE II and SAPS II) seems to have resulted from the averaging used by the 
different tests. All models show significant differences when patients are grouped by 
both source of admission and their admitting diagnosis and it could be argued that they 
have faih~d to adjust adequately for case-mix. 
10.1.1 Quality of care 
There are a number of possible reasons for the failure of these models in the Scottish 
population. They highlight a difference in quality of care between the ICUs in Scotland 
and those making up the original databases in which the models were developed. An 
other possible explanation is that they fail to adequately adjust for case mix in the 
Scottish ICU population. There is some evidence to suggest that quality of care may be 
an issue. The overestimation of mortality in the UK APACHE II model (based on data 
from the earlier UK ~ACHE II study) may represent a lower standard of care than that 
of the original US APACHE II study. The better calibration of the APACHE II model, it 
could be argued, represents the standard of care in the US in the early eighties, which 
represents the standard of care in Scottish ICUs at the present. The underestimation of 
mortality in the APACHE III models would then represent a higher level of care now 
practised in the US. The contrast of the three models appear to provide persuasive 
evidence for this argument. This may be supported by the fact that a recent large study of 
ICUs in South West Thames showed underestimation of mortality in the APACHE III 
model (84). The authors pointed to two possible reasons for this underestimation, 
differences in the standard of care between the original US study and the UK units, and 
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the failure of the model to adequately adjust for case mix. The study suggests that if the 
underestimation of mortality is a result of poor care, this would mean that the admission 
of an identical group of patients in both countries would result in a 25% higher mortality 
in the South of England. The authors suggest that there are some explanations for 
differences in quality. 
• Resource allocation for Intensive Care is considerably greater 
• United States recognise Intensive Care as a speciality 
• United States more likely to have dedicated critical care training programmes 
• Resource strategies in the UK often lead to refused admissions, delay in the ICU 
admission, high requirement for inter hospital transfer, early ICU transfer and 
increased ICU readmissions. 
, They suggest that it is more likely that differences between the observed and estimated 
mortality are due to the poor fit of the equation in the South of England data. The authors 
argue that this could be due to the model's inability to measure international differences 
in case mix, admission practice or lead time bias. Other differences include systematic 
differences in medical definitions or diagnostic labelling, effectiveness of therapy, data 
collection, and failure of the APACHE III system to weight sufficiently for their impact 
on the UK mortality. The authors point to the fact that there is no independent standard 
measure of quality of care by which to verify the accuracy of the model. 
However, there is evidence to contradict the argument that differences in quality of care 
are responsible for the underestimation of mortality by the APACHE III model. Both the 
MPM II and SAPS II models represent data from a similar time period to the APACHE 
III system and show no consistent under or overestimation. A large UK study showed 
similar fit in the APACHE II model to the performance of the model in this study with an 
underestimation of mortality at the highest end of severity of illness, and a poor 
estimation in certain subgroups (73). A small study in one ICU in Britain showed that 
both APACHE III and APACHE II underestimated mortality (83). Teres and Lemeshow 
argued that there have only been five studies which look at the performance of severity of 
illness models on new patients and that also used the correct statistics to measure 
performance (137). In these studies a pattern emerges where the models maintain their 
discrimination but show poor calibration. A similar pattern is also reflected in this study. 
A study evaluating the performance of the APACHE III model, in an independent US 
database, showed the model maintaining the discrimination but with poorer calibration 
(187). This poor calibration was also reflected in poor performance in some subgroups. 
The results from analysis of the uniformity of fit (Chapter 6) would also question the 
argument, that the poor performance of the models is a reflection of the quality of care in 
Scottish ICUs. With all models showing poor performance in two or more large 
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subgroups, it would seem unlikely that poor quality of care would not be reflected by 
poor performance in all subgroups. However, some of the groups overestimate mortality, 
and some underestimate mortality, which suggests that the models' failure to adjust for 
case mix is responsible for the models' poor performance. 
10.1.2 Other reasons for poor fit 
10.1.2.1 Differences in mortality 
So, why do these models not maintain performance in Scottish ICUs (and other ICUs)? 
There is no clear answer to this, but there ·are a number of hypotheses. One contributing 
factor may be the higher mortality in Scottish units than in the original studies. The 
mortality in the original databases was considerably less than that reported in .this study 
(MPMII, 20.8%; APACHE 111,17.3%; APACHE"II, 19.7%; SAPS II, 21.9%; Scottish 
Study, 29.4%). It would be.over simplistic to surmise that the much lower mortality rate 
in the APACHE III database is responsible for the consistent underestimation of 
mortality by the model in this study. However, the lower mortality rate in the APACHE 
III database must have some impact on the weights allocated to the variables in the 
model, if compared to the equivalent probabilities in Scottish ICUs. The higher mortality 
rate in this study probably reflects the fewer available ICU beds per head of the Scottish 
population. 
10.1.2.2 Selection bias 
It could be argued that the high mortality in this study reflects a selection bias when 
compared to the original databases. Selection bias must be a consideration when looking 
at the performance of the models. Four units in the study were HDU/ICUs who did not 
admit consecutive patients but rather decided when patients were "ICU type patients". It 
would have been preferable for these units to admit all their patients to the study but 
because of the large throughput of patients in these units they would not have had the 
resources to collect the large amount of data required by the Audit. The profile of those 
patients being admitted is similar to the ICUs in the study. If there is a selection bias then 
it is more likely to be because of the level ofICU beds available to clinicians in Scotland. 
The presumption would then be that the average severity of illness for units in the 
Scottish Audit is considerably higher than that of the units involved in the development 
of the original models. The original APACHE III database had an average APS of 50, 
with the average APS in the Scottish database 60.8, which may reflect a higher level of 
severity of illness. 
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10.1.2.3 Data quality 
For severity of illness models to accurately adjust for case mix it is important that the 
data collection is accurate, complete and consistently collected. It is possible that the data 
accuracy affected the performance of the models. However, the re-scoring of 10% of 
patients over a nine month period showed that all models, with the exception of the 
MPMO model, had no significant over or underscoring. This suggests that although errors 
in collecting the data may have had an effect, errors did not cause the models to 
systematically over or underscore. The APACHE models all need a diagnosis before 
probabilities can be calculated. There were a small number of records with missing 
diagnoses (n=67) but this is so small it is unlikely to have had an effect on the 
performance of the models. All models treat missing da~ as normal, however, it is 
impossible to say whether dati riot recorded had an effect on the accuracy of the models. 
It is possible to hypothesise that, in bette~ resourced l!S units; more nursing time and less 
constraints on the purchasing of blood tests led to more complete data with higher scores 
and probabilities for less severe patients. One study showed that increasing the amount of 
data collected by using a computerised system raised the estimated mortality by 15-25% 
depending on the, model (APACHE II, MPMQ, SAPS II) (177). It is also very difficult for 
this study to assess the impact of variability of data collection on different units, or 
variability 'between different data collectors. Although the Research Nurse did report 
variability betweeri units in the way data were collected this has never been quantified. 
Although, it is unlikely that this aspect is solely responsible for the poor performance of 
the models, it is not possible to rule it out. Future work, especially if it involves the 
comparison of different units, must address issues of data quality. 
The consistent collection of data is vital if a model is to be effective in accurately 
measuring case mix. The Audit has attempted to ensure that this has been the case. It was 
hoped that a number of steps would help to ensure consistent data: 
• providing software with extensive range checking 
• training ICU staff both in the use of the software and data collection 
• providing manuals and help screens with data collection rules 
• reporting data errors to ICU s on 10% of all their records 
• providing a support service for both the software and for answering questions on the 
rules of collection. 
The Audit has attempted to collect data as consistently as possible, however, there are 
areas where it was impossible to determine policy on the different ICUs. Issues such as 
who collected the data, what blood tests were routinely collected by ICUs, where ICU 
treatment started, and the amount and frequency of data collection, were all decisions that 
were made exclusively by the different ICUs. The study made every attempt to follow the 
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protocols available for the different models. However, for most of the scores the 
infonnation available on this subject was not complete. The APACHE III model, because 
of the support of AMS, has the most infonnation on this subject. They provided a data 
collection manual for APACHE III and support in answering questions on rules for data 
collection. It is difficult to know what effect different data collection has on comparisons 
with the original studies, or even within the original studies themselves. Attempts are 
being made by the Intensive Care National Audit and Research Centre (ICNARC) in 
England and Wales to standardise data collection in ICUs providing data to its case mix 
programme. 
10.1.2.4 ICU culture 
It is hard to assess what actual differences there are in ICUs and their treatment in the 
Scottish setting compared to the ICUs contributing data to the construction of the 
different models. However, data in this study showed a considerable improvement in the 
estimated mortality for those patients for whom a GCS from the 24 hour period was not 
available, and a pre-sedated GCS was used (Chapter 7). This may reflect a difference in 
the nature of ICUs in the US and Britain. It could be sunnised that patients in American 
ICUs are admitted at an earlier stage of their disease, before they are sedated and 
ventilated. This would allow for the use of a GCS score in the APACHE models. Patients 
in Britain may enter ICU at a later stage of their disease, when they have already been 
intubated and sedated and where the rules of the APACHE models will assume a nonnal 
GCS. Without knowing more about differences between the ICU cultures in the units 
from which the original models were developed and cultures in Scottish units, it is hard 
to know what impact this may have had on the perfonnance of the models. This is an area 
that needs to be investigated before any meaningful comparisons can be made between 
Scottish ICUs and the ICUs collecting data for the original development of these models . 
. 10.2 Improving performance in models 
The models in this study were being investigated to identify the most legitimate tools for 
allowing valid comparisons between different Scottish ICUs. The success, illustrated in 
the literature by a number of authors, in improving the perfonnance of various models 
made the customising of the models in this study a logical next step (139,141,142). The 
process of customisation in Chapter 8 has no doubt improved the perfonnance of all the 
models, with all but the APACHE II (A) and the new MPM24 (A) models having 
improved performance when compared to the original analysis. However, despite having 
considerably reduced Chi Squared values, all except the new SAPS IIhad significant 
Hosmer-Lemeshow GOF tests. Results for the uniformity of fit showed significant 
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differences between observed mortality and the mortality expected by the models except 
in the New APACHE II (A & B) systems. This was an aspect for which the original 
studies did not publish any data, making it impossible to assess if this was a weakness in 
the original models. It was also not possible to customise the APACHE III model as the 
original equation and complete methodology were copyrighted. As the APACHE III 
model had consistent underestimation of mortality and less variation in uniformity of fit, 
it could be the ideal model for this approach. As the Audit had decided that it was no 
longer going to pay for the use of the APACHE III model it was clear that there was little 
to be gained for the Scottish units in pursuing this possibility. The inclusion of the 
diagnostic weighting may be, in part, responsible for the good uniformity of fit in the 
APACHE II model. The results from the second random sample and also from analysis in 
Chapter 9 would seem to indicate that the process is reproducible and therefore robust. 
The APACHE II models (new APACHE II (check), new APACHE II (C» created from 
both these samples maintained similar performance to that of the original customised 
model (new APACHE II (B». Though the poor performance of the SAPS II (B) model in 
Chapter 9 might question the stability of the original customised model (new SAPS II 
(A» in other samples. When the data was split temporally there was no evidence of 
poorer performanc~ of the model (new APACHE II (C» in the latter half of the data. This 
may be due to the relatively short period ( two and half years) covered by the sample. It 
would be important to repeat this analysis over a longer period, maybe with time periods 
that are not consecutive. Despite the improvements gained by the models using the 
customisation process there still remain questions about their accuracy. This has also 
been reflected in other studies (129,139). However, as there is no bench mark at which 
these models become legitimate this does not necessarily rule out their use for comparing 
units' performance. 
Teres and Lemeshow have argued that while customisation is a legitimate method, it is 
important that it is used appropriately (188). Once a model has been customised it should 
then be used to focus on explaining the differences based on case mix or quality of care 
differences. They argue that the main reason for the need for customisation is the change 
of treatment over time. 
10.3 Future of severity of illness models 
10.3.1 Future research and improvement into severity of illness models 
There would appear to be a presumption made about severity of illness models that, 
properly calibrated, they accurately adjust for case mix (21,151). However, even a well 
calibrated model will be unlikely to account for all the variation in mortality. Some of 
Page 167 Chapter 10 Discussion 
this variation will be due to differences in clinicians' practice or elements of an ICU's 
structure and organisation. However, some unmeasured variation may be due to other 
factors. There is considerable evidence in a number of Scottish studies of the effect that 
deprivation has on outcome. Work in Glasgow on the differences in outcome from a 
number of surgical procedures was shown to be associated with deprivation (181). A 
recent report into deprivation and health in Scotland also found that there were 
differences in outcome associated with deprivation (179). Other work done on a large 
cohort of patients from the Renfrew and Paisley areas in Scotland found deprivation 
associated with less favourable profiles of cardiovascular risk factors (180). Some of the 
evidence may demonstrate differences in access to services but there is considerable 
evidence that point to a' "miles on the clock" effect. Future work needs to be done to 
identify whether deprivation is associated with higher mortality, especially when adjusted 
for case mix. Other, less tangible variables like "will to live" may also have an impact on 
. outcome from an ICU. It is easy to see that if issues like deprivation do have some 
bearing onbutcome then they may have varying effect on individual ICUs. Any future 
. , . 
research'into improving severity of illness models should look into other possible 
determinants of outcome not already included in the models. 
This study, like others, has shown that when models are implemented in different cohorts 
than those in which they were developed, discrimination remains high but calibration 
deteriorates. Although, the models' accuracy can be improved, there still remain doubts 
when their accuracy in subgroups is tested. There is considerable effort required in 
developing models from scratch. The collection of large amounts of information on large 
numbers of patients is required. However, all the models have maintained reasonable 
discrimination with the possible implication that the variables in the model remain 
predictive of mortality in different ICU cultures. However, there is some evidence to 
suggest that the areas under the curves are not as sensitive to changes in accuracy as the 
Hosmer-Lemeshow test (142). More complete understanding of the existing models is 
needed before any new major models are developed. 
Teres and Lemeshow have pointed to the possible effects of having status at end of 
hospital stay as an outcome measure (188). As patients will be followed up for varying 
lengths of time, this might be a possible source of bias. They also argue that increasing 
numbers of patients are transferred to other hospitals for specialist treatment, giving a 
positive outcome at the original ICU for patients that subsequently die. They point to the 
use of 90 days as a less arbitrary outcome measure. The authors say that future research 
should also concentrate on the acute episode of care, rather than the first 24 hours of 
Intensive Care treatment (137,188). Many patients receive treatment in other intensive 
areas, and by the time they arrive on the ICU they have been sedated and stabilised. This 
Page 168 Chapter 10 Discussion 
prevents the accurate measurement of their severity of illness. There also needs to be 
further understanding as to what other factors have a significant impact on variation of 
mortality. It would be possible to use the existing models to investigate this and Knaus et 
al have gone some way in doing so (98). 
There has also been little investigation into data variability and quality. Like this study, 
most studies have had limited analysis of the effect of errors in the data they have 
collected. These models require the collection of a considerable amount of data and there 
is a need for more in-depth research into the effect of errors. Research is also needed to 
identify the effect on the quality of data of different data collectors, the way data are 
collected, where ICU treatment starts, and the consistency of data collection. 
This study demonstrated that it is possible to improve. the performance of the models 
using a process of customisation. The examination of this process in a separate random 
sample and in a temporal split in the data would seem to indicate that the new APACHE 
II models produced are both stable and robust. As there would appear to be no 
perceivable differences in the data over time a new model developed from the whole data 
set, using the methods employed in this thesis, would allow for the creation of the best 
possible model from the data available .. 
10.3.2 Future of severity of illness models in Audit 
It is clear that there remain doubts in the ability of these models to adjust for case mix 
and therefore do not allow comparison of different ICUs. This thesis has not attempted to 
look at variation between ICUs and this remains an important issue. The results from this 
study show that even using the new Scottish coefficients, where patients are admitted 
from and the type of patient admitted may affect a unit's apparent performance. The 
effort to collect these data are considerable and it is hard to justify the resources to do this 
if there is no benefit to patient care. For these models to be used as an Audit tool then 
they must be of use in the Audit Cycle. If the data do not allow any conclusions to be 
drawn on quality of care and consequent changes in practice then they can not be used in 
Audit. 
How these models have been used: As part of the Scottish Intensive Care Audit an annual 
Audit meeting is organised to feedback results from the Study as well as the reporting of 
results of local Audits. As part of this, comparisons are made and performance of ICUs 
reported using mortality ratios. Information is anonymised with ICUs being represented 
by a letter. Personnel from each ICU are made aware of which letter refers to their unit. 
However, as yet, no ICU has been significantly different from the rest of the units and the 
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rank of the different ICUs has not been investigated. So, there has been limited use of 
these models as a measure of quality of care. However, the Audit has attempted to use 
them to assess practice in some limited way. A paper by Connors et al on the 
effectiveness of Pulmonary Artery (PA) catheterisation in ICUs showed that this 
procedure was associated with poor hospital outcome even when adjusted for case mix 
(93). In response to this evidence the Audit retrospectively analysed data using the 
AP ACHE II model and found similar poor outcome associated with the procedure. PA 
catheterisation is not a therapy in itself but rather provides the means for intensive 
monitoring and is associated with certain types of therapy. There is strong evidence that 
PA catheterisation can be used to deliver beneficial therapies when associated with strict 
protocols (189). To stop using this technique would seem to be inappropriate when there 
are clear benefits. However, in the light of the evidence found by the Audit, clinicians 
from the ICUs in the study are now reviewing these protocols. 
As well as work done centrally by the Audit, clinicians from the ICUs have reported a 
number of studies which have relied on case mix adjustment. Two Glasgow units used 
data from the APACHE II model to identify patients who died but who had low 
probabilities of mortality. Case note reviews were then used to investigate the reasons for 
these patients' deaths in an effort to identify problems in care. Another study used the 
AP ACHE II model to adjust for case mix to allow comparisons of levels of workload to 
be associated with outcome. The study found that even after adjustment there was a 
threefold increase in mortality at the highest levels of workload. The unit has since been 
allocated more staff and the intention is to re-run the study to assess the effect of the 
extra staff. 
The future of severity of illness models in Audit: Any Audit in Intensive Care that uses 
death as the outcome measure must have some means of adjusting for case mix. The 
heterogeneous nature of ICU patients make it difficult to imagine how direct comparisons 
of mortality could be used to make conclusions about the effectiveness of care. At 
present these models remain the most accurate means of case mix adjustment. Despite 
the failure of the models in this study, even when customised, to totally satisfy all the 
tests of performance applied to them, it is clear from the calibration curves and the GOF 
table (Table 5.8), that (Figures 5.1-5.6, Figures 8.1-8.11) rising estimates of mortality are 
highly correlated with rising observed mortality. If comparisons are to be made between 
ICUs then the use of the models in this study, rather than crude mortality rates, would be 
preferable. All the models in this study have impressive discrimination and, after 
customisation, considerable agreement between observed mortality and the mortality 
estimated by the model. However, given the considerable effort required to collect these 
data, it is important that once collected this information should be used, or the data 
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collection abandoned. At present, although comparisons of mortality ratios are made, as 
none of the units have ever fallen outside the overall CIs, it has been presumed that 
differences between units could be explained by normal variance. If these models are 
only used in this way comparisons of units may only serve to hide poor care rather than 
help identify poorly perfonning ICUs. It would be possible to investigate ICUs with the 
lowest and highest mortality ratios to allow comparisons of the care on these units. This 
might help identify areas of care which make a positive or negative impact on outcome. 
There have only been a few studies which have attempted to use these models to examine 
differences between ICUs (58,94,140). More research needs to be carried out into 
differences in ICUs as judged by these severity models. As there is no measurement of 
quality of care by which to validate severity of illness models, original and innovative 
ways need to be considered to judge their success. Miranda argues that although case mix 
adjustment is not totally accurate, the models remain the most accurate way of making 
comparisons (190). 
As well as these direct comparisons of ICUs some independent investigation of possible 
detenninants of outcome could be made. There have been a' number of studies in the 
literature which have tried to identify variables that may have an effect on outcome 
(13,98,103). There are a number of factors which it would be possible to hypothesise 
have an effect on the perfonnance of ICUs. The organisation of nursing and medical 
staff, numbers and skill mix of staff, availability of equipment, nursing and medical 
training and management structures are all in areas which it may be presumed to have an 
affect on the effectiveness of care. By profiling units and using severity of illness models 
to adjust for case mix it may be possible to identify practices which have a positive or 
negative effect on outcome. This might help identify standards which ICUs could use to 
judge their current practice against. 
One way of investigating these models would be to concentrate on patients whose 
probabilities lie at the extremes of the severity of illness scales. Concentrating on patients 
who die but have low probability of mortality might allow researchers to identify 
problems in the care patients received or where models have failed to adequately adjust 
for case-mix. Alternatively· by concentrating on patients who live but have high 
probabilities of mortality might help identify where high quality of care has worked. To 
do this requires carefully designed protocols with clear hypotheses and outcome 
measures. 
A consensus conference suggested that mortality probability models concentrating on a 
homogenous population were more successful in adjusting for case mix than generic 
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models in a heterogeneous population (22). Some research has shown success in using a 
customised version of both SAPS II and MPMO in adjusting for case mix in ICU patients 
with sepsis (141). With the advent of powerful personal computers and the ease with 
which statistical analysis can be carried out, generating coefficients for the severity of 
illness models in specific disease categories is a relatively easy process. Rather than 
making judgements about clinical efficacy in heterogeneous populations, an alternative 
approach might be to concentrate on specific disease categories. The large numbers of 
patients in the Scottish Audit database would allow disease specific versions of these 
models to be generated. This approach might also make it easier to draw conclusions on 
care in different units without the confusing picture of the normal heterogeneous 
population. 
10.4 Implications of this research 
10.4.1 Implications for researchers 
The evidence from this study would suggest that the severity of illness models have 
impressive discrimination and, after customisation, improved calibration. There remains 
doubt in the ability of these models to fully adjust for case mix. While no model can ever 
be perfect, there still remains a considerable amount unknown about severity of illness 
models. Clinicians remain divided on their usefulness and the question of variations . 
within ICUs needs to be analysed to allow these models to be used with confidence. 
Results from this study have provided some insight for future researchers to build on. As 
Teres and Lemeshow have reported, other studies have now shown that there is 
deterioration of these models when applied outside the cultures they where developed in 
(137). Studies have also shown the ability of customisation to improve these models 
(111,134,143). There has been considerable debate and evidence to suggest that the lack 
of an accurate GCS score in the APACHE models might have an effect on the models 
accuracy. This study has confirmed this and shown that the use of a pre-sedated GCS can 
improve the accuracy of probabilities generated by the model. These results have been 
confirmed by the customisation of the APACHE II model where the APACHE models 
with the best performance were those which used a pre-sedated GCS. Future researchers 
need to bear this in mind when developing models. When applying models outside the 
original ICU culture researchers need to be aware of organisational differences that might 
effect the performance of the model. 
Other research into the customisation process have shown that even after customisation 
of the SAPS II and MPM II there is considerable problems with the uniformity of fit 
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(134,143). However, this study has shown that the APACHE II model has good 
uniformity of fit after customisation. This would suggest the value of the inclusion of a 
diagnosis element in the model and future researchers should consider this when 
developing new models. 
Further research needs to be carried out to identify other factors significantly associated 
with mortality, allowing for the identification of variables like deprivation, that may need 
to be added to the model. Work also needs to be done on identifying aspects of care, 
management and organisation of ICUs that may contribute to improved outcome. 
The effect of variability of data collection and the quality of data needs to be more fully 
understood. Any further work should help·to establish standards for data collection and 
allow for the assessment of the robustness of the Qata. 
Researchers into modelling of severity of illness must continue to identify weaknesses in 
the present approach of these models. Teres and Lemeshow have suggested that models 
should concentrate on the acute phase of illness and on less arbitrary outcome measures. 
Work needs to also look at the effect treatment in the first 24 hours may have on the 
accuracy of these models. 
There have been a number of studies where these models have been used to adjust for 
case mix to allow groups of similar severity of illness to be compared. (85,93). However, 
if these models are to be used in this way then the caveats on their accuracy must be 
explicit. 
10.4.2 Implications for clinicians 
There has been limited use of these models in Scotland's ICUs, with most work 
concentrating on assessing their accuracy and improving their performance. This 
reluctance to use them is part due to the belief that they are not accurate enough and that 
differences are due to failures of the models rather than differences in care. However, 
with customisation there is significant improvement in the models' performance. 
If these models are to have a positive impact on patient care then they need to be used. 
As well as direct comparisons of units there are other ways that these models could be 
used, including highlighting patients expected to live, examining other factors that may 
effect mortality, examining care in specific disease categories. These have already been 
described in 10.3.2. 
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10.4.3 Implications for managers 
Managers and planners have need of good quality information to both manage and plan 
Intensive Care services. These models have been shown to be useful for assessing 
resource use and workload (88,96,97). However, managers and planners need to fully 
understand how to interpret this data and the caveats that apply. 
When using these models to assess quality of care and current practice it is important that 
clinicians within ICUs do this in an atmosphere of co-operation. It is important that the 
quality of care of patients is measured and shown to be of a good standard. However, it 
also needs to be acknowledged that to allow the open investigation of their practice 
requires considerable courage on the part of the clinicians and nursing staff. The 
- . 
collection of the data for these models is done by the ICU staff themselves and unless 
they feel ownership of these data it is unlikely that the data will be accurate. It is possible 
to deliberately inflate the scores to give higher probabilities, making an ICUs mortality 
ratio look good. 
While this study has shown that even after customisation there is doubt as to the ability of 
these models to adjust totally for case mix, they remain the most accurate tool for this 
purpose. 
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· Appendix 1 . 
Participating hospitals and co-ordinating consultant . 
List of participating hospitals and co-ordinating consultant 
Participating Hospital 
Aberdeen Royal Infirmary 
Borders General Hospital 
Crosshouse Hospital 
Edinburgh Royal Infirmary 
Falkirk and District Royal Infirmary 
Inverclyde Royal Hospital 
Law Hospital 
Monklands District Hospital 
Ninewells Hospital 
Perth Royal Infirmary 
Queen Margaret Hospital 
Raigmore Hospital 
Royal Alexandra Hospital 
Southern General Hospital 
St John's Hospital at Howden 
Stirling Royal Infirmary 
Stobhill Hospital 
Vale of Leven District General Hospital 
Victoria Hospital 
Victoria Infirmary 
Western General Hospital 
Western Infinnary 
Co-ordinating consultant 
Dr M.S.P. MacNab 
DrN. Leary; 
DrR. White 
Dr S. Mackenzie 
DrD. Simpson 
Dr T. Winning 
Dr D. MacLean 
DrM. Inglis 
Dr AJ.Shearer 
DrF.D. Magahy 
Dr P. Nicholas 
Dr I. Ski psey 
Dr S. Madsen 
Dr lC. MacDonald 
Dr P. Armstrong 
DrM. Worsley 
Dr C. Miller 
DrW. Easy 
Dr A. Mowbray 
Dr J.C. Howie 
. Dr I. Grant 
Dr L. Plenderleith ... 
Appendix 2 
Main Ward Watcher data collection screens. 
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.. Appendix 3 
, APACHE III diagnostic groups and APACHE III to APACHE II 
Mapping. 
Condition and operation codes 
Operative 
1 Neoplasm-mouth/sinuses 
2 Neoplasm-larynx/trachea 
3 Neoplasm-lung parenchyma 
4 Broncho-pleural fistula 
5 All other pleural disease 
6 Respiratory infection/abscess 
7 Tracheal-oesophageal fistula 
8 Other respiratory surgery 
Non-operative 
9 ARDS (non cardiogenic pulmonary oedema) 
10 Pneumonia-viral 
1 1 Pneumonia-parasitic 
12 . Pneumonia-bacterial 
1 3 Pneumonia-fungal 
1 4 Pneumonia-aspiration/toxic 
15 Neoplasm-mouth/sinuses 
1 6 Neoplasm-larynx/trachea 
1 7 Neoplasm-lung parenchyma 
1 8 Pulmonary embolus 
19 Pulmonary hypertension (primary) 
20 Localised airway obstruction/oedema (mechanical) 
2 1 Emphysema 
22 Asthma 
23 Smoke inhalation 
24 Cystic fibrosis 
230 Respiratory arrest 
25 Other respiratory disorder 
Respiratory 
Operative 
2 6 Carotid endarterectomy 
27 Aorto-femoral, fern-fern bypass graft 
28 Fern-popliteal bypass graft 
29 Aortic aneurysm: pre-Ieak/ dissection 
30 Aortic aneurysm: dissection 
3 1 Aortic aneurysm: rupture 
32 Peripheral ischaemia 
33 Gangrenous extremity 
34 Cellulitis 
35 Septic shock - lungs (pneumonia) 
36 Septic shock - urinary tract infection 
37 Septic shock - gastrointestinal tract 
38 Septic shock - unknown origin 
39 Pericardial effusion 
40 Valvular repair/replacement 
41 Valvular repair/replacement with CABG 
42 Coronary artery bypass graft(s) 
43 Heart transplant ± lungs 
44 Fibrosarcoma (leg, shoulder) 
45 Atrial myxoma 
46 Congenital anomaly 
47 Ventricular aneurysm 
48 Automatic implantable cardiac defibrillator 
49 Vena cava clipping 
50 Vena cava filter 
5 1 Other cardiovascular surgery 
Non-opera tive 
5 2 Carotid diseaselTlAs 
5 3 Aortic aneurysm 
54 Peripheral ischaemia 
55 Hypertension 
5 6 Unstable angina 
57 Rhythm disturbance 
58 Acute myocardial infarction 
59 Rule out MI 
60 Congestive heart failure 
6 1 Cardiogenic shock 
62 Gangrenous extremity 
63 Cellulitis 
64 Septic shock - lungs (pneumonia) 
65 Septic shock - urinary tract infection 
66 Septic shock - gastrointestinal tract 
67 Septic shock.,. unknown origin 
68 Pericardial tamponade 
69 Post cardiac arrest (± respiratory arrest) 
70 Heart transplant rejection 
Cardiovascular 
7 1 Cardiomyopathy 
72 Anaphylaxis 
73 Other cardiovascular disorder 
Operative 
74 Subarachnoid haemorrhage/intracranial aneurysm 
7 5 Subdural/epidural haematoma 
76 Intracerebral haemorrhage/haematoma 
77 Craniotomy for neoplasm 
78 Transphenoidal removal of neoplasm 
79 Neurological abscess 
80 Encephalitis/inflammation 
81 Spinal cord surgery 
82 Other. neurosurgery 
Non-opera tive 
Neurological 
83 Subarachnoid haemorrhage/intracranial aneurysm 
84 Subdural/epidural haematoma 
85 Intracerebral haemorrhage/haematoma 
86 Cerebrovascular accident (CVA}/stroke 
87 Neurological neoplasm 
88 Seizures· 
89 Neurological abscess· 
90 Encephalitis/inflammation 
91 Meningitis 
92 Self-inflicted overdose 
93 Myaesthenia gravis 
94 Guillain Barre 
95 Other neuromuscular disorder 
96 Non traumatic coma - metabolic disturbance 
9 7 Non traumatic coma - anoxia/ischaemia 
98 Non traumatic coma - cause unknown 
99 Other neurological disorder 
Operative 
1 1 0 Bleeding - ulcer 
111 Bleeding - laceration/tear 
11 2 Bleeding - varices 
11 3 Bleeding - diverticulosis 
11 4 Bleeding - angiodysplasia 
11 5 GI perforation/rupture 
116 GI obstruction (any cause) 
Gastroi ntest ina I 
117 GI neoplasm (not perforation/obstruction) 
118 Localised Glabscess/cyst 
11 9 Peritonitis 
. 1 20 Pancreatitis 
121 Cholangitis/cholecystitis 
1 22 Diverticulosis 
123 GI vascular insufficiency/embolism/infarction 
1 24 GI inflammatory disease 
1 25 Liver transplant 
1 26 Portal-systemic shunt surgery 
1 27 SurgerY for obesity 
128 Other Glsurgery 
Non-opera tive 
1 29 Bleeding - ulcer 
130 Bleeding - laceration/tear 
1 31 Bleeding - varices 
1 32 Bleeding - diverticulosis 
1 33 Bleeding - angiodysplasia 
134 GI perforation/rupture 
1 3 5 GI obstruction (any cause) 
1 36 GI neoplasm (not perforation/obstruction) 
137 Localised GI abscess/cyst 
1 38 Peritonitis 
1 39 Pancreatitis 
140 Cholangitis/cholecystitis 
1 41 Diverticulosis 
142 GI vascular insufficiency/embolism/infarction 
1 43 GI inflammatory disease 
1 44 Rejection of liver transplant 
145 Hepatic failure - virus 
146 Hepatic failure - toxin 
1 47 Hepatic failure - drug reaction 
1 48 Hepatic failure - drug overdose 
149 Acute corrosive injury 
150 Other GI disorder 
Operative 
1 56 Kidney transplant 
1 57 Renal neoplasm 
158 Renal infection/abscess 
1 59 Renal bleeding 
160 Renal vascular insufficiency/infarction/embolism 
1 61 Transurethral resection 
1 62 Renal obstruction 
163 Other renal surgery 
Non-opera tive 
164 Kidney transplant rejection 
1 65 Renal neoplasm 
166 Renal infection/abscess 
1 67 Renal bleeding 
168 Renal vascular insufficiency/infarction/embolism 
169 Nephrotoxic injury 
1 70 Renal obstruction 
171 Hepato-renal syndrome 
1 72 Other renal disorder 
Renal 
Operative 
1 73 Adrenal neoplasm 
1 74 Thyroid neoplasm 
Metabolic/ endocrine 
175 Other metabolic/endocrine surgery 
Non-operative 
1 76 Diabetic ketoacidosis 
1 77 Adrenal neoplasm . 
1 78 Thyroid neoplasm 
1 79 Myxoedema 
180 Hypoadrenalcrisis 
181 Cushing's syndrome/disease 
182 Hyperthyroid storm/crisis 
1 8 3 Acid-base/electrolyte disturbance: diuretic induced 
184 Acid-base/electrolyte disturbance: diarrhoea induced 
185 Acid-base/electrolyte disturbance: GI fistula 
186 Hypothermia/hyperthermia 
187 Other metabolic endocrine disorder 
Operative 
188 Bone marrow transplant 
1 89 Haematological neoplasm 
1 90 Other haematological surgery 
Non-operative 
1 91 Sickle cell crisis 
1 92 Neutropenia 
193 Thrombocytopenia. 
194 Blood transfusion reaction 
1 95 Coagulopathy 
1 96 Other haematological disorder 
Haematological 
Operative 
1 97 Trauma - head/brain 
198 Trauma - spine 
1 99 Trauma - face 
200 Trauma - chest 
201 Trauma - abdomen 
202 Trauma - pelvis 
203 Trauma - ~extremities 
204 Trauma - multiple sites plus head/brain 
205 Trauma -" multiple site without, head/brain 
Non-opera tive 
209 Trauma - head/brain 
21 0 Trauma - spine 
21 1 Trauma - face 
21 2 Trauma - chest 
213 Trauma - abdomen 
21 4 Trauma - pelvis 
21 5 Trauma - extremities 
2 1 6 Trauma - multiple sites plus head/brain 
21 7 Trauma - multiple site without head/brain 
Trauma 
Obs and gynae 
22 1 Septic abortion 
222 Pre-eclampsia/eclampsia 
223 Hysterectomy 
Elderly 
224 Fracture of hip 
225 Fracture of extremity 
226 Other elderly disorder 
Miscellaneous 
227 Snake bite 
228 Food/plant/mushroom poisoning 
229 Other miscellaneous 
General 
AP3 APACHE III Diagnosis Type WW AMS APACHE II Diagnosis WW AP2 
No code Label Code 
1 Neoplasm-mouth/sinuses Post-op 77 SRESPLAR Thoracic surgElry for neoQiasm lOj» 38 
2 Neoplasm-larynx/trachea Post-op 77 SRESPLAR Thoracic surgery for neoplasm (op) 38 
3 Neoplasm-lung parenchym a Post-op 79 SRESPCA Thoracic surgery for neoplasm (op) 38 
4 Broncho-pleural fistula Post-op 80 SRESOTH Other respiratory (op) 48 
5 All other pleural disease Post-op 80 SRESOTH Other respiratory (op) 48 
6 Respiratory infection/abscess Post-op 78 SRESPINF Other respiratory (op) 48 
7 Tracheal-oesophaQeal fistula Post-op 80 . SRESOTH Other resQiratory( opl 48 
8 Other respiratory surgery Post-op 80 SRESOTH Other respiratory (op) 48 
9 ARDS (non cardi~genic pulmonary oedema) Medical 39 PULEDEM Pulmonary oedema (noncardioQenic) (med) 3 
10 Pneumonia-viral Medical 32 BACVPNEU Respiratory failure (infection) (med) 7 
11 Pneumonia-parasitic Medical 33 PARAPNEU Respiratory failure (infection) (med) 7 
12 Pneumonia-bacterial Medical 32 BACVPNEU Respiratory failure (infection) (med) 7 
13 Pneumonia-fungal Medical -33 PARAPNEU . RespiratolY failure (infection) (med) 7 
14 Pneumonia-aspiration/toxic Medical 34 ASPPNEU Respiratory failure (Aspiration) (medJ 5 
15 Neoplasm-m outh/sinuses Medical 37 RESPCA Respiratory neoplasm (med) 8 
16 Neoplasm-larynx/trachea Medical 37 RESPCA Respiratory neoplasm (med) 8 
17 Neoplasm-lung parenchyma Medical 37 ·RESPCA Respiratory neoplasm (med) 8 
18 Pulmonary embolus Medical 38 PULEMB Pulmonary embolus (med) 6 
19 Pulmonary hypertension (primary) Medical 40 RESPOTH Other respiratory (med) 26 
20 Localised airway obstruction/oedema (mechanical) Medical 35 AIROBS Other respiratory (med) 26 , 
21 Emphysema Medical 42 COPDD COPD (med) 2 
22 Asthma Medical 41 ALLERGY . Asthma/allergy (med) 1 
23 Smoke inhalation Medical 40 RESPOTH Other respiratory (med) 26 
24 Cystic fibrosis Medical 40 RESPOTH Other respiratory (med) 26 
230 Respiratory arrest Medical 36 RESPARR Postrespiratory arrest (med) 4 
25 Other respiratory disorder Medical 40 RESPOTH Other respiratory (med) 26 
26 Carotid endarterectomy Post-op 81 SCAROTID Peripheral vascular surg~ryj op) 32 
27 Aorto-femoral fem-fem bypass Qraft Post-op 82 SFEMAORT Peripheral vascular surgery (op) 32 
28 Fem-popliteal bypass graft Post-op 85 SPERISC . Peripheral vascular surgery (op) 32 
'29 Aortic aneurysm: pre-leak/dissection Post-op 83 SELAORT -Peripheral vascular surgery (op) 32 
30 Aortic aneurysm: _di~_section 
- - - ---- -----
Post-op 84 SAORTDIS Peripheral vascular surgery (op) 32 
31 Aortic aneurysm: rupture Post-op 84 SAORTDIS Peripheral vascular surgery (op) 32 
32 Peripheral ischaemia Post-op 85 SPERISC Peripheral vascular surgery (op) 32 
33 Gan9renous extremity Post-ap 85 SPERISC Peripheral vascular surgery (op) 32 
34 Cellulitis Post-ap 86 SCAR DOTH Peripheral vascular surgery (op) 32 
35 Septic shock - lungs (pneumonia) Post-op 43 SEPSIS Sepsis (op) 14 
36 Septic shock - urinary tract infection Post-op 4S SEPTICUT Sepsis (op) 14 
37 Septic shock - gastrointestinal tract Post-ap 43 SEPSIS Sepsis (op) 14 
38 Septic shock - unknown origin Post-op 43 SEPSIS Sepsis (op) 14 
39 Pericardial effusion Post-ap 86 SCAR DOTH Other cardiovascular (op) 47 
40 Valvular repair/replacement Post-op 88 SVALVE Heart valve surQery (op) 33 
41 Valvular repair/replacement with CABG Post-op 88 SVALVE Heart valve surgery (op) 33 
42 Coronary artery bypass graft(s) Post-op 72 GENOTH Other cardiovascular (op) 47 
43 Heart transplant + lungs Post-op 72 GENOTH Other 'cardiovascular (op) 47 
44 Fibrosarcoma (leg shoulder) Post-op 86 SCAR DOTH Other cardiovascular (op) 47 
45 Atrial myxoma Post-op 86 SCAR DOTH Other cardi.ovascular (op) 47 
46 Congenital anomaly Post-op 86 SCAR DOTH Other cardiovascular (op) 47 
47 Ventricular aneurysm Post-op 86 SCARDOTH Other cardiovascular (op) 47 
48 Automatic imQlantable cardiac defibrillator Post-op 86 . SCARDOTH ,Other.cardiovascular (op) 47 
49 Vena cava cliQping Post-op 86 SCAR DOTH Other cardiovascular (op) 47 
50 Vena cava filter Post-op 86 SCAR DOTH Other cardiovascular (op) 47 
51 Other cardiovascular surgery Post-op 86 SCAR DOTH Other cardiovascular (op) 47 
52 Carotid diseaselTlAs Medical 51 PERIART Other cardiovascular (med) 28 
53 Aortic aneurysm Medical 48 MEDAORT Dissecting t/a aneurysm (med) 17 
54 Peripheral ischaemia Medical 51 PERIART Other cardiovascular. (medl 28 I 
55 Hyp_ertension Medical 49 HYPERT Hypertension (med) 9 
56 Unstable angina Medical 46 ACUTMI Coronary artery disease (med) 13 
57 Rhythm disturbance Medical SO' RHYTHM Rhythm disturbance (med) 10 
58 Acute myocardial infarction Medical 46 ACUTMI Coronary artery disease (med) 13 
59 Rule out MI Medical 46 ACUTMI Coronary artery disease (med) 13 
60 Congestive heart failure Medical 47 CVOTH Congestive heart failure (med) 11 
61 Cardiogenic shock Medical S2 CARDIOG Cardiogenic shock (med) 16 
62 Gangrenous extremity Medical 51 PERIART Other cardiovascular (medl 28 
63 Cellulitis Medical 51 PERIART Other cardiovascld!~L(l'Tle~ 28 
64 Septic shock - lungs (pneumonia) Medical 43 SEPSIS Sepsis (med) 14 
65 Septic shock - urinary tract infection Medical 45 SEPTICUT Sepsis (med) 14 
66 Septic shock - gastrointestinal tract Medical 43 SEPSIS Sepsis (med) 14 
67 Septic shock - unknown origin Medical 43 SEPSIS Sepsis (medl 14 
68 Pericardial tamponade Medical 47 CVOTH Other .cardiovascular (med) 28 
69 Post cardiac arrest (:+- respiratory arrest) Medical 44 CARDARR Postcardiac arrest (med) 15 
70 Heart transplant rejection Medical 47 CVOTH Other cardiovascular (med) 28 
71 Cardiomyopathy Medical 47 CVOTH Other cardiovascular. (medl 28 
72 Anaphylaxis Medical 47 CVOTH Other cardiovascular (med) 28 
73 Other cardiovascular disorder Medical 47 CVOTH Other cardiovascular (med) 28 
74 Subarachnoid haemorrhage/intracranial aneurysm Post-op 92 SSAH Craniotomy for ICH/SDH/SAH .lop) 39 
75 Subdurall epidural haematoma Post-op 93 SSDH Craniotomy for ICH/SDH/SAH (op) . 39 
76 Intracerebral haemorrhage/haematoma Post-op 90 SICH Craniotomy for ICH/SDH/SAH (op) 39 
77 Craniotomy for neoplasm Post-op 89 SCRANNEO Craniotomy for neoplasm (op) 34 
78 Transphenoidal removal of neoplasm Post-op 89 SCRANNEO Other neuro (op) 46 
79 Neurological abscess Post-op 94 SNEUROTH Other heuro (op) 46 
80 Encephalitis/inflammation Post-op 94 SNEUROTH Other neuro .l.oj) 46 
81 Spinal cord surgery Post-op 91 SLAMINE Laminectomy and other spinal cord surgery (op) 40 
82 Other neurosurgery Post-op 94 SNEUROTH Otherneuro (op) 46 
83 Subarachnoi d haem orrhage/intracrani alaneurysm Medical 60 SAHMED ICH/SDH/SAH (med) 21 
84 Subdural/epidural haematoma Medical 60 SAHMED ICH/SDH/SAH (med) 21 
85 Intracerebral haemorrhage/haematoma Medical 59 ICHMED ICH/SDH/SAH (med) 21 
86 Cerebrovascular accident (CVA)/stroke Medical 61 STROKE Other neuro (med) 27 
87 Neurological neoplasm Medical 53 NEONEUR Other neuro (medl 27 
!88 Seizures Medical 62 SEIZ Seizure disorder (med) 20 
189 Neurological abscess Medical 54 NEURINF Other neuro (med) 27 
90 Encephalitis/inflammation Medical 54 NEURINF Other neuro (medl 27 
91 Meningitis Medical 54 NEURINF Other neuro (med) 27 
92 Self-inflicted overdose Medical 58 OD Drug overdose _(med) 22 
93 Myaesthenia gravis Medical 55 NEURMUSC Other neuro (med) 27 
94 Guillain Barre Medical 55 NEURMUSC Other neuro(med) 27 
95 Other neuromuscular disorder Medical 5S NEURMUSC Other neuro (med) 27 
96 Non traumatic coma - metabolic disturbance Medical 57 COMAMETU Other neuro (med)/Other metabolic renilimed) 27/25 
97 Non traumatic coma - anoxia/ischaemia Medical 44 CARDARR Other neuro (med) 27 
98 Non traumatic coma - cause unknown Medical 57 COMAMETU Other neuro (med)' 27 
99 Other neurological disorder Medical 56 NEUROTH Other neuro (med) 27 
110 Bleeding - ulcer Post-op 100 SGIBLEE GI bleedingJoJU 42 
111 Bleeding - laceration/tear Post-op 100 SGIBLEE GI bleeding (op) 42 
112 Bleeding - varices Post-oD 100 SGIBLEE GI bleeding (o~l 42 
113 Bleeding - diverticulosis Post-op 100 SGIBLEE GI bleeding (op) 42 
114 Bleeding - angiodysplasia Post-op 100 . SGIBLEE GI bleeding (op) 42 
115 Glperforation/rupture Post-op 101 SGIPERF GI perforation/obstruction (op) 45 
116 GI obstruction (any cause) Post-op 95 SGIOBS GI perforation/obstruction (op) 45 
117 GI neoplasm (not perforation/obstruction) Post-op 99 SGICA GI surgery for neoplasm (op) 43 
118 Localised GI abscess/cyst Post-op 96 SGIINFL Other GI (op) 49 
119 Peritonitis Post-op 96 SGIINFL Other GI (op) 49 
120 Pancreatitis Post-op 96 SGIINFL Other GI (op) 49 
121 Cholangitis/cholecystitis Post-op 97 SGICHOL Other GI (op) 49 
122 Diverticulosis Post-op 96 SGIINFL Other GI (op) 49 
123 GI vascular insufficiency/embolism/infarction Post-op 96 SGIINFL Other GI (op) 49 
124 GI inflammatory disease Post-op 96 SGIINFL Other GI (op) 49 
125 Liver transplant Post-op 105 SLiVERTR EXCLUDED 1r* 
126 Portal-systemic shunt surgery Post-op 98 SGIOTH Other GI (op) 49 
127 Surgery for obesity Post-op 98 SGIOTH Other GI (op) 49 
128 Other GI sur~eJY Post-op 98 SGIOTH Other GI (op) 49 
129 Bleeding - ulcer Medical 63 GIBLEED GI.bleed (med) 24 
130 Bleeding - laceration/tear Medical 63 GIBLEED GI bleed (med) 24 
131 Bleeding - varices Medical 65 GIBLVAR GI bleed (med) 24 
132 Bleeding - diverticulosis Medical 64 GIBLEUL GI bleed (med) 24 
133 Bleeding - angiodysplasia Medical 64 GIBLEUL GI bieed(med) 24 
134 GI perforation/rupture Medical 66 GIPERF . Other GI (med) 29 
135 GI obstruction (any causel Medical 66 GIPERF Other.GI (med) 29 
, 136 GI neoplasm (not perforation/obstruction) Medical 68 GIOTHER Other GI (med) 29 
137 Localised GI abscess/cyst Medical 67 GIINLFA 'Other GI (med) 29 
138 Peritonitis Medical 67 GIINLFA 'Other GI (med) 29 
139 Pancreatitis Medical 67 GIINLFA Other GI (med) 29 
--
140 Cholanqitis/cholecystitis Medical 67 GIINLFA Other GI (med) 29 
141 Diverticulosis Medical 67 GIINLFA Other GI (med) 29 
142 GI vascular insufficiency/embolism/infarction Medical 67 GIINLFA Other GI (med) 29 
143 GI inflammatory disease Medical 67 GIINLFA Other GI (med) 29 
144 Rejection of liver transplant Medical 72 GENOTH EXCLUDED * * 
145 Hepatic failure - virus Medical 69 HEPATF Other GI(medl 29 
146 Hepatic failure - toxin Medical 69 HEPATF Other GI (med) 29 
147 Hepatic failure - drug reaction Medical 69 HEPATF Other GI (med) 29 
148 HeQatic failure - drug overdose Medical 69 HEPATF Other GI (med) 29 
149 Acute corrosive injury Medical 67 GIINLFA Other GI (med) 29 
150 Other GI disorder Medical 68 GIOTHER Other GI (med) 29 
156 Kidney transplant Post-op 104 SRENTRAN Renal transplant (op) 36 
157 Renal neoplasm Post-op 103 SRENCA Renal surgery for neoplasm lop) 35 
158 Renal infection/abscess Post-op 102 SRENOTH Other metabolic/renal (op) 50 
159 Renal bleedilN Post-op 102 SRENOTH Other metabolic/renal (op) 50 
160 Renal vascular insufficiency/infarction/embolism Post-op 102 SRENOTH Other metabolic/renal (op) 50 
161 Transurethral resection Post-op 102 SRENOTH· Other metabolic/renal.(op) 50 
162 Renal obstruction Post-op 102 SRENOTH Other metabolic/renal (op) 50 
163 Other renal surgery Post-op 102 SRENOTH Other metabolic/renal (op) 50 
164 Kidney transplant rejection Medical 73 RENOTH Other metabolic/renal (med) 25 
165 Renal neoplasm Medical 73 RENOTH Other metabolic/renal (med) 25 
166 Renal infection/abscess Medical 73 RENOTH Other metabolic/renal (med) 25 
1167 Renal bleeding Medical 73 RENOTH Other metabolic/renal (med) 25 
: 168 Renal vascular insufficiency/infarction/embolism Medical 73 RENOTH Other metabolic/renal (med) 25 
169 NeJ)hrotoxic injury Medical 73 RENOTH Other metabolic/renal (med) 25 
170 Renal obstruction Medical 73 RENOTH Other metabolic/renal (med) 25 
• 171 Hepato-renal syndrome Medical 69 HEPATF Other metabolic/renal (med) 25 
172 Other renal disorder Medical 73 RENOTH Other metabolic/renal (med) 25 
173 Adrenal neoplasm Post-op '11 HEMAMISC Other metabolic/renal (op) 50 
174 Thyroid neoplasm Post-op 1 1 1 HEMAMISC Other metabolic/renal (op) 50 
175 Other metabolic/endocrine surgery Post-op 1 11 HEMAMISC Other metabolic/renal (op) 50 
176 Diabetic ketoacidosis Medical 76 DIABETIC Diabetic ketoacidosis (med) 23 
177 Adrenal neoplasm Medical 68 GIOTHER Other metabolic/renal (med) 25 
178 Thyroid neoplasm Medical 70 METAMISC Other metabolic/renal (medJ 25 
179 Myxoedema Medical 70 METAMISC Other metabolic/renal (med) 25 
180 Hypoadrenal crisis Medical 70 METAMISC Other metabolic/renal (med) 25 
181 Cushing's syndrome/disease Medical 70 METAMISC Other metabolic/renal (med) 25 
182 Hyperthyroid storm/crisis Medical 70 METAMISC Other metabolic/renal (med) 25 
183 Acid-base/electrolyte disturbance: diuretic induced Medical 70 METAMISC Other metabolic/renal (med) 25 
184 Acid-base/electrolyte disturbance: diarrhoea induced Medical 70 METAMISC Other metabolic/renal (med) 25 
185 Acid-base/electrolyte disturbance: GI fistula Medical 70 METAMISC Other metaboliclrenal (med) 25 
186 Hypotherm ia/hypertherm ia Medical 70 METAMISC Other metabolic/renal (med) 25 
187 Other metabolic endocrine disorder Medical 70 METAMISC Other metabolic/renal (med) 25 
188 Bone marrow transplant Post-op 72 GENOTH· Other cardiovascular (op) 47 
189 Haematological neoplasm Post-op 111 HEMAMISC Other cardiovascular (op) 47 
190 Other haematological surgery Post-op 111 HEMAMISC Other cardiovascular (op) 47 
191 Sickle cell crisis Medical 111 HEMAMISC Other cardiovascular (med) 28 
192 Neutropenia Medical 71 COAGTHRO Other cardiovascular (med) 28 
193 Throm bocytopenia Medical 71 COAGTHRO Other cardiovascular (med) 28 
194 Blood transfusion reaction Medical 71 COAGTHRO Other cardiovascular (med) 28 
195 Coagulopathy Medical 71 COAGTHRO Other cardiovascular (med) 28 
196 Other haematological disorder Medical 111 . HEMAMISC Other cardiovascular (med) 28 
197 Trauma - head/brain Post-op 107 SHEADTR Head trauma (op) 37 
198 Trauma - spine Post-op 108 SMULTR Multiple trauma (op) 30 
199 Trauma - face Post-op 108 SMULTR Multiple trauma (op) 30 
200 Trauma - chest Post-op 108 SMULTR Multiple trauma (op) 30 
201 Trauma - abdomen Post-op 108 SMULTR Multiple trauma (op) 30 
202 Trauma - pelvis Post-op 108 SMULTR Multiple trauma (op) 30 
203 Trauma - extremities Post-op 108 SMULTR Multiple lrauma(op) 30 
204 Trauma - mUltiple sites plus head/brain Post-op 107 SHEADTR Head trauma (op) 37 
205 Trauma - multiple site without head/brain Post-op 108 SMULTR Multiple trauma (op) 37 
209 Trauma - head/brain Medical 74 HEADTR Head trauma (med) 19 
210 Trauma - spine Medical 7S MULTRAUM Multiple trauma (med) 18 
211 Trauma - face Medical 7S MULTRAUM Multiple trauma (med) 18 
212 Trauma - chest Medical 7S MULTRAUM Multiple trauma (med) 18 
213 Trauma - abdomen Medical 7S MULTRAUM Multiple trauma (med) 18 
- -------------
214 Trauma - pelvis Medical 75 MULTRAUM Multiple trauma (med) 18 
215 Trauma - extremities Medical 75 MULTRAUM Multiple trauma (med) 18 
216 Trauma - multiple sites plus head/brain Medical 74 HEADTR Head trauma (med) 19 
217 Trauma - multi~le site without head/brain Medical 75 MULTRAUM Multiple trauma (med) 18 
221 Septic abortion Medical/Post-op 72 GENOTH Other cardiovascular (med)/(opl 28/47 
222 Pre-eclampsia/eclampsia Medical/Post-op 49 HYPERT Other cardiovascular (med)/(op) 28/47 
223 Hysterectomy Medical/Post-op 106 SOBHYST Other cardiovascular (med)/(op) 28/47 
224 Fracture of hip Medical/Post-op 87 SHIPS Other cardiovascular (med)/Admission due to 28/31 
chronic CV disease( op) 
225 Fracture of extremity Medical/Post-op 87 SHIPS Other cardiovascular (med)/Admission due to 28/31 
chronic CV disease( op) 
226 Other elderly disorder Medical/Post-op 86 SCAR DOTH Other cardiovascular (med)/(op) 28/47 
227 Snake bite Medical/Post-op 58 00 Other cardiovascular (med}/(opl 28/47 
228 Food/plant/mushroom poisoning M ed i cal /Post -op 58 00 Other cardiovascular (med)/( op) 28/47 
229 Other miscellaneous Medical/Post-op 72 GENOTH Other cardiovascular (med)/( op) 28/47 
~ 
